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ABSTRACT 
PA\-trans retinoic acid (RA), the bioactive metabolite of vitamin A, is a 
vital signaling molecule in embryonic development. Tight regulation of RA levels 
in the embryo is crucial for organogenesis. It has been demonstrated that murine 
fetuses with vitamin A deficiency exhibited renal malformations ranging from 
renal hypoplasia to agenesis. On the contrary, our laboratory found that maternal 
administration of excess RA to mouse embryos at embryonic day (E) 9.0, a time 
point before formation of the kidney primordium (metanephros), could perturb 
kidney development. The metanephros of RA-treated embryos initially formed at 
El 1.0, but later underwent excessive apoptosis and then degenerated. In this 
RA-induced renal agenesis mouse model, the mRNA expression of RA 
synthesizing enzymes retinaldehyde dehydrogenases (Raldh) was found to be 
significantly downregulated a day after the teratogenic RA insult. The 
downregulation persisted at least till El2.0. Concomitantly, the amount of RA in 
the embryo and the metanephric rudiment was significantly reduced. However, 
supplementation of low doses of RA to the embryo during the period of RA 
deficiency could ameliorate apoptosis and restored kidney development. Based on 
these findings, it was proposed that excess RA caused prolonged suppression of 
RA synthesis and thus led to RA deficiency, which subsequently caused fulminant 
apoptosis in the metanephros and resulted in renal agenesis. This thesis aimed to 
test whether RA deficiency would indeed induce apoptosis in the metanephric 
rudiment and cause renal agenesis. To achieve this, bisdiamine, an inhibitor of 
RALDH enzymes, was employed in an attempt to induce RA deficiency in mouse 
embryos at around mid-gestation to determine if this would lead to renal agenesis 
- X X -
in the fetus. 
First, time- and dose- response studies on the susceptibility of embryos 
to bisdiamine-induced renal malformations were carried out. It was found that 
administration of 3 g/kg bisdiamine to pregnant ICR mice at El0.0 induced renal 
malformations in all fetuses, with 40% being bilateral renal agenesis. Significant 
reduction in RA levels was found in bisdiamine-treated embryos from El0.25, i.e. 
6 hours after treatment, and was prolonged to at least El2.0. Specifically, RA 
levels in the early developing metanephros from El 1.0 to E12.0 were very much 
reduced. Concurrently, there was disruption of RA signaling as observed in 
bisdiamine-treated RARE-hsp-LacZ embryos, which showed sites of RA activity 
upon (3-galactosidase staining. Although metanephric rudiments were formed after 
bisdiamine treatment, they underwent fulminant apoptosis. Some of the 
metanephric rudiments subsequently degenerated and resulted in renal agenesis. 
To test whether renal agenesis was caused by bisdiamine-induced RA 
deficiency, bisdiamine-treated metanephroi, isolated at Ell.25, were cultured in 
medium supplemented with various concentrations of RA for 6 days. Results 
showed that the development of bisdiamine-treated metanephric explants could be 
partially rescued by RA supplementation, with amelioration of apoptosis. 
Taken together, a bisdiamine-induced renal agenesis mouse model was 
established in this thesis. Results support that prolonged RA deficiency caused by 
inhibition of RA synthesis can induce apoptosis in the metanephric rudiment and 
lead to renal agenesis. 






































Chapter 1: General Introduction 
1.1 RENAL DEVELOPMENT 
Kidney is the organ for excretion and homeostasis in the body. One of 
the main fimctions of the kidney is to filter blood and excrete metabolic wastes, 
such as urea, from circulation through production of urine. The kidney is also 
responsible for regulation of the concentration of blood constituents such as salt 
and water, and maintenance of blood pressure and pH. The kidney has a highly 
complex structure that the adult human kidney has 500,000 to 2,000,000 nephrons 
(the functional unit of kidney) (Zimanyi et al., 2009), with each nephron 
containing over 10,000 cells and at least 12 distinct cell types (Gilbert, 2010). 
Complex cell and tissue interactions occur during kidney organogenesis in the 
embryo. Interruption of the process by gene mutation or environmental insult 
leads to renal malformations (Woolf’ 1997; Song & Yosypiv, 2010). 
1.1.1 The three embryonic excretory systems 
Arising from the intermediate mesoderm, the kidney and the gonad 
form the urogenital system in mammalian embryos. Kidney development involves 
formation of three renal systems: pronephros, mesonephros and metanephros. The 
pronephros and the mesonephros are transient structures while the metanephros is 
the permanent and functional kidney. 
1.1.1.1 Pronephros and mesonephros 
The gestation period of human and mouse takes around 280 days and 
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19 days respectively. Among the three renal systems, the pronephros forms first at 
embryonic day (E) 22 in humans and E8 in mice. Comprising of pronephric 
tubules and the pronephric duct, the pronephros arises from the intermediate 
mesoderm at a position just ventral to the anterior somites. Pronephric tubules 
appear first by epithelial transformation of nephrogenic mesenchyme at the 
anterior region while the pronephric duct elongates along the caudal region. In 
fishes and amphibians, the pronephros possesses functional nephrons to filter 
metabolic wastes. In contrast, the pronephros is not functional in mammals. 
Instead, pronephric tubules and the anterior part of the pronephric duct degenerate. 
The remaining caudal portion of the pronephric duct, named Wolffian duct (WD), 
persists and becomes part of the permanent excretory system (Vize et al., 1997). 
As the second transient kidney, the mesonephros appears at E24 in 
humans and E9.5 in mice. When the WD elongates along the caudal region, it 
induces the adjacent mesenchymal cells to condense and differentiate into 
mesonephric tubules, eventually forming nephrons. Development of the 
mesonephros is morphologically and genetically similar to that of metanephros 
(refers to section 1.1.1.2) in that mesonephric nephrons possess glomeruli, and 
proximal and distal tubules. In embryos of humans and some other mammalian 
species (but not of murine), the mesonephros is a functional excretory organ to 
produce dilute urine. Shortly after formation, the anterior mesonephric tubules 
undergo apoptosis and degenerate as more tubules are still being induced along 
the caudal end. In female, the mesonephros eventually completely disappears. In 
male, some of the mesonephric tubules persist and develop into tubules of the 
testes. 
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1.1.1.2 Metanephros 
Metanephros, the permanent mammalian kidney, begins to develop at 
around E30 in humans and El0.5 in mice. Metanephric development begins with 
the condensation of mesenchymal cells in the posterior region of the intermediate 
mesoderm at the level of the hind limb bud. The aggregated cells, referred as the 
metanephric mesenchyme (MM), induce an outgrowth from the caudal end of the 
WD to form the epithelial ureteric bud (UB). The UB then invades the MM, 
leading to formation of the metanephric rudiment. As primitive components of the 
metanephric kidney, the UB and the MM interact and induce each other 
reciprocally to differentiate into appropriate renal structures. The MM induces the 
UB to undergo a series of dichotomous branching and eventually leads to 
formation of the collecting ducts. The UB, in turns, induces condensation, 
proliferation and differentiation of the MM into nephrons. 
In details, after invading the MM, the UB provides molecular signals 
that rescue the MM from apoptosis and induces the mesenchymal cells that 
surround it to condense and form a cap of tightly associated cells around the UB 
tip. The peripheral loosely packed mesenchymal cells form the stroma, which 
supports the differentiation and patterning of the UB and the MM cap. The 
condensed MM cells then induce the UB to grow and branch symmetrically into a 
UB tree. The newly formed UB tips in turn promote formation of new cap of MM 
from other undifferentiated mesenchymal cells and induce their differentiation 
into nephrons. In the process of nephrogenesis, MM cells around the UB tip first 
condense to form a pre-tubular aggregate. The aggregate then undergoes 
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mesenchymal-to-epithelial transition to give rise to an epithelial structure called 
the renal vesicle. The vesicle first develops into a comma-shaped body, and then a 
S-shaped body. The S-shape body eventually fuses with the UB and joins the 
collecting duct system. Capillary grows into the S-shaped body and assembles 
into the nephron as glomerulus. The other end of the S-shaped body, which is 
fused with the UB, forms the proximal tubules, distal tubules and the loop of 
Henle. These structures are responsible for blood filtration, urine production and 
reabsorption of essential molecules from urine. Continuous reciprocal induction 
between the two renal components eventually leads to formation of the collecting 
duct system from the UB and nephrons from the MM. 
Molecular events of early metanephric development, which involve 
induction of UB outgrowth and prevention of apoptosis in the MM, are of 
particular interest. Glial cell line-derived neurotrophic factor (GDNF) is a 
signaling molecule first expressed in the condensing MM at El0.5 of the mouse 
embryo and plays an essential role in UB formation. c-Ret, which is expressed in 
the WD, encodes a receptor tyrosine kinase and is a receptor for GDNF. GDNF 
secreted from the MM diffuses towards the WD and interacts with c-Ret. This 
induces the growth and proliferation of the UB from the WD towards the MM. 
The UB eventually invades the MM under the guidance of GDNF signal, leading 
to formation of the metanephric rudiment. Knockout of either Gdnf or c-Ret in 
mice can result in failure of UB outgrowth and renal agenesis (i.e. absence of 
kidney) (Pichel et al., 1996; Schuchardt et al., 1996). Given its important role in 
early kidney development, it is found that a complex genetic network governs the 
spatial distribution and expression levels of Gdnf in the MM. Transcription factors, 
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such as paired box 2 (Pax2) (Brophy et aL, 2001), eyes absent homolog 1 (Eyal) 
(Xu et al., 1999), Sal-like 1 (Salll) (Nishinakamura et al., 2001) and 
forkhead/winged-helix transcription factor dl (Foxcl) (Kume et aL, 2000), are all 
shown to orchestrate UB induction through regulation of Gdnf expression. 
Prevention of apoptosis in the MM is another critical event in early 
metanephric development. Wilms' tumour 1 (WTl), a transcription factor 
essential for renal development, is a key regulator of apoptosis in the MM. It is 
first expressed in the condensing MM at El0.5 of the mouse embryo. In 
homozygous Wtl knockout {Wtl'^') mice, it was found that the MM formed but 
the UB failed to grow out from the WD (Kreidberg et al., 1993). Fulminant 
apoptosis occurred in the MM, eventually leading to complete failure of kidney 
development. The mutant MM failed to differentiate when co-cultured with 
wild-type UB, while the mutant UB was competent to induce nephrogenesis in 
wild-type MM, showing that there is an autonomous defect in the MM (Donovan 
et aL, 1999). Expression of genes essential for UB outgrowth, such as Gdnf and 
Pax2, was unaffected in the mutant MM. Thus, WTl is thought to regulate UB 
outgrowth independent of GDNF and prevent the condensed MM from apoptosis 
in early renal development. During nephrogenesis, WTl may also play a role in 
the formation of S-shaped body by inhibiting MM cap cells proliferation 
(Pritchard-Jones et al” 1990). 
1.1.2 Renal malformations 
Given the complexity of renal development, genetic or environmental 
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interruption of the process commonly results in renal defects. Congenital renal 
anomalies of the kidney and the urinary tract account for around 20 to 30 percent 
of all anomalies identified in the prenatal period (Queisser-Luft et al., 2002). 
Renal malformations are classified into various types (Table 1.1). Some of the 
malformations can be unilateral or bilateral. Among them, renal agenesis, i.e. the 
absence of kidney, is the most severe malformation. Unilateral renal agenesis 
occurs at a rate of 1 in 5,000 newborns while bilateral agenesis, which is lethal, 
occurs at a rate of 1 in 30,000 newborns (Wiesel et al., 2005). Occurrence of renal 
agenesis can be due to a failure in formation of the UB or the MM. In some cases, 
the metanephric kidney was indeed formed, but underwent degeneration by 
apoptosis due to abnormal development (Winyard et al., 1996; Hiraoka et al., 
2002). Either a primary defect in the MM or the UB affects the development of 
both components due to disrupted reciprocal inductive interaction. Depending on 
the causes, renal malformations may occur as an isolated congenital defect or as 
part of a multiorgan malformation syndrome (Woolf & Winyard, 1998). 
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Table 1.1 Common renal malformations in humans and their signs. 
Type of Malformation Signs 
‘‘• •_ ‘ ‘ ‘ '-"'• • ••“ , . ‘ irasa ••••,•,• ••,"•,•-••; ‘ ‘ •', • 二 • • 一 • • •",•!', •,••!•, •••••• • ‘ i ,',!•:•• ,, fj, •'-',••'••.'•',•••,•• , ••••••••••• , ： , ‘ “ . — 
Renal agenesis Absence of kidney 
Renal hypoplasia Reduction of kidney size caused by reduced number 
of nephrons and UB branches 
Renal dysplasia Kidney with abnormally developed structures, such 
as disorganization of renal tubules or collecting 
ducts. Frequently associated with renal hypoplasia 
(hypodysplastic kidneys) 
Polycystic Kidneys Presence of cysts in tubules or collecting ducts 
Duplex (multiple) ureter Formation of more than one ureter caused by 
defect(s) in UB induction 
Hydronephrosis Distention of the pelvis and calices caused by ureter 
obstruction 
Horseshoe kidney Fusion of the two kidneys at inferior lobes to form a 
horseshoe-shape 
Ectopic kidneys Malpositioned kidneys usually caused by failure of 
the kidney to ascend from its origin in the true pelvis 
I _•!-•-• , , • _ 
1.1.2.1 Causes of renal malformations 
There are three major causes of renal malformations (WooIf, 1997; 
Woolf & Winyard, 1998; Song & Yosypiv, 2010): (1) physical obstruction of the 
urinary tract; (2) mutation of genes responsible for metanephric development; and 
(3) environmental insults. They cause renal malformations through altering the 
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expression of genes essential for kidney organogenesis. 
1.1.2.1.1 Physical obstruction 
Physical obstruction of the urinary tract at the level of the pelviureteric 
junction where the renal pelvis meets the ureter in the renal hilum, the ureter or 
the urethra is associated with half of renal malformations in male and a minority 
in female (Potter, 1972). Obstruction in early gestation usually resulted in 
dysplastic kidneys, whereas occurrence in the last one-third of gestational period 
is associated with hydronephrosis and cysts formation. Bilateral urinary tract 
obstruction is associated with lung hypoplasia and oligohydramnios (deficiency of 
amniotic fluid). Obstruction of the urinary tract is suspected to increase apoptotic 
cell death in the kidney through suppression of Bcl-2, an apoptosis inhibitor 
(Chevalier, 1996). Expression of other proteins responsible for kidney 
development, such as epidermal growth factor and angiotensin II, are also 
disrupted by ureteral obstruction. 
1.1.2.1.2 Mutation 
Gene mutation is a common cause of human renal malformations. In 
many cases, the anomaly is associated with a multiorgan malformation syndrome 
(Woolf & Winyard, 1998). One example is the heterozygous mutation of Pax2 in 
the renal-coloboma syndrome. Similar to heterozygous knockout mice of Pax2, 
humans with heterozygous mutation of Pax2 exhibited blindness due to optic 
nerve defect, together with vesicoureteric reflux and hypoplastic kidneys 
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(Sanyanusin et al., 1995; Favor et al., 1996). Another example is the X-linked 
Kallmann's syndrome, in which mutation of the Kal gene resulted in anosmia and 
hypogonadotrophic hypogonadism associated with unilateral renal agenesis in 
40% of patients (Kirk et al., 1994; Duke et al., 1998). Although bilateral renal 
agenesis occurring in homozygous Wtl knockout mice has not been found in 
humans with Wtl mutations, point mutations of Wtl cause Denys-Drash 
syndrome (Drash et al., 1970) and Frasier syndrome (Frasier et al., 1964)，in 
which glomerulosclerosis is associated with genital anomalies. Mutations of Wtl 
in these syndromes are believed to interrupt nephrogenesis and functioning of the 
kidneys. 
1.1.2.1.3 Environmental insults 
Maternal environmental alterations have been shown to affect renal 
development. One example is the change of maternal glucose level. In humans, 
renal malformations, such as agenesis and hypoplasia, are increased in mothers 
with diabetes mellitus (Parikh et al., 2002; Banhidy et al., 2010). Hyperglycaemia 
in animal models was shown to perturb nephro genesis (Zhang et al., 2007; Tran et 
al., 2008). On the other hand, maternal protein level affects renal development 
through alteration of genes expression. Reduction in the number of glomeruli was 
found in the offspring when pregnant rats were fed with low protein diets 
(Langley-Evans et al., 1999; Welham et al., 2005). Maternal vitamin A deficiency 
is another cause of renal malformations. In animal models, severe vitamin A 
deficiency can induce renal malformations, such as agenesis, hypoplasia and 
horseshoe kidneys, together with a spectrum of malformations of the face, neural 
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crest, eye, heart, and nervous system (Wilson & Warkany, 1948; Wilson et al., 
1953; Dickman et al., 1997). Even in the case of moderate vitamin A deficiency 
that does not cause any significant abnormalities in other organs, reduction in 
nephron number was reported (Lelievre-Pegorier et al., 1998). 
Renal malformations can also be induced by teratogenic insult during 
gestation. Angiotensin converting enzyme inhibitors, which are drugs used for 
treating maternal hypertension, were found to cause renal failure and renal 
dysplasia together with hypotension, oligohydramnios, pulmonary hypoplasia and 
hypocalvaria in humans (Cooper et al., 2006; Quan, 2006). In experimental 
animal models, maternal ethanol exposure led to reduced glomeruli number and 
hydronephrosis in fetuses (Gage & Sulik, 1991; Gray et al., 2008). While vitamin 
A deficiency causes congenital malformations in a number of organ systems 
including the kidney, maternal administration of large doses of vitamin A or 
retinoic acid (the metabolite of vitamin A) is also teratogenic. Renal 
malformations, such as agenesis, dysplasia and hypoplasia, were resulted 
concurrently with defects in the face, eye, heart and other organs in the presence 
of excess vitamin A or retinoic acid in humans and animal models (Cohlan, 1953; 
Robens, 1970; Shenefelt, 1972; Bernhardt & Dorsey, 1974; Geelen, 1979; Hunt, 
1996). 
1.2 RETINOIC ACID 
Vitamin A and its derivatives (retinoids) are a group of organic 
compounds that play indispensable roles throughout mammalian embryonic 
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development and adulthood. Natural sources of retinoids include liver, milk, fruits 
and vegetables. In adults, retinoids regulate fertility, maintain normal vision, and 
prevent neoplastic growth and neurodegenerative diseases. In embryo 
development, retinoids play complex and pleiotropic fiinctions in early axial 
patterning, central nervous system patterning, limb development and 
organogenesis (Niederreither & Dolle, 2008). A\\-trans retinoic acid (RA), the 
bio active metabolite of vitamin A, is a signaling molecule responsible for 
regulation of genes expression. RA mediates most, if not all, of the actions of 
vitamin A during embryo genesis (Clagett-Dame & DeLuca, 2002). 
1.2.1 Retinoic acid synthesis, signaling and degradation in the embryo 
In mammals, circulating maternal vitamin A (retinol) is taken up by the 
embryo via placental transfer. Retinol is then carried by embryonic retinol-binding 
protein 4 (RBP4) in the embryonic circulation system. RBP4 binds to its receptor 
protein, Stimulated by Retinoic Acid Gene 6 Homo log (STRA6), expressed in 
specific embryonic cells and transfers the bound retinol intracellularly 
(Kawaguchi et al., 2007). Taken up by cellular retinol-binding protein II (CRBPII), 
retinol is converted into RA in the cytoplasm via two oxidation steps. The first 
step involves reversible oxidation of retinol into retinaldehyde, which can be 
catalyzed by either alcohol dehydrogenases (ADH) or retinol dehydrogenases 
(RDHs) (Chen et al., 1995). Expression of these enzymes is widespread and 
overlapping. RDHIO has been shown to be the major retinaldehyde synthesizing 
enzymes in the embryo (Sandell et al., 2007). The second step involves oxidation 
of retinaldehyde to RA. This irreversible reaction is catalyzed by three 
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retinaldehyde dehydrogenases (RALDH 1, RALDH2 and RALDH3), which 
display non-overlapping tissue-specific expression patterns. Among the three 
enzymes, RALDH2 is the major RA synthesizing enzymes in the embryo 
responsible for almost all RA production during early development (Niederreither 
et al., 2001). RALDH3 is mainly responsible for eye and nasal development 
whereas RALDH 1 acts partly redundantly with RALDH3 in eye development 
(Dupe et al., 2003; Matt et al., 2005). The spatial distribution and temporal 
expressions of RALDHs largely determine the availability of RA in various 
regions of the embryo. 
As a diffusible lipophilic molecule, RA is released into the surrounding 
once synthesized. RA target cells express cellular retinoic acid-binding protein II 
(CRABPII) to facilitate uptake and transport of RA into the nucleus. RA is a 
ligand for retinoic acid receptors (RARs), a family of nuclear receptor that can 
bind DNA and regulates transcription. The three RARs in mammals (RARa, 
RARp and RARy) have distinct expression patterns during embryogenesis 
(Mollard et al., 2000). RAR dimerizes with another family of nuclear receptor 
known as retinoid X receptors (RXRs). The three family members of RXRs 
(RXRa, RXRp, and RXRy) function as scaffold protein to facilitate DNA binding 
for other receptors (Chawla et al., 2001). In the absence of RA, RAR/RXR 
heterodimers bind to DNA sequences known as RA-response elements (RAREs) 
and recruit co-repressors to suppress transcription (Germain et al., 2002; Bastien 
& Rochette-Egly, 2004). In the presence of RA, binding of the ligand to 
RAR/RXR heterodimer results in the release of the co-repressor and recruitment 
of CO-activator, leading to initiation of gene transcription. Although the expression 
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of over 500 genes are shown to be regulated by RA, RAREs are only found in 
around 30 of them (Baimer & Blomhoff, 2002). Other RA-regulated genes are 
likely to be indirect targets. 
Distribution of RA in the embryo is regulated not only by spatially and 
temporally controlled synthesis, but also by degradation. The three cytochrome 
P450 CYP26 enzymes (CYP26A1, CYP26B1 and CYP26C1) are responsible for 
oxidation of RA, leading to its degradation (White et al., 1996; MacLean et al., 
2001; Tahayato et al., 2003). These enzymes have distinct expression domains 
during embryogenesis, regulating the availability of RA in different regions. Cells 
express CYP26 enzymes to protect against ectopic RA signaling. 
1.2.2 Retinoic acid and embryonic development 
The importance of RA in mammalian embryonic development has 
been widely implicated in a number of loss-of-function experimental models. The 
first batch of evidence came from pregnant animals fed with vitamin A-deficient 
diets. A large array of congenital malformations, described as vitamin A deficient 
(VAD) syndrome, was observed in rat fetuses with vitamin A deficiency (Jackson 
& Kinsey, 1946; Warkany & Schraffenberger, 1946; Wilson & Warkany, 1948; 
Wilson & Barch, 1949; Wilson & Warkany, 1949; Wilson et al., 1953). This 
syndrome included embryonic defects of the hindbrain, spinal cord, heart, eye, 
skeleton, forelimb bud, lung, diaphragm, pancreas and kidney (Clagett-Dame & 
DeLuca, 2002). To further elucidate the role of RA in development, knockout 
mice of different combinations of RAR and RXR isoforms and subtypes were 
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generated. Mouse embryos with homozygous disruption of any of the two RAR 
isoforms demonstrated congenital abnormalities highly similar to those observed 
in the VAD syndrome (Lohnes et aL, 1994; Mendelsohn et al., 1994; Grondona et 
al., 1996; Luo et al., 1996). Compound null mutants of any one of the RAR 
iso forms with RXRa also showed malformations exhibited by double mutant mice 
of any two of the RAR iso forms (Kastner et aL, 1994; Kastner et al., 1997). 
Furthermore, malformations in similar organ systems were observed in Raldhl, 
Raldh2 and RaldhS knockout mice (Niederreither et al., 1999; Niederreither et al., 
2000; Dupe et al., 2003). In addition to displaying congenital malformations, 
embryos were not viable in some models of vitamin A deficiency and targeted 
disruption of RA synthesizing and signaling machineries (Kastner et al., 1994; 
Niederreither et al., 1999; White et al., 2000a). Further studies with the above 
loss-of-function models have highlighted the pleiotropic and indispensable roles 
of RA in embryonic body shaping, organogenesis, tissue homeostasis, cell 
proliferation, differentiation and apoptosis. 
1.2.2.1 Retinoic acid and renal development 
RA is essential for kidney organogenesis. In the developing kidney, RA 
synthesizing and signal transduction machineries are present. RALDH2 is the 
major RA synthesizing enzyme in the metanephros. Raldh2 mRNA expresses 
strongly in the MM at E l l and later in the stroma (Marlier & Gilbert, 2004; 
Rosselot et al., 2010). In contrast, expression levels of Raldhl and RaldhS are 
much lower in the embryonic kidney (Niederreither et al., 2002). Raldhl 
expresses at UB branches while RaldhS expresses at UB tips and later at 
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collecting ducts (Mic et al., 2000; Niederreither et al., 2002; Rosselot et al., 2010). 
For RA receptors, RARa expresses throughout the kidney including the UB, 
whereas expression of RAR^2 is restricted to the stroma (Mendelsohn et al., 
1999). 
As discussed earlier, vitamin A deficiency can result in renal 
malformations, such as agenesis and hypoplasia. Renal defects were indeed one of 
the most common congenital malformations in vitamin A-deficient rats (Wilson & 
Warkany, 1948). Homozygous RARdy and RARa/RXRa compound knockout 
mutants exhibited renal agenesis while renal hypoplasia occurred in 
Raldh2/RaldhS double knockout embryos (Mendelsohn et al., 1994; Kastner et al., 
1997; Rosselot et al., 2010). In addition to hypoplasia, the kidney of RARoJp2 
mutants was ectopic (failing to ascend from the pelvic region to its normal 
position at the lumbar region), which was similar to the phenotype observed in 
VAD syndrome (Wilson et al., 1953; Mendelsohn et al., 1994). Together, these 
findings strongly suggest that RA signaling is essential for metanephric 
development. 
One of the roles of RA in metanephric development involves the 
regulation of c-Ret, which is responsible for UB branching (Mendelsohn et al., 
1999; Batourina et al., 2001; Rosselot et al., 2010). Studies of the RARa//]2 and 
Raldh2/Raldh3 compound mutants showed that RA synthesized in the stromal 
cells maintained the expression of c-Ret in the UB tip. This enables the UB to 
respond to GDNF secreted from the MM. The UB subsequently undergoes 
dichotomous branching and in turn induces the MM to undergo nephro genes is. 
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Thus, RA is responsible for the continuous reciprocal inductive interaction 
between the UB and the MM. So far, this is the only known role of RA in kidney 
organogenesis. However, other than c-Ret, a number of retinoid target genes, such 
as midkine and sonic hedgehog�Shh), is also expressed in the developing 
metanephros (Burrow, 2000). It is speculated that RA may participate in the 
regulation of genes other than c-Ret to orchestrate metanephric development. 
1.2.3 Retinoic acid teratogenicity 
As discussed earlier, excess vitamin A or RA is teratogenic to a number 
of experimental animals, including mouse, rat, guinea pig, hamster, rabbit, dog, 
pig, chicken and monkey (Geelen, 1979). In humans, vitamin A is taken from food 
and as supplements. Vitamin A derivatives or synthetic retinoids, such as 
isotretinoin (or Accutane®) and etretinate, are used as drugs for treatment of acne, 
psoriasis and various forms of cancer. There were clinical reports showing that 
these drugs and supplements caused congenital malformations in humans (Rosa, 
1983; Happle et al., 1984; Lammer et al., 1985; Rothman et al., 1995). For 
example, the risk of malformations caused by fetal exposure to isotretinoin was 
estimated to be 25 times higher than normal (Lammer et al., 1985). Similar to 
malformations observed in animal models, defects in the craniofacial region, 
central nervous system, thymus, heart, musculoskeletal system, genitourinary tract 
and gastrointestinal system were found in humans upon excessive retinoids intake 
(Rothman et al., 1995). 
In a thorough study of the embryonic sensitivity to RA-induced 
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malformations and lethality in hamsters, it was revealed that embryo at the stage 
of organogenesis is highly sensitive to teratogenic RA insult, while embryos in 
early (cleavage, blastocyst and early germ-layer stages) and late (fetal period) 
developmental stages are relatively insensitive (Shenefelt, 1972). The term 
“critical period" in teratology refers to the time period during development when 
treatment with a specific agent will cause a specific malformation. At least 40 
distinct malformations could be induced by a single teratogenic dose of RA during 
organogenesis, each with specific critical period(s). Shenefelt (1972) showed that 
about a quarter of critical periods of RA teratogenicity ended before the precursor 
cells of the corresponding organ appeared, whereas the other ended after the 
primordium appeared. 
Since both deficiency and excess of vitamin A or RA result in 
congenital malformations of similar organ systems including renal malformations, 
this indicates that the concentration of RA must be controlled within a very 
narrow range in embryogenesis. These observations also lead to the speculation 
that there may be a potential mechanistic link between teratogenesis induced by 
deficiency and excess of RA. 
1.2.3.1 Retinoic acid teratogenic mechanism 
In humans, the teratogenic mechanism of retinoids, together with that 
of other teratogens like ethanol and glucose, remains largely unresolved. However, 
insight into pathogenic pathways of excess RA may be provided from studies on 
animal models. As discussed, the action of RA on embryogenesis is mediated 
- 1 8 -
Chapter 1: General Introduction 
through transcriptional regulation and it is estimated that there are over 200 genes 
with altered expressions after retinoid treatment (Gudas, 1994). Thus, it is 
generally believed that most, if not all, of the actions of retinoid teratogenesis are 
mediated via alteration of gene expressions. 
To date, there are several known RA teratogenic mechanisms. First, 
teratogenic dose of RA can cause malformations by directly inducing cell death in 
the progenitor cells shortly after the teratogenic insult (Alles & Sulik, 1990; 
Osumi-Yamashita et al., 1992; Padmanabhan, 1998; Shum et al., 1999). For 
instance, Osumi-Yamashita et al (1992) showed that RA-induced abnormal facial 
morphogenesis in the mouse could be caused by excessive cell death in the 
mesenchyme of the facial primordium 12 hours after the insult. Moreover, 
Padmanabhan (1998) and Shum et al (1999) respectively demonstrated that 
excessive apoptosis induced by RA in the tail bud mesenchyme, which contains 
progenitor cells for formation of the lower vertebrate and nervous tissue, was the 
cause of vertebral agenesis in RA-induced caudal regression mouse models. It is 
noted that in these models, the critical periods of RA teratogenesis lied at a time 
when the progenitor cells have already appeared. Thus, excess RA could directly 
cause cell death in these cells. 
RA can also cause malformations through inhibition of cell 
proliferation. RA has been shown to inhibit cell proliferation in a number of 
human cell lines, including Kaposi's sarcoma (Nagpal et al., 1997), oral 
squamous-cell carcinoma (Giannini et al., 1997), neuroblastoma (Irving et al., 
1998) and myeloma (Okamura et al., 1998). It is speculated that some of the 
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RA-induced congenital malformations may be caused by reduced cell 
proliferation. Indeed, it was reported that teratogenic dose of RA administered at 
ElO to mouse embryos caused reduction in proliferation of forelimb bud cells 
from ElO to El2, resulting in forelimb defects (Abbott et al., 1990). 
Excess RA can induce congenital malformations through alteration of 
neural crest cells (NCCs) migration. Arising at the lateral edge of the neural plate, 
NCCs are multipotent migratory cells in the vertebrate embryo, which can give 
rise to a wide variety of cell types, including neuronal, glial, craniofacial, bone, 
smooth muscle and pigment cells (Huang & Saint-Jeannet, 2004). RA signaling 
has been implicated in NCC migration and patterning (Lohnes et al, 1994; Dupe 
& Pellerin, 2009). Teratogenic dose of RA administered at E7 to pregnant mice 
was found to perturb migration of NCCs, resulting in eye malformations, such as 
microphthalmos (small eye) and anophthalmos (absence of eye) (Ozeki & Shirai, 
1998). It has also been demonstrated that excess RA altered the migration of 
NCCs in murine embryos, leading to malformation of the branchial arches (Lee et 
al., 1995) and the heart (Li et al., 2001). 
RA teratogenicity can also be mediated via repatteming and alteration 
of cell fate. Pattern formation refers to the process by which initially identical 
cells in a developing tissue proliferate and differentiate into a structure with 
complex spatial arrangement and diverse cell types. As a diffusible morphogen, 
one of the main roles of RA in embryonic development involves patterning of the 
body, such as the left-right axis (Vermot & Pourquie, 2005) and the central 
nervous system (Durston et al., 1989; Niederreither et al., 2000). It is not 
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surprising that exogenous RA treatment, which disrupts RA gradient along the 
body axis, can interfere with the patterning processes. Teratogenic RA treatment 
to murine embryos at E7 was reported to disrupt the expression of Hox genes 
(Kessel & Gmss, 1991). This induced homeotic transformation of vertebrae, 
causing posterior transformation along the complete body axis. Another example 
of disrupted patterning is RA-induced craniofacial malformations (Helms et al., 
1997). Excess RA inhibited the expression of a polarizing signal, Shh, in the 
cranial facial primordia, resulting in abnormal growth and patterning in cranial 
facial morphogenesis. Accompanying patterning is the determination of cell fate. 
It has been shown that excess RA altered the fate of cells in the central nervous 
system from neuronal to epidermal, resulting in severe brain truncation (Agarwal 
&Sato, 1993). 
1.2.3.2 Retinoic acid-induced renal agenesis mouse model 
In humans, renal agenesis and other kidney defects can occur 
concurrently with caudal regression syndrome, which is characterized by agenesis 
of the lower vertebral column, imperforate anus and caudal spinal cord 
malformations (Rubenstein & Bucy, 1975; Andrish et al., 1979; Spamon & 
Ahmed, 1984). Caudal regression syndrome can be caused by excessive intake of 
vitamin A during pregnancy (Padmanabhan, 1998). Previously, our laboratory has 
established a mouse model in which maternal treatment with excess RA at 
mid-gestation led to a spectrum of malformations in the mouse fetus that closely 
resembled caudal regression syndrome in the human (Shum et al., 1999). Renal 
agenesis and other kidney defects were observed in this mouse model (referred as 
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the "RA-induced renal agenesis mouse modd”) (丁se et aL, 2005). The cellular 
and molecular mechanisms of RA-induced renal agenesis were studied in details. 
In the RA-induced renal agenesis mouse model, intraperitoneal 
administration of 125 mg/kg RA to pregnant Institute of Cancer Research (ICR) 
mice at E9.0 resulted in bilateral renal agenesis in fetuses at El8.0 (Tse et al., 
2005). Histological examination revealed that the metanephros was formed in 
RA-treated embryos at El 1.0, with the UB penetrated into the MM. However, the 
metanephric rudiment failed to undergo proliferation and differentiation, but 
exhibited fulminant apoptosis in the MM. The RA-treated metanephros eventually 
regressed by El6.25 to produce a renal agenesis phenotype in the fetus. 
The teratogenic mechanism of RA in perturbing kidney development 
in the RA-induced renal agenesis mouse model is of particular interest. A 
pharmacokinetic study has shown that administration of 100 mg/kg RA into 
pregnant ICR mice at E l l caused a peak endogenous RA level in the embryo at 
the 3rd hour after treatment, which corresponded to a 300-fold increase in 
comparison with the control (Satre & Kochhar, 1989). However, the teratogenic 
dose of RA was rapidly metabolized and the endogenous RA level returned to 
pretreatment level 8 hours after administration. In the RA-induced renal agenesis 
mouse model in which the teratogenic dose was administered at E9.0, the high 
dose of exogenous RA should have been completely removed by the time the 
metanephros formed at El 1.0, i.e. 48 hours after RA treatment. Thus, it is unlikely 
that the exogenously applied RA causes renal agenesis by acting directly on the 
metanephros to induce cell death or through other known RA teratogenic 
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mechanisms as discussed in section 1.2.3.1. Hence, the action of the teratogenic 
dose of RA in causing renal agenesis cannot be explained by any of the RA 
teratogenic mechanisms currently known. 
Niederreither et al (1997) reported that the expression of Raldh2, 
encoding the key RA synthesizing enzyme in the embryo and the metanephros, 
was downregulated in the caudal region 12 hours after teratogenic RA insult at 
E8.5 (Niederreither et al, 1997). Recent studies of the RA-induced renal agenesis 
mouse model by our laboratory showed that mRNA expressions of Raldhl, 
Raldhl and RaldhS were significantly downregulated in the whole embryo from 
E9.5 to El 1.0, i.e. 12 to 48 hours after the RA teratogenic insult (unpublished 
data). Concomitantly, the RA content in the RA-treated whole embryo was 
reduced by approximately 33% at ElO.O and El0.5 when compared with the 
control. The downregulation of Raldhl, Raldhl and RaldhS expressions was also 
prominent in the early RA-treated metanephros, such that the amount of RA in the 
RA-treated metanephric rudiment was significantly reduced by over 50% from 
Ell.O to E12.0. Thus, a teratogenic dose of RA administered at E9.0，surprisingly, 
caused RA deficiency in the whole embryo and the metanephric rudiment. 
Compensation for the RA deficiency by maternal oral feeding with 3 
low doses of RA (1.25 mg/kg) from ElO.O to Ell.O at 12-hour interval could 
rescue kidney development in RA-treated embryos (unpublished data). While 
78% of RA-treated fetuses showed bilateral renal agenesis, the incidence reduced 
dramatically to 20% with low doses of RA supplementation. Moreover, while 
renal malformations were consistently found in all RA-treated fetuses, 28% of 
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RA-treated fetuses fed with low doses of RA showed normal kidney development. 
Gene expression analysis revealed a reduction of c-Ret expression by 30.2% in 
RA-treated metanephroi at El2.0. However, low doses of RA supplementation 
could restore c-Ret expression with amelioration of apoptosis. These results 
suggested that RA-induced apoptosis in the metanephros and renal agenesis could 
be caused by RA deficiency. Based on these findings, it was speculated that excess 
RA administered at E9.0 led to prolonged downregulation of Raldh expression so 
that there was a deficiency of endogenous RA upon early metanephric 
development. The RA deficit led to excessive apoptosis in the metanephros, 
resulting in renal agenesis. 
While downregulation of Raldhs, RA deficiency, fulminant apoptosis 
and renal agenesis were features observed in the kidney rudiment of the 
RA-induced renal agenesis mouse model, mechanistic linkages between reduced 
RA synthesis and subsequent events had yet to be determined. In this thesis, the 
aim was to test whether temporary RA deficiency, caused by reduced RA 
synthesis at around ElO to El2 as observed in the RA-induced renal agenesis 
mouse model, could indeed cause renal agenesis. To achieve the target, it was 
aimed at setting up a RA deficiency mouse model by suppressing RA synthesis at 
around mid-gestation to mimic the condition in the RA-induced renal agenesis 
mouse model. 
1.2.4 Induction of RA deficiency 
As mentioned earlier, RA synthesis in the embryo involves first the 
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conversion of retinol into retinaldehyde by retinol dehydrogenases (RDHs), 
followed by oxidation of retinaldehyde into RA by retinaldehyde dehydrogenases 
(RALDHs). In the RA-induced renal agenesis mouse model, the expressions of 
Raldhl, Raldhl and RaldhS were downregulated, concomitantly, there was RA 
deficiency in the whole embryo and the early metanephros at around El0 to El2. 
Thus, to mimic the condition in the RA-treated embryo, the target in this project 
was to achieve temporary RA deficiency at similar periods through inhibition of 
the second step of RA synthesis, i.e. the conversion of retinaldehyde into RA 
catalyzed by RALDHs. 
While there are knockout mouse models of Raldhl, Raldh2 and 
RaldhS (Niederreither et al., 1999; Dupe et aL, 2003; Fan et al., 2003), these 
transgenic models will not fit the desired conditions in this study. First, temporary 
RA deficiency induced at around mid-gestation through suppression of RALDHs 
activity was desired. However, the knockout mouse embryos of Raldhs suffer 
from RA deficiency throughout the gestation period. This prolonged RA 
deficiency beyond El 2 may exert effects on later stage of renal development and 
result in malformations, which may not necessarily be caused by RA deficiency in 
early kidney development. Second, knockout models of Raldhl require in vivo 
supplementation of low doses of RA (2.5 mg/kg) from E6.75 to E10.25 at 12-hour 
interval to bypass lethality due to heart defects (Niederreither et al., 1999). Thus, 
RA deficiency in Raldh2 mutants was actually compensated (at least partially) 
during early kidney development at mid-gestation. Third, the knockout mice of 
Raldhs were in C57/BL6 background while mice of ICR strain were preferred 
(Niederreither et al., 1999; Dupe et al., 2003; Fan et aL, 2003). It is because it has 
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been shown that different strains of mice demonstrated differential susceptibility 
to RA-induced malformations (Lee et al., 2004). For example, in our laboratory, it 
was found that mice of C57/BL6 strain demonstrated reduced frequency of 
RA-induced renal malformations when compared with mice of ICR strain (Tse et 
al., 2005). If RA-induced renal agenesis was indeed caused by RA deficiency, it is 
likely that different mouse strains may have different susceptibility to RA 
deficiency too. Thus, it is preferred to use the same mouse strain (ICR) in the 
present project as in the RA-induced renal agenesis mouse model. 
Other than the knockout models, RA deficiency models induced by 
maternal vitamin A depletion have similar problems, such as prolonged RA 
deficiency and requirement of RA supplementation to bypass lethality at 
mid-gestation (White et al., 2000b). Thus, a better approach to induce RA 
deficiency in the specific time window in ICR mice would be using chemical 
inhibitors to inhibit RA synthesizing enzymes. Tetraethylthiuram disulfide 
(disulfiram) (Stratford et al., 1996), nitrofen (Mey et al., 2003; Babiuk et al., 
2004), N,N'-bis(dichloroacetyl)-1,8-octamethylenediamine (bisdiamine) (Mey 
et al., 2003), citral (Tanaka et al., 1996) and diethylaminobenzaldehyde (DEAB) 
(Chute et al” 2006) are known chemical inhibitors of RA synthesizing enzymes. 
While some drugs, like citral, inhibit both steps of RA synthesis (Connor & Smit, 
1987), inhibitors, such as disulfiram, can specifically suppress RALDH activity. 
However, most of the inhibitors, except nitrofen and bisdiamine, have only been 
extensively used to suppress RALDH activity in vitro. While nitrofen, previously 
used as a herbicide, has been shown to cause diaphragmatic hernia through 
inhibition of RALDH activity in vivo (Mey et al., 2003; Clugston et al., 2010)， 
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this chemical is carcinogenic and can cause serious health hazards upon exposure 
(Hurt et al, 1983). 
Another RA synthesis inhibitor, bisdiamine, is a well-known male 
contraceptive that inhibits spermatogenesis (Amory et al., 2011). When orally 
administered to pregnant rats and hamsters, bisdiamine has been shown to induce 
a spectrum of congenital malformations similar to those observed in vitamin 
A-deficient fetuses, which included defects in the face, heart, eye, skeleton, 
forelimb, lung, diaphragm, thyroid, spleen and kidney (Taleporos et al,, 1978; 
Kilburn et al., 1982; Oster et al,, 1983; Binder, 1985; Tasaka et al., 1991). Recent 
studies with the mouse suggested that bisdiamine exerted its teratogenic effect 
through inhibition ofRALDH (Mey et aL, 2003; Clugston et al., 2010; Amory et 
al., 2011), hence inducing RA deficiency and malformations that recapitulated the 
VAD syndrome. 
There are several advantages of using bisdiamine to induce RA 
deficiency. First, it is one of the most potent inhibitors of RALDH among 
different types of inhibitors as shown by in vitro RA synthesizing activity assay 
(Mey et al., 2003). Moreover, while it is a potent teratogen to the embryo, it is 
non-toxic to the mother even when a high dose is administered (Oster et al., 1974; 
Binder, 1985). Thus, bisdiamine could be a desirable RALDH inhibitor to induce 
RA deficiency at mid-gestation in vivo. 
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1.3 STRATEGY OF THE THESIS 
The aim of this project was to test whether temporary RA deficiency, 
caused by reduced RA synthesis at around ElO to El2 as observed in the 
RA-induced renal agenesis mouse model, could indeed cause renal agenesis. To 
achieve the aim, bisdiamine was used to induce RA deficiency at around 
mid-gestation to mimic the condition in the RA-induced renal agenesis mouse 
model. 
The first part of this project was to test whether bisdiamine could 
induce renal malformations, especially renal agenesis, in mouse fetuses. In 
Chapter 3, a detailed in vivo time-response study was first carried out to determine 
at which stage of development bisdiamine administration could induce renal 
agenesis in the fetus. After finding out the optimal injection time, a dose-response 
study to determine the most effective dose to induce renal agenesis was performed. 
In these studies, near-term fetuses were examined for changes in various growth 
parameters, resorption, as well as renal and non-renal malformations. After 
determining the optimal time and dose of bisdiamine injection to induce renal 
agenesis, the pathogenic mechanism was studied. To confirm that RA deficiency 
was induced by bisdiamine in the embryo at mid-gestation, the RA concentration 
in bisdiamine-treated embryos was determined at different time points 
post-injection. The changes in pattern of RA signaling in bisdiamine-treated 
embryos were studied using a RARE-hsp-LacZ transgenic mouse strain that 
expresses p-galactosidase {lacZ gene) under the control of the retinoic acid 
responsive element (RARE). RA deficiency in the metanephros was confirmed by 
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quantification of RA content in the metanephric rudiment using a RA-responsive 
cell line. After showing that bisdiamine induced RA deficiency in the whole 
embryo and the early metanephros, the expression level of genes critical for renal 
development, including c-Ret and Gdnf, was examined. The amount of apoptotic 
nuclei in the metanephros was also quantified to determine whether RA deficiency 
induced by bisdiamine would lead to increased apoptosis. 
In Chapter 4, to prove that it was indeed RA deficiency which 
perturbed kidney development, RA deficit in the bisdiamine-treated metanephros 
was corrected by using an in vitro approach and the effect on renal development 
was examined. The metanephric rudiment was isolated from bisdiamine-treated 
embryos at Ell .25 and cultured in the presence of low concentrations of RA. The 
development of the metanephric explant was assessed by the extent of UB 
branching and nephrogenesis. After proving that low concentrations of RA 
supplementation could rescue the development of bisdiamine-treated metanephric 
explants, experiments were carried out to determine if the rescue effect could be 
mediated via amelioration of apoptosis and restoration of expression of genes 
important for early kidney development. To this end, the amount of apoptotic 
nuclei and the expression levels of c-Ret and Gdnf in the metanephric explant 
were quantified. 
Finally, in Chapter 5, comparison between the bisdiamine-induced 
renal agenesis mouse model and the RA-induced renal agenesis mouse model was 
made. A conclusion was drawn based on the experimental results of this project. 
Future perspectives on this work were discussed. 
- 2 9 -
Chapter 2 
General Materials and Methods 
- 3 0 -
Chapter 2: General Materials & Methods 
2 .1 MOUSE MAINTENANCE AND MATING METHOD 
Mice of The Institute of Cancer Research (ICR) strain were originally 
obtained from Harlan Laboratories, UK. Breeding pairs of RARE-hsp-lacZ 
transgenic mice in outbred CDl background, which express p-galactosidase (lacZ) 
gene under the control of the retinoic acid responsive element (RARE) (Rossant et 
al., 1991), were obtained from Prof. Peter McCaffery (University of Aberdeen). 
Mice were housed and random-bred at the Laboratory Animal Services Center of 
the Chinese University of Hong Kong. Irradiated LabDiet for Rodents {PMI 
Nutrition) and ozone-sterilized tap water were fed to the animals. All animal 
experiments were conducted according to the guidelines for the care and use of 
laboratory animals set by The Chinese University of Hong Kong. 
Mice were kept in a humidity- and noise-controlled room under a 
14:10 hour light-dark cycle with the dark period from 1:00 am to 11:00 am. One 
male ICR mouse or RARE-hsp-lacZ mouse was paired up with one female ICR 
mouse for 2 hours from 9:00 am to 11:00 am. At the end of the mating period, 
successful mating was confirmed by the presence of a copulation plug in the 
vagina of the female mouse. Fertilization was assumed to have taken place at 
10:00 am, which was assigned as gestation day 0 (EO). 
All animal experiments, except the X-gal staining of RARE-hsp-lacZ 
embryos described in section 3.3.3, were performed with embryos of pure ICR 
strain (offspring of ICR male and ICR female). RARE-hsp-lacZ embryos refer to 
the offspring of RARE-hsp-lacZ male mouse and ICR female mouse. Hence, 
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RARE-hsp-lacZ embryos were heterozygous for the RARE-hsp-lacZ transgene. 
2 .2 BISDIAMINE PREPARATION 
N,N'-bis(dichloroacetyl)-l,8-octamethylenediamine (Bisdiamine, PI 
Chemicals) was suspended in peanut oil {Sigma) in glass containers to make up 
stock suspensions of 50 mg/ml, 100 mg/ml, 150 mg/ml or 200 mg/ml. 
Suspensions were sonicated and vortexed vigorously for 4 hours respectively to 
yield a viscous milky mixture. The suspension was stored at room temperature. 
2 .3 ALL-TRANS RETINOIC ACID PREPARATION 
To prepare RA as standards for RA-responsive cell line (refer to 
section 3.3.4) or supplements for metanephric explant culture (refer to section 
4.3.1), 50 mg of diW-trans retinoic acid {Sigma) was dissolved in 1.66 ml of 
dimethyl sulfoxide (DMSO, Sigma) to make up a 100 mM stock solution under 
sterile condition in a class II biological safety cabinet under dim light to prevent 
photoisomerizaton. The stock solution was divided into 15 [i\ aliquots in 
microfuge tubes, which were gassed with nitrogen, sealed with parafilm and 
wrapped in aluminum foil. The tube was then snap frozen in liquid nitrogen and 
stored at -80°C. 
2.4 EMBRYO DISSECTION 
At the desired gestation day, the pregnant mouse was sacrificed by 
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cervical dislocation. The abdominal wall was cut open and the uterus was taken 
out from the mouse. The uterus was then cut along the anti-mesenteric side to 
expose the embryos. Embryos were then transferred to ice-cold Leibovitz's L-15 
medium (Gibco) for metanephric explant culture experiments or 
phosphate-buffered saline (PBS) for other experiments. The decidual tissues, 
extra-embryonic membranes, yolk sac and amnion were removed from the 
embryo under a stereo microscope (Stemi SVll , Zesis). 
2 .5 REAL-TIME QUANTITATIVE REVERSE TRANSCRIPTION-
POLYMERASE CHAIN REACTION ( R T - P C R ) 
2.5.1 Sample collection 
Freshly dissected metanephroi or metanephric explants were washed 
with diethylene pyrocarbonate (DEPC)-treated RNase-free ice-cold PBS. The 
sample was then immersed in 10-fold volume of RNAlater RNA stabilization 
reagent (Qiagen) in a microfUge tube. The sample was stored at 4 � C overnight for 
complete penetration of the reagent into the tissue. The next day, the sample was 
transferred to -20°C for storage prior to total RNA extraction. 
2.5.2 Total RNA extraction 
FavorPrep Tissue Total RNA Mini Kit {Favorgen) was used to extract 
total RNA from tissue samples. Extraction was performed according to the 
manufacturer's protocol. In brief, RNAlater RNA stabilization reagent was first 
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withdrawn from the sample. FARE Buffer at a volume of 350 \i\ was then added. 
The sample was lysed by vigorous vortexing. The lysate was passed through a 
Filter Column by centrifiigation at 14,000 revolutions per minute (rpm) for 2 
minutes. Subsequently, the clear lysate was mixed with 350 |il of 70% ethanol in 
DEPC-treated water by vortexing. The mixture was transferred to a FARB Mini 
Column and centriftiged at 14,000 rpm for 1 minute. With the flow-through 
discarded, 500 of Wash Buffer 1 was added to the RNA-bound FARB Mini 
Column and centrifiiged for 14,000 rpm for 1 minute. After that, the FARB Mini 
Column was washed twice with 700 p.! of Wash Buffer 2 at 14,000 rpm for 1 
minute each. After discarding the flow-through, the column was dried by further 
centrifiigation at 14,000 rpm for 3 minutes. The FARB Mini Column was then 
transferred to a new microfUge tube. DEPC-treated water at a volume of 40 |al was 
added to the center of the membrane in the column and incubated for 1 minute. 
Finally, the total RNA was eluted into the microfUge tube by centrifugation at 
14,000 rpm for 2 minutes. The concentration of total RNA was quantified by a 
spectrophotometer (GeneQuant RNA/DNA Calculator, Pharmacia Biotech) at the 
wavelength of 260 nm. The extracted total RNA was stored at -80°C. 
2.5.3 Reverse transcription 
High Capacity cDNA Reverse Transcription Kit {Applied Biosystems) 
was used to synthesize cDNA from the total RNA extracted from the metanephric 
samples. Reverse transcription was performed according to the manufacturer's 
protocol. Total RNA at a weight of 0.5 |ig was mixed with the reaction master mix 
to make up a 10 reaction mixture according to the recipe in Table 2.1. Reverse 
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transcription was performed in a thermal cycler (CI000 Thermal Cycler, BioRad) 
at 25°C for 10 minutes, 37°C for 120 minutes (reverse transcription) and then 
85°C for 5 seconds (denaturation of reverse transcriptase). The cDNA synthesized 
was stored at -20°C. 
Table 2.1 Composition of the master mix for cDNA reverse transcription. 
j “ •' 
Components Amount 
lOx RT buffer Ij^ 
25x dNTP mix (100 mM) 0.4 |il 
lOx RT random primers 1 }il 
MultiScribeTM reverse transcriptase 0.5 |il 
RNase inhibitor 0.5 jil 
RNA sample 0.5 [ig 
DEPC-treated water Adjusted to a total volume of 10 jil 
2.5.4 Polymerase chain reaction 
To quantify the expression level of target genes in the synthesized 
cDNA of each metanephric sample, the 7900HT ABI Fast Real Time Polymerase 
Chain Reaction (PCR) system {Applied Biosystems) was used. The cDNA was 
first subjected to 10-fold dilution with DEPC-treated water and then mixed with 
the reaction master mix to make up a 5 |al reaction mixture according to the recipe 
in Table 2.2. Various sets of forward and reverse primers for different target genes 
were used (refer to section 3.3.6 and Table 3.3). Absolute quantification of gene 
expression level was achieved by including a set of external standards of known 
quantity as template for each target gene (refer to section 2.5.5). Each sample was 
amplified in triplicate to ensure accurate quantification. Equivalent volume of 
DEPC-treated water to replace the cDNA template was included in each set of 
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reaction with different target genes as the negative control. PGR was performed 
on a 384-well plate (Applied Biosystems). 
The PGR conditions began at 50°C for 2 minutes, followed by 95°C 
for 10 minutes to activate the DNA polymerase. After that, 40 cycles of 
amplification, consisting of denaturation at 95°C for 15 seconds and 
annealing/extension at 58°C for 1 minute, were carried out. To ensure specificity 
of the PCR product, a dissociation stage was introduced after completion of PCR. 
The dissociation stage started at 95°C for 15 seconds, and then 60°C for another 
15 seconds. The temperature was slowly ramped to 95°C for 15 seconds. The 
amplification data was analyzed by Sequence Detection Systems Software version 
2.3 {Applied Biosy stems) to quantify expression of target genes. 
Table 2.2 Composition of the master mix for polymerase chain reaction. 
Components Amount 
iTaqTM SYBR® Green Supermix with ROX (Bio-Rad) 2.5 
400 ^M forward primer {Invitwgen) 0.125 |il 
400 fiM reverse primer (Invitwgen) 0.125 |il 
10-fold diluted cDNA Ijd 
DEPC-treated water 1.25 |il 
Total volume 5 |il 
2.5.5 Preparation of DNA standards 
Serially-diluted genomic DNA (gDNA) was used as standards for 
real-time RT-PCR (Yun et al., 2006). The gDNA was prepared from El2.0 whole 
mouse embryo of ICR strain using the FavorPrep Tissue Genomic DNA 
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Extraction Mini Kit {Favorgen) according to the manufacturer's protocol. Briefly, 
El2 whole embryo was dissected out in PBS. About 20 mg of whole embryo 
tissue was transferred to a microfUge tube. FATGl Buffer at a volume of 200 |il 
was then added. The sample was grinded into small pieces by a micropestle. After 
addition of 20 |il of Proteinase K (10 mg/ml), the mixture was mixed thoroughly 
by vortexing. The sample was then incubated at 60°C for 1 hour until complete 
lysis of the tissue. After incubation, 200 \i\ of FATG2 Buffer was added to the 
sample mixture and further incubated at 70°C for 10 minutes. Subsequently, the 
sample was mixed with 200 |xl of absolute ethanol by vortexing. The mixture was 
then transferred to a FATG Mini Column, which was fitted into a collection tube, 
and centrifiiged for 1 minute at 14,000 rpm. With the flow-through discarded, the 
FATG Column was washed with 500 jil of W1 Buffer by centrifugation for 1 
minute at 14,000 rpm. The column was washed again with 750 jol of Wash Buffer 
by centrifugation for 1 minute at 14,000 rpm. After discarding the flow-through, 
the FATG Mini Column was dried by further centrifugation for 3 minutes at 
14,000 rpm. The column was transferred to a new microfUge tube. DEPC-treated 
water at a volume of 200 j^ l was added to the center of the membrane of the 
column. After 3 minutes of incubation, the column was centrifuged for 2 minutes 
at 14,000 rpm to elute the total gDNA. The concentration of gDNA was quantified 
by a spectrophotometer at the wavelength of 260 nm. The gDNA was stored at 
-20°C. The gDNA was subjected to 3-fold serial dilution with DEPC-treated water 
to obtain a set of external standards ranging from 1 ng to 27 ng for real-time 
RT-PCR. 
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2 .6 TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE-MEDIATED 
dUTP NICK-END LABELING ( T U N E L ) STAINING 
2.6.1 Fixation, dehydration and embedding 
El2.0 embryos were dissected out in ice-cold PBS and fixed in freshly 
prepared 4% paraformaldehyde {Sigma) in PBS at 4°C for 24 hours. After fixation, 
embryos were washed with distilled water for 15 minutes. Each embryo was cut 
into halves at the level just posterior to the forelimbs. The lower portion of the 
embryo, where the metanephros resides, was kept for fiirther procedures. They 
were dehydrated serially in 70%, 80% and 95% ethanol, each for 15 minutes. 
Subsequently, embryos were dehydrated twice in 100% ethanol, each for 10 
minutes. After dehydration, embryos were cleared in xylene twice for 7 minutes 
each. For wax infiltration, each embryo was transferred to a glass embedding 
mould filled with molten Fibrowax {BDH) at 60°C with 3 changes of wax in 1 
hour. The orientation of the embryo was adjusted with a pair of forceps such that 
the kidney would be sectioned at transverse plane. The wax infiltrated embryo 
sample was left at room temperature for solidification. The resulting wax block 
was kept at room temperature until sectioning. 
For cultured metanephric explants (refer to section 4.3.1), they were 
washed in ice-cold PBS once and fixed in fresh 4% paraformaldehyde at 4°C for 
24 hours. After fixation, the explants were washed thoroughly in PBS. The teflon 
membrane with the metanephric explants growing on top was cut out from the 
plastic holder of the culture insert using a pair of 1 ml syringe fitted with 30G 
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needle. The metanephric explants on the membrane were then washed with water 
and dehydrated serially in 70% ethanol for 10 minutes, 80% and 95% ethanol for 
5 minutes each and twice in 100% ethanol for 4 minutes each. After dehydration, 
the sample was cleared in xylene twice for 4 minutes each. For wax infiltration, 
each explant attached to the membrane was transferred to a plastic embedding 
mould filled with molten Fibrowax at 60°C with 3 changes of wax in 30 minutes. 
Subsequently, explants with the membrane in molten wax were left at room 
temperature for solidification. 
2.6.2 Microtome sectioning 
Solidified wax block was trimmed and attached to an embedding 
cassette, which was then mounted to a rotary microtome {Leica) for sectioning. 
The embedded tissue in the wax block was serially sectioned at a thickness of 7 
|im to form a ribbon of paraffin sections. The sections were spread out in a water 
bath at 40°C and then transferred onto a SuperFrost Plus microscopic slide 
(Menzel-Glaser) in serial manner. The slide was dried on an electrothermal slide 
drying bench (Barnstead International) at 37°C and stored in a desiccator at room 
temperature until use. 
2.6.3 TUNEL staining 
Slides with serial paraffin sections of whole embryo or metanephric 
explants were first melted on the electrothermal slide drying bench at 60°C for 1 
minute. Slides with molten wax were then cooled down to room temperature for 
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another minute. Slides were placed in a coplin jar and de-waxed by washing with 
xylene for 3 times, each for 5 minutes. Re-hydration was carried out by washing 
the slide twice in 100% ethanol, followed by 95%, 80% and 70% ethanol (each 
for 5 minutes). Subsequently, hydrated slides were washed with water for 1 
minute, and then with PBS for 5 minutes. The endogenous peroxidase in tissues 
was quenched by incubating with 3% H2O2 in PBS for 5 minutes at room 
temperature. Slides were then rinsed with PBS for 3 times, each for 2 minutes. 
After re-hydration and quenching of endogenous peroxidase, TUNEL 
staining was performed with the ApopTag® Plus Peroxidase In Situ Apoptosis 
Detection Kit (Chemicon) according to the manufacturer's protocol with slight 
modifications. First, slides were incubated with Equilibration Buffer for 1 minute 
at room temperature. With excess Equilibration Buffer being removed, Working 
Strength TdT (terminal deoxynucleotidyl transferase) Enzyme was applied to the 
slide. Slides were then covered with plastic cover-slips and incubated in a 
humidified slide chamber for 1 hour at 37°C. After that, the reaction was stopped 
by putting the specimen in a coplin jar containing Working Strength Stop/Wash 
Buffer for 10 minutes at room temperature. The slide was washed with 3 changes 
of distilled water, followed by another 3 changes of PBS (each for 1 minute). With 
the specimen washed thoroughly, Anti-Digoxigenin (DIG)-Peroxidase was applied 
to the slide. Covered with plastic slips, slides were incubated in a humidified 
chamber for 30 minutes at room temperature. At the end of incubation, the 
specimen was washed in Tris-buffered saline (TBS), which consisted of 50 mM 
Tris-base and 0.8% NaCl at pH7.5, for 4 times with 2 minutes each. 
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To develop colour, slides were incubated with 100 |ag/ml 3,3’ 
diaminobenzidine (DAB) substrate with 0.01% H2O2 in TBS at room temperature. 
Depending on signal intensity, incubation time could range from 15 minutes to 1 
hour. Upon achievement of optimal intensity, slides were washed in running tap 
water for at least 5 minutes to stop the enzymatic reaction. After that, the slide 
was counterstained with 0.5% methyl green for 1 minute. They were then washed 
briefly in tap water. Dehydration was carried out by placing the slide in 70%, 80%, 
95% and 100% ethanol for 1 minute in each step. After two additional wash in 
100% ethanol for 5 minutes each, the specimen was cleared by xylene for 3 times 
(2 minutes each). Finally, slides were mounted in Permount {Fisher Chemicals). 
Slides were examined and images were captured under an inverted 
microscope (Axiophot 2, Zesis) mounted with a SPOT digital camera {SPOT 
Imaging Solutions). To quantify the number of apoptotic nuclei in the 
metanephros in the embryo or in the metanephric explant, the number of apoptotic 
nuclei per sectional area of the metanephros was counted using the Stereo 
Investigator system {MBF Bioscience). A positive signal was defined by the 
observation of darkly-stained apoptotic bodies found within a single cell, which 
was counterstained by methyl green. To avoid counting signals from the same 
apoptotic nuclei across adjacent sections, quantification was performed 1 in every 
3 sections covering the entire metanephros. 
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3.1 INTRODUCTION 
3.1.1 Time and dose responses to bisdiamine-induced renal 
malformations 
As mentioned in section 1.2.4, administration of bisdiamine to 
pregnant rats and hamsters was found to induce a spectrum of congenital 
malformations in the fetuses, such as defects in the face, heart, eye, skeleton, 
forelimb, lung, diaphragm and spleen (Taleporos et aL, 1978; Kilbum et al., 1982; 
Oster et al., 1983; Binder, 1985; Tasaka et al., 1991). In addition to the above 
defects, renal malformations were also observed in fetuses treated with specific 
dose of bisdiamine administered at certain time points of gestation. In particular, 
Taleporos et al. (1978) demonstrated that hydronephrosis, ftised kidneys and 
ectopic kidneys could be induced in rats. It was found that these malformations 
were frequently observed in rat fetuses whose mother was treated with a single 
dose of 200 mg of bisdiamine at E l l , E12 or E13 (corresponds to E9 to E l l in 
mice) by oral gavage. When the treatment time was shifted earlier to ElO, the 
incidence of the above mentioned renal malformations was drastically reduced. 
Oster et al. (1983) reported similar results. Hydronephrosis was most frequently 
observed in rat fetuses when two bisdiamine doses of 100 mg/day of bisdiamine 
were given to pregnant rats at ElO and E l l . Renal agenesis, the most severe type 
of renal malformation, has also been observed in bisdiamine-treated hamster 
fetuses (Binder, 1985). When bisdiamine at the dose between 1.5 to 4 g/kg was 
administered to pregnant hamsters at E9 (corresponding to ElO in mice), about 
5% of the fetus demonstrated renal agenesis. Although these studies illustrated 
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that the kidney is prone to bisdiamine-induced malformations, the mechanism of 
bisdiamine-induced renal malformations remains largely unresolved. As recent 
studies suggested that bisdiamine suppressed the process of RA synthesis through 
inhibition of RALDHs (Mey et al., 2003; Clugston et al., 2010; Amory et al., 
2011), it is possible that bisdiamine-induced renal malformations could be linked 
to RA deficiency. 
3.1.2 Methods to detect endogenous RA in embryonic tissues 
To study whether bisdiamine can induce RA deficiency in the embryo, 
techniques for quantifying endogenous RA levels in embryonic tissues are 
required. One common method involves the use of high pressure liquid 
chromatography (HPLC). The method has been used to quantify RA in embryos 
of mouse (Sakhi et al., 1998) and chick (Maden et al., 1998), as well as RA in 
other organs (Pappas et al., 1993). One advantage of using HPLC to detect 
endogenous RA is that it is a quantitative method which can measure the exact 
amount of RA in the sample. Besides RA level, the amount of other retinoids, 
such as diW-trans retinol and retinyl palmitate, can also be determined by HPLC 
using a single sample. Although the sensitivity of HPLC is not high enough to 
quantify RA content in early stage embryos, this method can be used to detect RA 
in mouse embryos of El 0.0 or later. 
Another method to detect RA in the whole embryo involves the use of 
transgenic technique. In a reporter construct, the RARE of RARp was cloned into 
the promoter region of a LacZ reporter gene. This transgene has been used to 
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generate several RARE-LacZ transgenic mouse lines (Reynolds et al., 1991; 
Rossant et aL, 1991; Balkan et al., 1992). In the presence of RA, the activated 
RAR/RXR heterodimers will bind to the RARE and cause transcriptional 
activation of the LacZ gene, which encodes the p-galactosidase enzyme. The 
expression of P-galactosidase can be determined by its enzymatic activity in 
converting the substrate, 5-bromo-4-chloro-3-indolyl P-D-galactopyranoside 
(X-gal), into a blue colored product. Expression of the transgene in embryos has 
been reported to closely mimic the expression of the RAR/3 gene. Thus, the 
transgenic mouse lines can be used to determine the relative level and pattern of 
RA signaling in the embryos. 
Other than the generation of transgenic mouse lines, the RARE-LacZ 
reporter construct has also been transfected into the F9 teratocarcinoma cell line 
for detection of picomolar level of RA in small tissues (Wagner et al., 1992; 
McCaffery & Drager, 1994). Similar to the RARE-LacZ mouse, (3-galactosidase 
expresses dose-dependently with the RA level in the culture medium, which can 
be detected by X-gal staining. The cell line has been widely used to detect RA 
content in various embryonic tissues, such as the spinal cord and limb buds. It can 
also be used to measure the rate of RA synthesizing and degradation activity (Mey 
et al,, 2001). Given its high sensitivity, the RA-responsive cell line would be a 
good tool to quantify RA content in tiny embryonic tissues such as the 
metanephros. 
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3.2 EXPERIMENTAL DESIGN 
The aim of this chapter was to set up a bisdiamine-induced renal 
agenesis mouse model that mimics the RA-deficient condition in the RA-induced 
renal agenesis mouse model. 
Time- and dose-response studies were first carried out to determine the 
optimal condition to induce renal malformations, especially renal agenesis, by 
bisdiamine. Based on the results of previous experiments on rats and hamsters as 
described in section 3.1.1, it was speculated that development of the kidney is 
likely to be most susceptible to bisdiamine challenge at around E9.0 to El 1.0 in 
mouse. Thus, time points of E9.0, El0.0 and El 1.0 were chosen for the 
time-response study. In considering the dosage to start with, up to 4 g/kg 
bisdiamine was administered to the hamster to induce renal agenesis in the fetus 
(Binder, 1985), a comparable dose is likely to be required to induce renal agenesis 
in the mouse. Indeed, bisdiamine at a dosage of 3.2 g/kg has been administered to 
pregnant mice to induce facial anomalies in the fetuses (Igawa, 1986). Thus, 3 
g/kg bisdiamine was chosen as the initial dose for the time-response study. For the 
method of delivery, instead of oral gavage, intraperitoneal injection was employed 
as the embryo could be more directly and effectively exposed to the drug. After 
finding out the optimal time to induce renal agenesis in the fetus, a dose-response 
study was performed to determine the most effective dose to induce renal agenesis. 
Dosages of 1, 2, 3 and 4 g/kg were tested. In the time- and dose-response studies, 
near-term fetuses were examined for resorption frequency, changes in various 
growth parameters, as well as renal and non-renal malformations. 
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After determining the optimal time and dose of bisdiamine injection to 
induce renal agenesis, the pathogenic mechanism was studied. To confirm that RA 
deficiency was induced by bisdiamine, the RA concentration in the embryo was 
determined at 6, 12, 24 and 48 hours after bisdiamine treatment by HPLC. In 
addition to overall RA content, changes in the pattern of RA signaling in 
bisdiamine-treated embryos were studied at the above mentioned time points 
using the RARE-hsp-LacZ transgenic mouse embryos (Rossant et al., 1991). To 
confirm that there was RA deficiency in the early metanephros, the RA content in 
the metanephric rudiment at El 1.0 and El2.0 was determined using a 
RA-responsive cell line (Wagner et al., 1992). 
Concomitant with RA deficiency, fulminant apoptosis was observed in 
the metanephros of the RA-treated embryo (Tse et al., 2005). Thus, apoptotic 
nuclei in bisdiamine-treated metanephros were stained by the TUNEL method to 
determine if RA deficiency would indeed lead to an increase in apoptosis. 
Furthermore, the expression level of genes critical for renal development, 
including c-Ret and Gdnf was examined. 
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3.3 MATERIALS AND METHODS 
3.3.1 Time and dose responses to bisdiamine administration 
Bisdiamine was prepared as described in section 2.2. To determine the 
developmental stage specificity of the effect of bisdiamine on kidney development, 
3 g/kg bisdiamine from 150 mg/ml stock suspension was intraperitoneally injected 
into pregnant ICR mice at E9.0, ElO.O and Ell.O with a 1 ml syringe fitted with 
19 gauge (G) needle. Mice injected with equivalent volume of vehicle (peanut oil, 
20 |xl/g body weight) at ElO.O served as the control. At El8.0, pregnant mice were 
sacrificed by cervical dislocation. Fetuses were delivered by caesarean section. 
The number of implantations and resorption sites was counted. Fetuses were then 
weighed. The head length and crown-rump length of each fetus were measured 
with an eyepiece graticule under a stereomicroscope (Stemi SVll , Zesis). 
External malformations were noted. The eyeball was dissected out to examine its 
size. The mouth was open to examine for cleft palate. The thorax and abdomen 
were opened to examine for malformations of internal organs, including the 
kidneys. 
After figuring out that ElO.O was the optimal time point for inducing 
the highest frequency and severity of renal malformations in fetuses by 
bisdiamine, pregnant ICR mice were injected with 1 ,2 ,3 and 4 g/kg bisdiamine at 
ElO.O to determine the optimal dose for inducing renal malformations. Mice 
treated with various dosages of bisdiamine received equivalent volume of stock 
suspensions (20 |al/g body weight) by adjusting the bisdiamine stock 
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concentration for different injection doses (stock concentrations of 50, 100, 150 
and 200 mg/ml for doses of 1, 2, 3 and 4 g/kg respectively). Pregnant mice 
injected with equivalent volume of vehicle (peanut oil) at ElO.O served as the 
control. Similar to the time-response study described above, El8.0 fetuses were 
harvested and subjected to measurement of the body weight, head length and 
crown-rump length. Renal and non-renal malformations induced by various 
dosages of bisdiamine were examined. 
3.3.2 Quantification of RA and retinol content in whole embryo by high 
pressure liquid chromatography (HPLC) 
3.3.2.1 Bisdiamine injection and sample collection 
At ElO.O, 3 g/kg bisdiamine (150 mg/ml stock suspension) or 
equivalent volume of vehicle (control) was injected intraperitoneally into pregnant 
ICR mice. At E10.25, E10.5, Ell.O and E12.0, i.e. 6, 12, 24 and 48 hours after 
injection, each litter of embryos maternally treated with vehicle or bisdiamine was 
dissected out in ice-cold PBS in the dark under dim yellow light as described in 
section 2.4. Embryos were washed thoroughly with 3 changes of PBS. Each litter 
of embryos was pooled as one sample and transferred to a 5-ml round-bottom tube 
with residual PBS being removed. The tube was gassed with nitrogen, sealed with 
parafilm and wrapped in aluminum foil before being snap frozen in liquid 
nitrogen. Samples were stored at -80°C and subjected to RA quantification within 
a week. For each treatment group, 3-4 litters of embryos were collected. 
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3.3.2.2 Chromatographic system 
HPLC was used to quantify RA and retinol content in whole embryos. 
The Alliance® HPLC System with a 2996 photodiode array detector (Waters) was 
used. Column temperature was controlled by the Alliance column heater. 
Instrument control, and data acquisition and processing were performed with 
Empower 2 software (Waters). Chromatography was performed on a 4.6 x 150 
mm SunFire CI8 Column containing 5 [im particles (Miters). The column was 
protected by a SunFire CI8, 5 |im, 4.6 x 20 mm Guard Column {Waters). 
3.3.2.3 Preparation of standards 
A\\-trans RA {Sigma), dX\-trans retinol {Sigma) and acitretin (Fluka) 
were dissolved in absolute ethanol to make up stock solutions at concentration of 
500 jig/ml. The tube was gassed with nitrogen, sealed with parafilm and wrapped 
in aluminum foil before storage at -20°C. The concentration of the stock solution 
was determined by a spectrophotometer (Lambda Bio 20, Perkin-Elmer) using 
Beer's Law (Absorbance = molar extinction coefficient x path length x 
concentration). The molar extinction coefficients and equivalent wavelengths are: 
45300 and 350 nm for RA; 48305 and 325 nm for retinol; and 41400 and 361 nm 
for acitretin (Gundersen & Blomhoff, 2001). 
Calibration standards of 1, 2, 5 and 10 ng/ml for RA and retinol were 
prepared by dilution of the stock solution with absolute ethanol. The standards 
were subjected to HPLC analysis (refer to section 3.3.2.5). The peak of each 
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retinoid was determined by injecting the retinoid alone to determine the 
corresponding retention time. Calibration curves were constructed by plotting the 
peak area (y-axis) against concentration (x-axis). 
3.3.2.4 Extraction of embryo samples 
Extraction of embryo samples was conducted according to published 
protocol (Suh et al,, 2006) with slight modifications. The extraction procedure 
was performed in the dark under dim yellow light to prevent photoisomerization 
of retinoids. Each litter of embryos was transferred to a 15 ml centrifuge tube with 
2 ml of ice-cold PBS added with 20 ng of acitretin (a type of retinoid) in absolute 
ethanol as an internal standard for subsequent calculation of recovery ratio (refer 
to section 3.3.2.6). The embryo was homogenized by sonication at 90% amplitude 
for 10 seconds using a sonicator (Vibra-Cell VCXI30, Sonics & Materials, Inc.), 
followed by 30 seconds of cooling. The sonication procedure was repeated for 6 
times to ensure complete homogenization. Ten microliters of the homogenate was 
used for determination of protein concentration (refer to section 3.3.2.7). After 
that, 1.4 ml of acetonitrile (5Z)//):butanol {BDH) (1:1, v/v) supplemented with 
0.01% butylated hydroxytoluene {Sigma) was added to the homogenate. The 
mixture was vortexed for 1 minute, followed by addition of 1.2 ml of saturated 
dipotassium phosphate (1.3 kg/L, USB). The mixture was vortexed for 30 seconds 
and centrifuged at 4,000 g for 10 minutes at 4°C for separation of the aqueous and 
organic phases. The upper organic layer was collected and dried by gassing with 
nitrogen. The dried extract was reconstituted by re-dissolving in 500 |il of 
methanol with sonicfication for 1 minute. After that, 500 of PBS was added to 
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the extract solution and was sonicated for another minute. The solution was then 
filtered by passing through a 0.22 |im nylon filter (Quandao). The extracted 
sample was transferred into a recovery vial (Waters) and subjected to the HPLC 
auto sampler for analysis. 
3.3.2.5 Conditions of HPLC 
The HPLC conditions were designed according to published protocol 
(Schmidt et al., 2003) with slight modifications. For elution buffers, Buffer A 
consisted of 40 nM ammonium acetate buffer (pH 5.75, USB) and 100% methanol 
(1:1, v/v) while Buffer B consisted of 100% methanol. The elution gradient was 
generated by mixing different proportions of Buffer A and Buffer B according to 
Table 3.1. The column temperature was fixed at 30°C while the detection 
wavelength was 340 nm. After analysis, the amount of each retinoid in each 
sample was determined by the peak area at the corresponding retention time by 
comparing with the external calibration standards (refer to section 3.3.2.3). 
Table 3.1 HPLC conditions for elution of retinoids. 
Time (min) Flow (ml/min) % of Buffer A % of Buffer B 
0 (U ^ 15 
1 0.8 85 15 
20 0.8 0 100 
22 0.8 0 100 
23 ^ 85 15 
34 85 15 
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3.3.2.6 Recovery of sample 
During the process of extraction, some portion of retinoids in the 
sample could be lost. Thus, to determine the actual retinoids concentrations in the 
sample, the recovery ratio was determined by adding 20 ng of acitretin to the 
sample as an internal standard before extraction. Subsequent to extraction and 
analysis, the recovery ratio was determined by comparing the acitretin peak area 
in the sample with the peak area obtained by direct injection of 20 ng of 
sample-free acitretin. The amount of RA and retinol in each sample was calculated 
with reference to the external calibration standard curves and corrected for the 
recovery ratio. The amount of RA and retinol in each sample was expressed in 
terms of ng per mg of protein. 
3.3.2.7 Bradford protein assay 
The protein concentration in the sample was determined by Bradford 
assay. The sample was diluted in Milli-Q water to a final volume of 800 \il 
Subsequently, 200 of Bradford Reagent (Bio-Rad) was added to the diluted 
sample. The mixture was incubated at room temperature for 10 minutes for 
formation of blue colored product. The absorbance of the mixture was determined 
by a spectrophotometer at the wavelength of 595 nm. A standard curve was 
established by measuring the absorbance of known concentrations of protein 
standards consisted of bovine serum albumin (Sigma) ranging from 0-25 |ag/ml. 
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3.3.3 X-gal staining of RARE-hsp-lacZ embryos 
At El0.0, 3 g/kg bisdiamine (150 mg/ml stock suspension) or 
equivalent volume of peanut oil (vehicle treatment as control) was injected 
intraperitoneally into pregnant ICR mice (mated with RARE-hsp-lacZ male mice). 
At E10.25, E10.5, Ell.O and E12.0, i.e. 6, 12, 24 and 48 hours after injection, the 
control and bisdiamine-treated RARE-hsp-lacZ embryos were harvested in 
ice-cold PBS. Embryos were washed in PBS for three times, each for 5 minutes. 
They were fixed in 0.2% glutaraldehyde in PBS {Sigma) for 15 minutes at 4°C. 
After fixation, embryos were washed in PBS for three times, each for 5 minutes. 
Fixed embryos were stored in PBS at 4°C for up to one week until collection of at 
least three litters of RARE-hsp-lacZ embryos for each treatment group at each 
time point. To ensure identical staining conditions, control and bisdiamine-treated 
embryos of the same time point were subjected to (3-galactosidase staining at the 
same time. The staining solution consisted of 0.04% 5-bromo-4-chloro-3-indolyl 
P-D-galactopyranoside (X-gal, Invitrogen), 10 mM potassium ferricyanide, 10 
mM potassium ferrocyanide, 1 mM magnesium chloride, 0.02% NP40 and 0.01% 
sodium deoxycholate in PBS. Each litter of RARE-hsp-lacZ embryos was 
incubated in 5 ml of staining solution in a 6-well plate {Corning) wrapped with 
aluminum foil for 6 hours at 37°C with gentle shaking. After staining, embryos 
were washed in PBS for three times, each for 5 minutes. They were then fixed in 
4% paraformaldehyde {Sigma) in PBS for overnight at 4°C. After re-fixation, 
embryos were washed in PBS for 3 times. The staining pattern in the embryo was 
observed under a stereo microscope. Images of representative control and 
bisdiamine-treated embryos of each time point were taken by a digital camera 
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(DFC480, Leica). 
3.3.4 Quantification of RA content in metanephroi by the RA-responsive 
cell line 
3.3.4.1 Bisdiamine injection and sample collection 
At ElO.O, 3 g/kg bisdiamine (150 mg/ml stock suspension) or 
equivalent volume of peanut oil (vehicle treatment as control) was injected 
intraperitoneally into pregnant ICR mice. At Ell.O and El2.0, embryos treated 
with bisdiamine or vehicle were dissected out in ice-cold PBS in the dark under 
dim yellow light. The metanephros was dissected out with the aid of a pair of 1 ml 
syringes fitted with 30G needles. Isolated metanephroi were washed thoroughly 
with 3 changes of PBS. Every 8 metanephroi of the same treatment group from 
the same litter were pooled as one sample. Samples were collected from 3-5 litters 
of embryos for each treatment group. The pooled metanephroi were transferred to 
a 1.5 ml micro fuge tube with residual PBS being removed. The tube was gassed 
with nitrogen, sealed with parafilm and wrapped in aluminum foil before being 
snap frozen in liquid nitrogen. Samples were stored at -80°C and subjected to RA 
quantification within a week. 
In parallel to sample collection for RA quantification, some of the 
isolated control and bisdiamine-treated Ell.O and El2.0 metanephroi were 
observed under an inverted microscope (Axiovert 40 CFL, Zeiss). Images were 
taken by a digital camera (DFC 480, Leica) to illustrate the morphology of the 
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metanephros. 
3.3.4.2 Maintenance of the RA-responsive cell line 
The RA-responsive cell-line (Wagner et aL, 1992), derived from F9 
teratocarcinoma cell line that was stably transfected with RARE-/acZ reporter 
constructs, was a gift from Prof. Peter McCaffery. 
All procedures were conducted under sterile condition in a class II 
biological safety cabinet. Sealed plastic ampule {Nunc) containing the 
RA-responsive cells as retrieved from the liquid nitrogen tank and immediately 
thawed in a water bath at 37°C. The ampule with thawed cells was sterilized with 
70% ethanol and cut opened with a heated knife. To dilute the DMSO present in 
the freezing medium, cells once thawed were transferred to a conical tube filled 
with 10 ml of Hanks Balanced Salt Solution (HBSS, Gibco). The cell suspension 
was then centrifliged at 1,500 rpm for 3 minutes. The supernatant was discarded 
while the cell pellet was re-suspended with 5 ml of culture medium. The culture 
medium consisted of Dulbecco's Modified Eagle's Medium (DMEM, Gibco) 
supplemented with 10% fetal bovine serum {Gibco), 2 mg/ml G418 {Sigma), 100 
units/ml penicillin G {Sigma) and 0.1 mg/ml streptomycin {Sigma). The cells in 
fresh medium were then cultured in a 25 cm culture flask {Nunc) in a 5% CO2 
incubator at 37°C. To help adherence of cells to the flask surface, the culture flask 
was pre-incubated with 0.2% gelatin for 10 minutes at 37°C. The gelatin-coated 
flask was washed with HBSS once before addition of cell suspension. 
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When cells reached 70% confluence, they were subjected to subculture. 
To subculture, the culture medium was discarded. Adhered cells were washed with 
5 ml of HBSS. Cells were then detached from the surface of the flask by 
incubating with 2 ml of 0.05% trypsin {Gibco) added with 0.53 mM EDTA for 1 
minute at 37°C. The reaction was stopped by mixing the cell suspension with 2 ml 
of fresh culture medium. The mixture was centrifuged at 1,500 rpm for 3 minutes. 
After discarding the supernatant, the cell pellet was re-suspended in 2 ml of fresh 
culture medium. Approximately 200 [i\ of cell suspension was transferred to a new 
gelatin-coated culture flask filled with 5 ml of culture medium. Cells were further 
cultured in a 5% CO2 incubator at 37°C. 
3.3.4.3 Seeding of cells and addition of samples 
RA-responsive cells grown in the culture flask were detached, 
centrifuged and re-suspended in fresh culture medium as described above (section 
3.3.4.2). The number of cells in the suspension was counted by a hemocytometer. 
Cell suspension at a density of 4x10^ cells per 100 jil of culture medium was 
seeded onto each well of a gelatin-coated 96-well plate (Nunc). Cells were 
cultured in a 5 % CO2 incubator at 37°C for approximately 20 hours to reach 80% 
confluence. 
To quantify RA levels, each metanephroi sample (collected as 
described in section 3.3.4.1) was lysed by pipetting up and down in 99 |il of 
DMEM supplemented with 2 mg/ml G418, 100 units/ml penicillin G and 0.1 
mg/ml streptomycin (devoid of 10% fetal bovine serum) in the dark under dim 
- 5 7 -
Chapter 3: Bisdiamine-induced Renal Malformations 
yellow light. To measure the protein content, 10 |il of the lysate was used for 
Bradford assay (refer to section 3.3.2.7). The remaining 89 |il of lysate was added 
with 10 [i\ of 100% fetal bovine serum and 1 of 5 i^M R115866 in DMEM 
{Johnson and Johnson), a potent Cyp26 enzyme inhibitor, to prevent RA 
degradation by Cyp26 enzymes (Stoppie et al., 2000). Before addition of samples 
to the 96-well plate, the medium in each well of the plate was discarded. 
Metanephroi sample (100 |il) was added to each well. RA standard solutions of 
10.7 M to 10-12 M (100 III), prepared by serial dilution of 100 mM RA stock 
solution (prepared as described in section 2.3) according to Table 3.2, were added 
in triplicate for establishment of a standard curve to determine RA concentrations 
in the sample. After that, the plate was loosely covered with aluminum foil and 
incubated in a 5% CO2 incubator at 37°C for 16 hours to allow transcriptional 
activation of the LacZ gene. 
Table 3.2 Preparation of RA standard solutions by serial dilution. 
Final RA Volume of Volume of Volume of 
concentration RA solution DMSO culture medium 
10 mM 10 111 of 100 mMRA 90 -
1 mM 10 i^l of lOmMRA 90 |il -
500 fiM S O ^ l o f l m M R A - 50 |il 
10 _ (10-5 M)* 20 til of 500 |iM - 980 
10-6 — 10—12 M 10-fold serial dilution with culture medium 
* RA solution in 1% DMSO 
3.3.4.4 X-gal staining 
The expression level of |3-galactosidase, which was governed by the 
concentration of RA present in the medium, was determined by its enzymatic 
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activity in converting X-gal into a blue colored product. After incubation, the 
medium was discarded. Cells in each well were washed briefly once with 100 \i\ 
of PBS. They were then fixed with 1% glutaraldehyde in PBS for 10 minutes at 
room temperature. Each well was washed with 100 |il of PBS for three times. 
Cells in each well were then subjected to X-gal staining by incubating with 100 
of staining solution, which consisted of 2% X-gal, 3.3 mM potassium ferricyanide, 
3.3 mM potassium ferrocyanide and 6 mM magnesium chloride in PBS. After 
incubating at 37°C for 16 hours in the dark, the staining solution was discarded. 
Cells in each well were washed with 100 [i\ of PBS for three times. The intensity 
of the blue colored product in each well (in PBS) was determined by a 
spectrophotometer (Benchmark, Bio-Rad) at the wavelength of 650 nm. The 
stained cells were then kept in 75% glycerol at room temperature. The 
concentration of RA in the metanephroi sample was determined by the standard 
curve established from RA standard solutions. The amount of RA in each sample 
was calculated as pg of RA per j^ g of protein. 
3.3.5 TUNEL staining 
For sample collection, 3 g/kg bisdiamine (150 mg/ml stock suspension) 
or equivalent volume of peanut oil (vehicle treatment as control) was injected 
intraperitoneally into pregnant ICR mice at ElO.O. At El2.0, control and 
bisdiamine-treated embryos were harvested, fixed, dehydrated, wax infiltrated and 
sectioned as described in section 2.6.1 and 2.6.2. 
Serially sectioned El2.0 embryo sample was subjected to TUNEL 
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staining according to the procedure described in section 2.6.3. The number of 
apoptotic nuclei per sectional area of each metanephros was counted as described. 
Six to eight metanephroi in embryos (randomly selected from 3 independent 
litters) of each treatment group were examined. 
3.3.6 Real-time quantitative RT-PCR 
At El0.0, 3 g/kg bisdiamine (150 mg/ml stock suspension) or 
equivalent volume of peanut oil (vehicle treatment as control) was injected 
intraperitoneally into pregnant ICR mice. At El2.00, embryos were harvested in 
DEPC-treated RNase-free ice-cold PBS. The metanephros was isolated with the 
aid of a pair of 1 ml syringes fitted with 30G needle under a stereo micro scope. 
Metanephroi isolated from the same litter of embryos were pooled as one sample. 
Samples were stored in RNAlater RNA stabilization reagent as described in 
section 2.5.1. 
The metanephroi sample was subjected to total RNA extraction, 
reverse transcription and real-time quantitative RT-PCR analysis of c-Ret and 
Gdnf mRNA expression according to the protocol described in section 2.5.2, 2.5.3, 
2.5.4 and 2.5.5. fi-actin, a house keeping gene, was used as the internal control for 
normalization of c-Ret and Gdnf expression. Information of primer pairs for 
various target genes was listed in Table 3.3. Gene expression in metanephroi from 
3-5 litters of embryos was measured for each treatment group. 
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Table 3.3 Information of primers for real-time RT-PCR. 
Corresponding Product 
Gene Primer sequence (5，to 3，） nucleotide of size 
target gene (bp) 
c-Ret Forward: 749-768 127 
TGG CAC ACC TCT GCT CTA TG 
Reverse: 875-856 
GAT GCG GAT CCA GTC ATT CT 
Gdnf Forward: 792-811 131 
TTG CAT TCC TGC TAC AGT GC 
Reverse: 922-903 
GGT GGC TAC CTT CCT CCT TC 
P-actin Forward: 304-323 165 
TGT TAC CAA CTG GGA CGA CA 
Reverse: 468-449 
GGG GTG TTG AAG GTC TCAAA 
3.3.7 Statistical analysis 
The time or dose response of various growth parameters, including 
weight, head length, crown-rump length and head length / crown-rump length 
ratio, to bisdiamine between different treatment groups was compared by 
One-way Analysis of Variance (ANOVA) followed by Bonferroni test. 
Comparison of the frequency of resorption and non-renal malformations in 
various time points or dosages of injection was performed by Chi-square test. For 
renal malformations, fetuses with various degrees of renal malformations were 
classified into 6 grades, from the least severe to the most severe as listed in Table 
3.4. The time or dose response to bisdiamine in inducing renal malformations was 
compared by Jonckheere-Terpstra test. Using the same grading system, correlation 
between the severity of renal malformations and the dose of bisdiamine treatment 
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was determined by Spearman's rank correlation, a non-parametric correlation test. 
In the test, a Spearman's rank correlation coefficient (r^), with values ranging from 
+1 to -1 is generated. A value closes to +1 represents a strong positive correlation 
between the two variables while a value closes to -1 represents a strong negative 
correlation. The statistical significance of the correlation is represented by a 
/>-value. 
Table 3.4 Grading system of renal malformations in E18.0 fetuses. 
Classification of renal malformations Grade 
Two normal kidneys 1 
Unilateral non-agenesis renal malformations ^ 
(contralateral kidney being normal) 
Bilateral non-agenesis renal malformations 3 
Unilateral renal agenesis ^ 
(remaining kidney being normal) 
Unilateral renal agenesis ^ 
(remaining kidney with non-agenesis renal malformations) 
Bilateral renal agenesis 6 
Comparison of the amount of RA and retinol in whole embryos, as 
well as the amount of RA in metanephroi between control and bisdiamine-treated 
groups at each developmental stage was determined by Independent Sample t-test. 
The amount of apoptotic nuclei and mRNA expression levels of c-Ret and Gdnf 
between control and bisdiamine-treated metanephroi were also compared by 
Independent Sample ,-test. All statistical analyses were performed with SPSS 13.0 
software (IBM). The statistical significant level was set at p <0.05. 
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3.4 RESULTS 
The aim of this chapter was to set up a bisdiamine-induced renal 
malformations mouse model that mimics the RA-deficient condition in the 
RA-induced renal agenesis mouse model. First, the optimal time and dose of 
bisdiamine injection to induce renal agenesis in the fetus were determined. With 
the time and dose optimized, RA levels in bisdiamine-treated embryos and 
metanephroi were quantified by three different approaches. After proving that 
bisdiamine could indeed induce RA deficiency in the whole embryo and the 
kidney rudiment, TUNEL assay was carried out to determine if 
bisdiamine-induced RA deficiency resulted in increased apoptosis in the early 
metanephros. Furthermore, expression of genes indispensable for early kidney 
development was studied to provide insight into the pathogenic mechanism. 
3.4.1 Time response to bisdiamine treatment 
For the time-response study, 3 g/kg bisdiamine was administered into 
pregnant ICR mice by intraperitoneal injection at E9.0, ElO.O and Ell.O. The 
frequency of resorption, various growth parameters, renal and non-renal 
malformations were examined in vehicle-treated (control) and bisdiamine-treated 
fetuses at El8.0. 
The general external morphology of fetuses treated with 3 g/kg 
bisdiamine at different time points was shown in Figure 3.1. While control fetuses 
treated with vehicle (peanut oil) at ElO.O demonstrated normal morphology 
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(Figure 3.1 A), the size of bisdiamine-treated fetuses was prominently smaller and 
also exhibited a shortening of the body axis (Figure 3.1B-D). With treatment at 
E9.0 (Figure 3.IB), external malformation such as blunt snout was observed (refer 
to section 3.4.1.3 for details of non-renal malformations). Fetuses treated at ElO.O 
(Figure 3.1C) and Ell.O (Figure 3.ID) also demonstrated open eye. 
3.4.1.1 Bisdiamine administration increased resorption and affected 
various growth parameters of the fetuses 
Bisdiamine treatment was found to increase resorption and affected 
various growth parameters of fetuses. Results were summarized in Table 3.5 while 
statistical analysis was listed in Table 3.6. Data were also presented in Graphs 3.1 
and 3.2. 
For resorption (Graph 3.1), a frequency of 2.99% was observed in 
control fetuses injected with vehicle at ElO.O. When 3 g/kg bisdiamine was 
injected at E9.0, the frequency of resorption increased drastically to 74.32% (p < 
0.001 vs. control). The frequency was significantly (p < 0.001 vs. E9.0) reduced to 
46.91% with treatment at ElO.O, but the figure was still significantly higher than 
that in the control (p < 0.001 vs. control). When bisdiamine was injected later at 
Ell.O, the frequency of resorption further reduced to 5.56%, a value similar to 
that in the control (p = 0.456 vs. control) but significantly lower than those at E9.0 
and ElO.O ( p < 0.001 vs. E9.0; p < 0.001 vs. ElO.O). In summary, a general trend 
was observed regarding bisdiamine-induced resorption: the earlier the time of 
bisdiamine injection, the higher the frequency of resorption. 
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Comparing with the control, bisdiamine treatment significantly 
reduced the weight of fetuses by up to 30% with injection at E9.0 (p < 0.001 vs. 
control), ElO.O (p < 0.001 vs. control) and Ell.O (p < 0.001 vs. control) (Graph 
3.2A). However, no significant difference was found in the weight between 
treatment groups of different injection time points. 
Crown-rump length, which refers to the length from the top of the head 
(crown) to the bottom of the buttock (rump) (Figure 3.2A), is a measurement for 
showing the general growth of the fetus. While the mean crown-rump length in 
control fetuses was 24.52 mm, bisdiamine treatment significantly reduced this 
parameter at different time points of injection (p < 0.001 vs. control for E9.0, 
ElO.O and Ell.O) (Graph 3.2B). In terms of time response, there was a trend that 
the crown-rump length got shorter when bisdiamine was injected at later stage. 
However, statistical significance was only observed between E9.0 and Ell.O (p < 
0.001). 
The head length is a measurement from the tip of the nose to the 
hindbrain (Figure 3.2B). Bisdiamine treatment reduced the head length of fetuses 
by approximately 13% (p < 0.001 vs. control for E9.0，ElO.O and Ell.O) (Graph 
3.2C). However, a time response of the head length was not observed as the value 
of this parameter was similar between fetuses treated at different time points. 
In addition to general reduction in the head length and the crown-rump 
length, the ratio of these two parameters was calculated as a measure of the body 
proportion. The head length / crown-rump length ratio of control fetuses was 
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0.462. Although both parameters were reduced in bisdiamine-treated fetuses, the 
head length / crown-rump length ratio was significantly greater than that in the 
control (p < 0.001 vs. control for E9.0, ElO.O and El 1.0) (Graph 3.2D). The ratio 
was observed to be greater when bisdiamine was injected at later time points. This 
change in the ratio suggested that the body of fetuses treated with bisdiamine was 
generally out of proportion due to a greater reduction in the crown-rump length 
than that in the head length, which implied that besides being smaller in size, they 
specifically exhibited a shortening of the body axis. 
Table 3.5 Effect of 3 g/kg bisdiamine administered at different time points 
on resorption and various growth parameters. 
Treatment groups Control 3 g/kg Bisdiamine 
Time of injection ElO.O E9.0 ElO.O Ell.O 
Number of litters 5 5 6 5 
Number of implantations 67 74 81 72 
65 19 43 68 
Number (%) of live fetuses … … 
^ ) (97.01) (25.68) (53.09) (94.44) 
2 55 38 4 
Number (%) of res orbed implantations ,，，、 
V ) P (2.99) (74.32) (46.91) (5.56) 
Mean weight (g) 1.32 0.99 0.92 0.95 
士 SEM 士 0.01 ±0.03 ±0.01 士 0.01 
Mean crown-rump length (mm) 24.52 19.24 18.66 18.41 
土 SEM 士 0.14 ±0.24 士 0.15 ±0.10 
Mean head length (mm) 11.30 9.80 9.84 9.96 
士 SEM 士 0.06 士 0.08 士 0.06 ±0.04 
Head length / crown-rump length ratio 0.462 0.513 0.528 0.542 
士 SEM 士 0.003 士 0.007 士 0.004 士 0.003 
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Table 3.6 Statistical analysis on the effect of 3 g/kg bisdiamine 
administered at different time points on resorption and various 
growth parameters. 
Resorption 
^ t o e of injection E9.0 ElO.O — Ell.O 
p-value vs. control < 0.001 # < Q.OOf 0.456 
；7-value vs. E9.Q - <0.001^ <0.001^ 
p-value vs. ElO.O - - < 0.001# 一 
Weight 
Time of injection E9.0 ElO.O Ell.O 一 
p-value vs. control <0.001* <0.001* <0.001* 
p-value vs. E9.Q - 0.079 0.666 
厂-value vs. ElO.O - - 0.965 
Crown-rump length 
^ m e of injection E9.0 — ElO.O Ell.O 
-value vs. control <0.001* <0.001* <0.001* 
；7-value vs. E9.0 - 0.009* 
/7-value vs. ElO.O - - 1.000 
Head length 
l ^ e of injection E9.0 ElO.O Ell.O 
尸-value vs. control <0.001* <0.001* <0.001* 
p-value vs. E9.0 - 1.000 
p-value vs. ElO.O - 一 - 0.669 
Head length / crown rump length ratio 
l ^ e of injection E9.0 ElO.O Ell.O 
；7-value vs. control < 0.001 * < 0.001 * <0.001* 
p-value vs. E9.Q - <0.001* 
" ^ a l u e vs. ElO.O | - | - | 0.046* 
# Statistically significant (Chi-square test). 
* Statistically significant (One-way AN OVA followed by Bonferroni test) 
- 6 7 -
Chapter 3: Bisdiamine-induced Renal Malformations 
3.4.1.2 Bisdiamine administration resulted in renal malformations 
Fetuses treated with 3 g/kg bisdiamine at different time points 
exhibited renal malformations including renal agenesis and hypodysplastic 
kidneys that were correctly or ectopically positioned. These renal malformations 
were illustrated in Figure 3.3. Figure 3.3A demonstrated the two normal kidneys 
in a control fetus. A pair of adrenal glands was lying on top of the bean-shape 
kidney. Figure 3.3B showed bilateral renal agenesis in a bisdiamine-treated fetus. 
This is the most severe type of renal malformation with both kidneys being 
missing, but a pair of adrenal glands was still present. Figure 3.3C showed a 
bisdiamine-treated fetus with a pair of ectopic hypodysplastic kidneys. In addition 
to distortion in shape and reduction in size, both kidneys failed to ascend from the 
pelvic region to the lumbar region as in normal kidneys. 
For quantitative analysis, renal phenotypes observed in control fetuses 
and fetuses treated with 3 g/kg bisdiamine at E9.0, El0.0 and El 1.0 were 
categorized according to the grading system listed in Table 3.4. Results were 
summarized in Table 3.7 while statistical analysis was shown in Table 3.8. Data 
were illustrated in Graph 3.3. 
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Table 3.7 Effect of 3 g/kg bisdiamine administered at different time points 
on induction of renal malformations. 
Treatment groups Control 3 g/kg Bisdiamine 
Time of injection ElO.O E9.0 ElO.O Ell.O 
Number of litters 5 5 6 5 
Number of live fetuses examined 65 19 43 68 
Number (%) of live fetuses with two 65 0 0 0 
normal kidneys (100) (0) (0) (0) 
Number (%) of live fetuses with renal 0 19 43 68 
malformations (0) (100) (100) (100) 
0 1 17 5 
Bilateral renal agenesis 
(0) (5.26) (39.53) (7.35) 
Unilateral renal agenesis � ^ ^ 11 
(remaining kidney with 
• (0) (21.05) (6.98) (16.18) 
non-agenesis renal malformations) 
Unilateral renal agenesis 0 0 0 0 
(remaining kidney being normal) (0) (0) (0) (0) 
Bilateral non-agenesis renal 0 14 23 52 
malformations (0) (73.68) (53.49) (76.47) 
Unilateral non-agenesis renal 
0 0 0 0 
malformations 
(0) (0) (0) (0) 
(contralateral kidney being normal) 
Table 3.8 Statistical analysis on the effect of 3 g/kg bisdiamine 
administered at different time points on induction of renal 
malformations. 
Renal malformations 
^Fime of injection E9.0 ElO.O Ell.O 
/?-value vs. control < 0.001* < 0.001* < 0.001* 
/?-value vs. E9.0 - 0.044* 0.853 
p-value vs. ElO.O - - 0.002* 
* Statistically significant (Jonckheere-Terpstra test). 
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In control fetuses, renal malformation was not observed. In contrast, 
all fetuses treated with bisdiamine, regardless of the time point of injection, 
exhibited renal malformations. With injection at E9.0, 5.26% of fetuses 
demonstrated bilateral renal agenesis while 21.05% showed unilateral renal 
agenesis with the remaining kidney exhibiting non-agenesis renal malformations. 
Bilateral non-agenesis renal malformations were observed in 73.68% of fetuses. 
The non-agenesis renal malformations observed were exclusively ectopic 
hypodysplastic kidneys. With injection at ElO.O, bilateral renal agenesis was 
observed in 39.53% of fetuses, which was the highest frequency among the three 
injection time points. Unilateral renal agenesis with the remaining kidney showing 
non-agenesis renal malformations was observed in 6.98% of fetuses while the 
frequency of bilateral non-agenesis renal malformations was 53.49%. Similar to 
injection at E9.0, all non-agenesis renal malformations observed at ElO.O were 
ectopic hypodysplastic kidneys. Only 7.35% of fetuses treated with bisdiamine at 
El 1.0 suffered from bilateral renal agenesis. Majority of the fetuses demonstrated 
bilateral non-agenesis renal malformations (76.47%) while 16.18% of them had 
unilateral renal agenesis with the remaining kidney exhibiting other types of renal 
malformation. In addition to ectopic hypodysplastic kidney, hypodysplastic 
kidney (successfully ascended to the lumbar region) was also observed with 
treatment at El 1.0. 
The frequency and severity of renal malformations at different time 
points of injection were statistically analyzed. Regardless of the time point of 
injection, bisdiamine-treated fetuses demonstrated significantly increased severity 
of renal malformations (p < 0.001 vs. control for E9.0, ElO.O and El 1.0). Renal 
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malformations induced by bisdiamine injection at ElO.O were found to be the 
most severe when compared to that at E9.0 and Ell.O (p < 0.05 vs. E9.0; p < 
0.005 vs. Ell.O). 
To sum up, the highest frequency of bilateral renal agenesis was 
observed in fetuses treated with 3 g/kg bisdiamine at ElO.O. This time point of 
treatment was regarded as most effective in inducing renal agenesis and was 
chosen for the subsequent dose-response study. 
3.4.1.3 Bisdiamine administration resulted in non-renal malformations 
In agreement to previous studies, administration of bisdiamine at 
around mid-gestation induced non-renal malformations, such as defects of the eye, 
thymus and lung. In this section, the time response of the frequency of non-renal 
malformations was studied by morphological observation. Results were 
summarized in Table 3.9 with statistical analysis shown in Table 3.10. Data were 
illustrated in Graph 3.4. In addition to the organs listed in Table 3.9, other organs, 
including the jaw, ear, central nervous system and adrenal glands, were examined 
for malformations but no defect was observed. 
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Table 3.9 Effect of 3 g/kg bisdiamine administered at different time points 
on induction of non-renal malformations. 
Treatment groups Control 3 g/kg Bisdiamine 
Time of injection ElO.O E9.0 ElO.O Ell.O 
Number of litters 5 5 6 5 
Number of live fetuses examined 65 19 43 68 
Number (%) of live fetuses with 0 19 43 46 
eye malformations (0) (100) (100) (67.65) 
Number (%) of live fetuses with 0 19 43 68 
blunt snout (0) (100) (100) (100) 
Number (%) of live fetuses with 0 0 0 14 
cleft palate (0) (0) (0) (20.59) 
Number (%) of live fetuses with 0 9 24 0 
cleft lip (0) (47.37) (55.81) (0) 
Number (%) of live fetuses with 0 5 1 8 
omphalocele (0) (26.32) (2.33) (11.76) 
Number (%) of live fetuses with 0 19 43 58 
imperforate anus (0) (100) (100) (85.29) 
Number (%) of live fetuses with 0 19 43 68 
thymus malformations (0) (100) (100) (100) 
Number (%) of live fetuses with 0 19 43 21 
lung malformations (0) (100) (100) (30.88) 
Number (%) of live fetuses with 0 17 43 68 
diaphragmatic hernia (0) (89.47) (100) (100) 
Number (%) of live fetuses with 0 7 7 0 
hypoplastic spleen (0) (36.84) (16.28) (0) 
Number (%) of male live fetuses with 0 9 27 32 
undescended testes (0) (100) (100) (100) 
Number (%) of live fetuses with 0 19 43 0 
small rib cage (0) (100) (100) (0) 
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Table 3.10 Statistical analysis on the effect of 3 g/kg bisdiamine 
administered at different time points on induction of non-renal 
malformations. 
Eye malformations 
^ ^ e of injection E9.0 ElO.O Ell.O 
；?-value vs. control <0.001* <0.001* <0.001* 
value vs. E9.0 - N/A 0.004* 
；;-value vs. ElO.O - <0.001* 
Blunt snout 
^ i m e of injection E9.0 ElO.O Ell.O 
p-value vs. control < 0.001* < 0.001* <0.001* 
p-value vs. E9.0 - N/A N/A 
/rvalue vs. ElO.O - - N/A 
Cleft palate 
^Time of injection E9.0 ElO.O Ell.O 
p-value vs. control N/A ^ <0.001* 
;?-value vs. E9.0 - N/A 0.031* 
/7-value vs. ElO.O - - 0.001* 
Cleft lip 
^Time of injection E9.0 ElO.O Ell.O 
p-value vs. control < 0.001* <0.001* N/A 
/?-value vs. E9.0 - 0.539 <0.001* 
-value vs. ElO.O - - <0.001* 
Omphalocele 
Time of injection E9.0 ElO.O Ell.O 
p-value vs. control <0.001* 0.217 0.004* 
p-value vs. E9.0 - 0.003* 0.116 
/?-value vs. ElO.O - - 0.076 
Imperforate anus 
l[Tme of injection E9.0 ElO.O Ell.O 
p-value vs. control <0.001* <0.001* <0.001* 
/7-value vs. E9.0 - N/A 0.076 
厂-value vs. EUIO - - 0.008* 
* Statistically significant (Chi-square test). 
Cont'd 
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Table 3.10 Statistical analysis on the effect of 3 g/kg bisdiamine 
administered at different time points on induction of non-renal 
malformations. 
Thymus malformations 
l ^ e of injection E9.0 ElO.O Ell.O 
/7-value vs. control < 0.001* < 0.001 * < 0.001 * 
pvalue vs. E9.0 - N/A N/A 
/7-value vs. ElO.O - - N/A 
Lung malformations 
� i m e of injection E9.0 ElO.O Ell.O 
；7-value vs. control < 0.001 * < 0.001 * < 0.001 * 
p-value vs. E9.0 - N/A < 0.001 * 
p-value vs. ElO.O - - <0.001* 
Diaphragmatic hernia 
Time of injection E9.0 ElO.O Ell.O — 
p-value vs. control < 0.001 * < 0.001* < 0.001 * 
p-value vs. E9.0 - 0.031* 0.007* 
/?-value vs. ElO.O - - N/A 
Hypoplastic spleen 
Time of injection E9.0 ElO.O Ell.O 
p-value vs. control < 0.001* < 0.001 * N/A 
;?-value vs. E9.0 - 0.074 <0.001* 
/?-value vs. ElO.O - - <0.001* 
Undescended testes 
^ m e of injection E9.0 ElO.O Ell.O 
/?-value vs. control < 0.001* < 0.001 * < 0.001* 
/?-value vs. E9.0 - N/A N/A 
/?-value vs. ElO.O - - N/A 
Small rib cage 
Time of injection E9.0 ElO.O Ell.O 
/7-value vs. control < 0.001* < 0.001 * N/A 
尸-value vs. E9.0 - N/A < 0.001* 
/?-valuc vs. ElO.O - - < 0.001* 
* Statistically significant (Chi-square test). 
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Control fetuses did not show spontaneous malformations in any of the 
organ systems examined. In contrast, all bisdiamine-treated fetuses developed 
blunt snout (Figure 3.IB; Graph 3.4B), undescended testes (in male fetuses) 
(Figures 3.3B and 3.3C; Graph 3.4K) and thymus malformations (Graph 3.4G), 
such as thymic agenesis (Figure 3.5B), regardless of the time point of injection. 
Eye malformations (Graph 3.4A) including open eye (Figure 3.4B) and small eye 
ball (microphthalmia), as well as lung malformations (Graph 3.4H) including 
hypoplastic lung (Figure 3.5D) and lung agenesis, were observed in 
bisdiamine-treated fetuses. Malformations of the eye and lung, together with 
imperforate anus (absence of anal opening) (Figure 3.4H; Graph 3.4F) and small 
rib cage (Figure 3.5H; Graph 3.4L) were found in 100% of fetuses treated at E9.0 
and ElO.O, but the frequencies were reduced with injection at Ell.O. Indeed, no 
fetus treated at Ell.O was found to be suffered from small rib cage. Cleft palate 
(Graph 3.4C) was exclusively observed in fetuses treated at Ell.O (20.59%) while 
cleft lip (Figure 3.4D; Graph 3.4D) and hypoplastic spleen (Graph 3.4J) were only 
found in fetuses treated at E9.0 and ElO.O. Omphalocele, in which the intestine 
remained outside of the abdomen (Figure 3.4F), was significantly found in fetuses 
treated at E9.0 (p < 0.001 vs. control) and Ell.O {p < 0.005 vs. control), but not at 
ElO.O (Graph 3.4E). Diaphragmatic hernia (diaphragm with hole) was observed in 
approximately 90% of fetuses treated at E9.0 and all fetuses treated at ElO.O and 
Ell.O (Graph 3.41). 
To sum up, while development of some organs, such as snout, thymus 
and testes, were susceptible to bisdiamine-induced malformations throughout E().0 
to El 1.0, some malformations, such as cleft palate, clcli lip and hypoplastic spleen, 
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had a more narrow time window to the teratogenicity of bisdiamine. 
3.4.2 Dose response to bisdiamine treatment 
In the time-response study, it was found that administration of 
bisdiamine to pregnant ICR mice at ElO.O was able to induce most severe renal 
malformations when compared to treatment at E9.0 and Ell.O. Specifically, 
bilateral renal agenesis was found in 39.53% of bisdiamine-treated fetuses while 
6.98% of the fetuses developed unilateral renal agenesis with the remaining 
kidney exhibiting non-agenesis renal malformations. The time point of ElO.O was 
therefore regarded as the optimal time to induce renal agenesis by bisdiamine. In 
this section, the target was to determine the most effective dose to induce renal 
agenesis. Specifically, 1, 2, 3 and 4 g/kg bisdiamine were intraperitoneally 
injected into pregnant ICR mice at ElO.O. Similar to the time-response study, 
resorption, various growth parameters, renal and non-renal malformations were 
examined in vehicle-treated (control) and bisdiamine-treated fetuses at El 8.0. 
The general external morphology of fetuses treated with different 
dosages of bisdiamine at ElO.O was shown in Figure 3.6. While control fetuses 
treated with vehicle at ElO.O demonstrated normal morphology (Figure 3.6A), the 
size of bisdiamine-treated fetuses was smaller (Figure 3.6B-E). Regardless of the 
dose, blunt snout, open eye and shortened body axis were common features 
observed in bisdiamine-treated fetuses. 
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3.4.2.1 Dose response of resorption and various growth parameters 
The effect of administration of different dosages of bisdiamine at 
ElO.O on resorption and various growth parameters was summarized in Table 3.11 
with statistical analysis shown in Table 3.12. Data were presented in Graphs 3.5 
and 3.6. 
For resorption (Graph 3.5), a frequency of 2.99% was observed in 
control fetuses. Regardless of the dosage, fetuses treated with bisdiamine showed 
significantly higher frequency of resorption when compared to the control (p < 
0.001 vs. control for 1, 2, 3 and 4 g/kg). With increasing dosages of bisdiamine 
from 1 g/kg to 4 g/kg, the frequency of resorption increased from 12.12% to 
72.06%. In particular, fetuses treated with 3 g/kg bisdiamine had a resorption 
frequency of 46.91%, which was significantly lower than the frequency of 72.06% 
in fetuses treated with 4 g/kg. 
The average weight (Graph 3.6A) of control fetuses was 1.32 g. In 
comparing with the control, bisdiamine treatment significantly reduced the weight 
of fetuses (p < 0.001 vs. control for 1, 2, 3 and 4 g/kg). While fetuses treated with 
1 g/kg of bisdiamine had the weight reduced by 21.21%, it was significantly 
higher than that in fetuses treated with 2, 3 and 4 g/kg {p < 0.001 vs. 1 g/kg for 2, 
3 and 4 g/kg). For doses of 2, 3 and 4 g/kg, the average weight was similar 
(approximately 30% reduction when compared to the control) and no statistically 
significant difference was observed between the three doses. 
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For other growth parameters, bisdiamine treatment was found to 
significantly reduce the crown-rump length (Graph 3.6B) and head length (Graph 
3.6C) of the fetus (p < 0.001 vs. control for 1, 2, 3 and 4 g/kg in both parameters). 
For the crown-rump length, the reduction was found to be greater with increasing 
dosages of bisdiamine. The head length / crown-rump length ratio in 
bisdiamine-treated fetuses was significantly increased in comparison to the 
control (p < 0.001 vs. control for 1, 2, 3 and 4 g/kg) (Graph 3.6D). Disproportion 
of the body, i.e. a shortening of the body axis, was most severe in fetuses treated 
with 4 g/kg bisdiamine (p < 0.05 vs. 1 g/kg; p < 0.001 vs. 2 g/kg; p < 0.005 vs. 3 
g/kg). 
Table 3.11 Effect of different dosages of bisdiamine administered at ElO.O 
on resorption and various growth parameters. 
Dose of bisdiamine (g/kg) Control 1 2 3 4 
Number of litters 5 5 4 6 5 
Number of implantations 67 66 57 81 68 
65 58 37 43 19 
Number (%) of live fetuses 
(97.01) (87.88) (64.91) (53.09) (27.94) 
Number (%) of resorted 2 8 20 38 49 
implantations (2.99) (12.12) (35.09) (46.91) (72.06) 
Mean weight (g) 1.32 1.04 0.95 0.92 0.92 
士 SEM ±0.01 士 0.01 士 0.01 士 0.01 ±0.02 
Mean crown-rump length (mm) 24.52 19,43 19.25 18.66 18.09 
士 SEM 士 0.14 士 0.15 士 0.15 士 0.15 士 0.18 
Mean head length (mm) 11.30 10.37 10.06 9.84 10.00 
士 SEM ±0.06 ±0.05 ±0.07 士 0.06 ±0.08 
Head length / crown-rump length 0.462 0.535 0.523 0.528 0.553 
ratio 士 SEM ± 0.003 ± 0.003 ±0.004 士 0.004 士 0.006 
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Table 3.12 Statistical analysis on the effect of different dosages of 
bisdiamine administered at ElO.O on resorption and various 
growth parameters. 
Resorption 
Dose of bisdiamine (g/kg) 1 2 3 4 
/7-value vs. control 0.046# <0.001# < O.QOf <0.001# 
-value vs. 1 g/kg bisdiamine - 0.002浮 <0.001^ < 0.001# 
/?-value vs. 2 g/kg bisdiamine - - 0.166 <0.001 
p-value vs. 3 g/kg bisdiamine - 0.002# 
Weight 
Dose of bisdiamine (g/kg) 1 2 3 4 
p-value vs. control <0.001* <0.001* <0.001* <0.001* 
j9-value vs. 1 g/kg bisdiamine - <0.001* <0.001* <0.001* 
/?-value vs. 2 g/kg bisdiamine - - 1.000 1.000 
/>-value vs. 3 g/kg bisdiamine - 1.000 
Crown-rump length 
Dose of bisdiamine (g/kg) 1 2 3 4 
p-value vs. control <0.001* <0.001* <0.001* <0.001* 
/7-value vs. 1 g/kg bisdiamine - 1.000 0.002* <0.001* 
p-value vs. 2 g/kg bisdiamine - - 0.110 0.001* 
p-value vs. 3 g/kg bisdiamine - 0.444 
Head length 
Dose of bisdiamine (g/kg) 1 2 3 4 
/7-value vs. control <0.001* <0.001* <0.001* <0.001* 
j9-value vs. 1 g/kg bisdiamine - 0.004* <0.001* 0.007* 
p-value vs. 2 g/kg bisdiamine - - 0.141 1.000 
value vs. 3 g/kg bisdiamine - 1.000 
Head length / crown rump length ratio 
Dose of bisdiamine (g/kg) 1 2 3 4 
p-value vs. control <0.001* <0.001* <0.001* <0.001* 
尸-value vs. 1 g/kg bisdiamine - 0.337 1.000 0.045* 
/?-value vs. 2 g/kg bisdiamine - - 1.000 <0.001* 
/?-value vs. 3 g/kg bisdiamine - 0.003* 
# Statistically significant (Chi-square test). 
* Statistically significant (One-way AN OVA followed by Bonferroni test). 
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3.4.2.2 Dose response to bisdiamine in inducing renal malformations 
Similar to the time-response study, renal phenotypes observed in 
control fetuses and fetuses treated with 1, 2, 3 and 4 g/kg bisdiamine at ElO.O 
were categorized according to the grading system listed in Table 3.4. Results were 
summarized in Table 3.13 while statistical analysis was shown in Table 3.14. Data 
were illustrated in Graph 3.7. 
Table 3.13 Effect of different dosages of bisdiamine administered at ElO.O 
on induction of renal malformations. 
Dose of bisdiamine (g/kg) Control 1 2 3 4 
Number of litters 5 5 4 6 5 
Number of live fetuses examined 65 58 37 43 19 
Number (%) of live fetuses with 65 0 0 0 0 
two normal kidneys (100) (0) (0) (0) (0) 
Number (%) of live fetuses with 0 58 37 43 19 
renal malformations (0) (100) (100) (100) (100) 
^ 0 0 1 17 10 
Bilateral renal agenesis , … 
(0) (0) (2.70) (39.53) (52.63) 
Unilateral renal agenesis 
(remaining kidney with 0 0 0 3 1 
non-agenesis renal (0) (0) (0) (6.98) (5.26) 
malformations) 
Unilateral renal agenesis 八 
^ 0 0 0 0 0 
(remaining kidney being � � � � � 
normal) 
Bilateral non-agenesis renal 0 58 36 23 8 
malformations (0) (100) (97.30) (53.49) (42.10) 
Unilateral non-agenesis renal 
malformations 0 0 0 0 0 
(contralateral kidney being (0) (0) (0) (0) (0) 
normal) 
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Table 3.14 Statistical analysis on the effect of different dosages of 
bisdiamine administered at ElO.O on induction of renal 
malformations. 
Renal malformations 
Dose of bisdiamine (g/kg) 1 2 3 ^ 
；?-value vs. control <0.001* <0.001* <0.001* <0.001* 
p-valuevs. Ig/kg - 0.211 <0.001* <0.001* 
/7-valuevs.2g/kg - - 〈 瞧 * < 0 慶 
-value vs. 3 g/kg - - ~ � 斯 
Spearman's rank correlation coefficient (r^ ) +0.682# 
p-\a\ue of Spearman's rank correlation < 0.001 
* Statistically significant (Jonckheere-Terpstra test). 
# Statistically significant (Spearman's rank correlation). 
Renal malformation was not observed in any control fetuses. However, 
all fetuses treated with bisdiamine exhibited renal malformations. With 1 g/kg 
bisdiamine, 100% of the fetuses suffered from bilateral non-agenesis renal 
malformations. The types of malformation included hypoplastic, dysplastic, 
hypodysplastic and ectopic hypodysplastic kidneys. For the dose of 2 g/kg, only 
2.7% of the fetuses had bilateral renal agenesis, whereas the remaining 97.3% 
exhibited bilateral non-agenesis renal malformations. For the dose of 2 g/kg and 
higher, the non-agenesis renal malformation observed was exclusively ectopic 
hypodysplastic kidney. With 3 g/kg of bisdiamine, the frequency of bilateral renal 
agenesis ftirther increased to 39.53% while 6.98% had unilateral renal agenesis 
with the remaining kidney being ectopic hypodysplastic. When the dose was 
further increased to 4 g/kg, the frequency of bilateral renal agenesis reached a 
peak at 52.63% and 5.26% of fetuses suffered from unilateral renal agenesis. 
The frequency and severity of various types of renal malformations 
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induced by different dosages of bisdiamine were statistically analyzed. Regardless 
of the dose of injection, bisdiamine-treated fetuses demonstrated significantly 
increased severity of renal malformations (p < 0.001 vs. control for 1, 2, 3 and 4 
g/kg). Dosages of 3 g/kg (p < 0.001 vs. 1 and 2g/kg) and 4g/kg {p < 0.001 vs. 1 
and 2g/kg) demonstrated greater ability to induce more severe renal 
malformations when compared with lower dosages. Moreover, fetuses treated 
with 4 g/kg bisdiamine had more severe renal malformations than those treated 
with 3 g/kg (p - 0.01 vs. 3 g/kg). 
Analysis by Spearman's rank correlation showed a significant positive 
correlation +0.682, p < 0.001) between the severity of renal malformations 
and the dose of bisdiamine injected. This suggested that more severe renal 
malformations were induced in fetuses treated with higher dosages of bisdiamine. 
With these results, the most effective dosage in inducing renal agenesis 
could be deduced. Although bilateral renal agenesis was most frequently observed 
in fetuses treated with 4 g/kg of bisdiamine, the resorption frequency with this 
dosage was found to be 72.06%. With such a high resorption frequency, the 
number of embryos available for experiments would be very limited if this dosage 
was adopted. The dose of 2 g/kg caused less resorption in fetuses (35.09%). 
However, only 2.7% of fetuses exhibited bilateral renal agenesis. Thus, the dosage 
of 3 g/kg was regarded as the most effective one, with a significant portion of 
fetuses exhibiting bilateral renal agenesis (39.53%), but a lower resorption 
frequency (46.91%) in comparison to the dose of 4 g/kg. 
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In summary, the optimal time point and dosage to induce renal 
agenesis with bisdiamine was found to be 3 g/kg bisdiamine administered at 
ElO.O. These time point and dosage were adopted in subsequent experiments to 
study the pathogenic mechanism of bisdiamine-induced renal malformations. 
3.4.2.3 Dose response to non-renal malformations 
In addition to renal malformations, different dosages of bisdiamine 
were found to affect the frequency of malformation in other organ systems. 
Results of dose response to non-renal malformations were summarized in Table 
3.15, with statistical analysis shown in Table 3.16. Data were illustrated as charts 
inGraph3.8A-3.8K. 
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Table 3.15 Effect of different dosages of bisdiamine administered at ElO.O 
on induction of non-renal malformations. 
Dose of bisdiamine (g/kg) Control 1 2 3 4 
Number of litters 5 5 4 6 5 
Number of live fetuses examined 65 58 37 43 19 
Number (%) of live fetuses with 0 37 37 43 19 
eye malformations (0) (63.79) (100) (100) (100) 
Number (%) of live fetuses with 0 58 37 43 19 
blunt snout (0) (100) (100) (100) (100) 
Number (%) of live fetuses with 0 0 0 0 0 
cleft palate (0) (0) (0) (0) (0) 
Number (%) of live fetuses with 0 13 21 24 2 
cleft lip (0) (22.41) (56.76) (55.81) (10.53) 
Number (%) of live fetuses with 0 0 3 1 2 
omphalocele (Q) (0) (8.11) (2.33) (10.53) 
Number (%) of live fetuses with 0 1 32 43 19 
imperforate anus (0) (1.72) (86.49) (100) (100) 
Number (%) of live fetuses with 0 1 37 43 19 
thymus malformations (0) (1.72) (100) (100) (100) 
Number (%) of live fetuses with 0 29 37 43 19 
lung malformations (0) (50.00) (100) (100) (100) 
Number (%) of live fetuses with 0 45 37 43 19 
diagphragmatic hernia (0) (79.31) (100) (100) (100) 
Number (%) of live fetuses with 0 4 7 7 2 
hypoplastic spleen (0) (6.90) (18.92) (16.28) (10.53) 
Number (%) of male live fetuses 0 28 18 27 7 
with undescended testes (0) (100) (100) (100) (100) 
Number (%) of live fetuses with 0 58 37 43 19 
small rib cage (0) (100) (100) (100) (100) 
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Table 3.16 Statistical analysis on the effect of different dosages of 




Dose of bisdiamine (g/kg) 1 2 3 4 
j9-value vs. control <0.001* <0.001* <0.001* <0.001* 
p-value vs. 1 g/kg bisdiamine - <0.001* <0.001* 0.002* 
/7-value vs. 2 g/kg bisdiamine - - N/A N/A 
p-value vs. 3 g/kg bisdiamine - N/A 
Blunt snout 
Dose of bisdiamine (g/kg) 1 2 3 4 
I I - • I I I ••• _ Ml I • • ！ -• ••• ；'_•',_• • = = a = : = = j = •••Tm.TJ; 
-value vs. control < 0.001* <0.001* <0.001* <0.001* 
/7-value vs. 1 g/kg bisdiamine - N/A N/A N/A 
p-value vs. 2 g/kg bisdiamine - - N/A N/A 
/7-value vs. 3 g/kg bisdiamine - - - N/A 
Cleft lip 
Dose of bisdiamine (g/kg) 1 2 3 4 
；7-value vs. control <0.001* <0.001* <0.001* 0.008* 
；7-value vs. 1 g/kg bisdiamine - <0.001* <0.001* 0.256 
p-value vs. 2 g/kg bisdiamine - - 0.932 < 0.001* 
/7-value vs. 3 g/kg bisdiamine - - - <0.001* 
Omphalocele 
Dose of bisdiamine (g/kg) 1 2 3 4 
p-value vs. control N/A 0.020* 0.217 0.008* 
p-value vs. 1 g/kg bisdiamine - 0.028* 0.243 0.012* 
p-value vs. 2 g/kg bisdiamine - - 0.237 0.764 
p-value vs. 3 g/kg bisdiamine - - - 0.165 
Imperforate anus 
Dose of bisdiamine (g/kg) 1 2 3 4 
/7-value vs. control 0.288 < 0 . 0 0 1 * < 0 . 0 0 1 * < 0 . 0 0 1 * 
；7-value vs. 1 g/kg bisdiamine - <0.001* <0.001* <0.001* 
j9-value vs. 2 g/kg bisdiamine - - 0.013* 0.093 
p-value vs. 3 g/kg bisdiamine - N/A 
* Statistically significant (Chi-square test). 
Cont'd. 
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Table 3.16 Statistical analysis on the effect of different dosages of 
bisdiamine administered at ElO.O on induction of non-renal 
malformations. 
-•• •_ •' ‘ - -__• • ‘ • ‘ ― — ^ ― ^ ― _ - • = = = “ = = = ' • 
Thymus malformations 
Dose of bisdiamine (g/kg) 1 2 3 4 
；7-value vs. omtrol 0.288 <0.001* <0.001* <0.001* 
j9-value vs. 1 g/kg bisdiamine - <0.001* <0.001* <0.001* 
/>-value vs. 2 g/kg bisdiamine - - N/A N/A 
value vs. 3 g/kg bisdiamine - - - N/A 
Lung malformations 
Dose of bisdiamine (g/kg) 1 2 3 4 
j9-value vs. control <0.001* <0.001* <0.001* <0.001* 
/?-value vs. 1 g/kg bisdiamine - <0.001* <0.001* <0.001* 
尸value vs. 2 g/kg bisdiamine - - N/A N/A 
/>-value vs. 3 g/kg bisdiamine - - - N/A 
Diaphragmatic hernia 
Dose of bisdiamine (g/kg) 1 2 3 4 
；?-value vs. control <0.001* <0.001* <0.001* <0.001* 
-value vs. 1 g/kg bisdiamine - 0.002* 0.001* 0.024* 
p-valuG vs. 2 g/kg bisdiamine - - N/A N/A 
尸value vs. 3 g/kg bisdiamine - - - N/A 
Hypoplastic spleen 
Dose of bisdiamine (g/kg) 1 2 3 4 
p-value vs. control 0.031* <0.001* 0.001* 0.008* 
p-value vs. 1 g/kg bisdiamine - 0.074 0.134 0.608 
p-value vs. 2 g/kg bisdiamine - - 0.757 0.418 
/7-value vs. 3 g/kg bisdiamine - - - 0.553 
Undescended testes 
Dose of bisdiamine (g/kg) 1 2 3 4 
;7-value vs. control < 0 . 0 0 1 * < 0 . 0 0 1 * <0.001* < 0 . 0 0 1 * 
p-value vs. 1 g/kg bisdiamine - N/A N/A N/A 
/7-value vs. 2 g/kg bisdiamine - - N/A N/A 
p-value vs. 3 g/kg bisdiamine - - - N/A 
* Statistically significant (Chi-square test). 
Cont'd. 
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Table 3.16 Statistical analysis on the effect of different dosages of 
bisdiamine administered at ElO.O on induction of non-renal 
malformations. 
Small rib cage 
Dose of bisdiamine (g/kg) 1 2 3 4 
；7-value vs. control <0.001* <0.001* <0.001* <0.001* 
p-vahie vs. 1 g/kg bisdiamine - N/A N/A N/A 
p-valuQ vs. 2 g/kg bisdiamine - - N/A N/A 
p-value vs. 3 g/kg bisdiamine - N/A 
* Statistically significant (Chi-square test). 
Control fetuses did not display spontaneous malformations in any 
organ systems examined. For blunt snout (Graph 3.8B), diaphragmatic hernia 
(Graph 3.8H), as well as malformations of the eye (Graph 3.8A), thymus (Graph 
3.8F) and lung (Graph 3.8G), 1 g/kg bisdiamine was only able to induce defects in 
a portion of the fetuses. With increasing dosages of bisdiamine (2 g/kg and higher), 
all fetuses were found to suffer from malformations in these organs. Similar trend 
was observed in the case of imperforate anus (Graph 3.8E). While dosages of 1 
and 2 g/kg of bisdiamine could induce imperforate anus in a portion of the fetuses, 
dosages of 3 and 4 g/kg were able to cause this malformation in all fetuses. In 
general, there was a trend that the frequency of occurrence of the above defects 
increased with increasing dosages of bisdiamine. However, for defects such as 
undescended testes (Graph 3.8J) and small rib cage (Graph 3.8K), malformations 
were observed in all bisdiamine-treated fetuses even at the dose of 1 g/kg, 
suggesting that these defects were relatively more susceptible to 
bisdiamine-induced teratogenesis. For cleft lip (Graph 3.8C), omphalocele (Graph 
3.8D) and hypoplastic spleen (Graph 3.81), a general trend was not noticed. The 
sample size for different treatment groups might have to be increased to determine 
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if there was any dose response in induction of these malformations. 
3.4.3 RA deficiency induced by bisdiamine 
In the time- and dose-response studies, it was found that 
intraperitoneal injection of 3 g/kg bisdiamine at ElO.O to pregnant ICR mice was 
most effective in inducing renal agenesis in the fetuses. These time point and 
dosage were used for subsequent experiments to study the pathogenic mechanism 
of bisdiamine-induced malformations. To determine if bisdiamine caused RA 
deficiency, RA and retinol levels in the whole embryo was first determined by 
HPLC (section 3.4.3.1). Alteration of RA signaling was studied using 
RARE-hsp-LacZ embryos (section 3.4.3.2). Finally, RA levels in the metanephros 
were quantified by the RA-responsive cell line (section 3.4.3.3). 
3.4.3.1 Comparison of endogenous RA and retinol levels in control and 
bisdiamine-treated whole embryos at different time points after 
treatment 
The endogenous RA level between vehicle-treated (control) and 
bisdiamine-treated whole embryos at E10.25, E10.5, Ell.O and E12.0, which 
corresponded to 6, 12, 24 and 48 hours after injection at ElO.O, was compared. 
Results were summarized in Table 3.17 and illustrated in Graph 3.9. 
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Table 3.17 Endogenous RA levels in control and bisdiamine-treated 
embryos at different time points after injection at ElO.O. 
Amount of RA /?-value of 
Developmental Treatment Number , . � ， 
(ng/mg protein) control vs. 
stages groups of litters • . ” . 
^ ^ ^ 士 SEM bisdiamine 
丨•, .•., - ！ I———III. — • “ — ' ' 4 ' • -
Control 4 0.271 ± 0.021 ^ ^^^^ 
E10.25 0.026* 
Bisdiamine 4 0.186 ±0.009 
Control 4 0.241 ± 0.021 ^ ^^^^ 
E10.5 0.002* 
Bisdiamine 3 0.083 db 0.008 
Control 4 0.301 ± 0.020 ^^^^^ 
Ell.O <0.001* 
Bisdiamine 4 0.093 dr 0.004 
Control 3 0.211 ± 0.004 ^ ^^^^ 
E12.0 0.020* 
Bisdiamine 3 0.146 ±0.015 
* Statistically significant (Independent Sample Mest). 
The amount of RA in control embryos varied between 0.2-0.3 ng/mg 
protein from E10.25 to E12.0, while the amount in bisdiamine-treated embryos 
was consistently lower than that in the control throughout this period. As early as 
6 hours post-injection, the amount of RA in El0.25 bisdiamine-treated embryos 
was significantly (p < 0.05) lowered by 31.4% when compared to control embryos. 
The reduction was exacerbated to 65.6% (p < 0.001) at 12 hours post-injection 
and reached the trough with 69.1% reduction (p < 0.05) at 24 hours post-injection. 
The difference in RA levels between control and bisdiamine-treated embryos 
narrowed down to 30.8% at El2.0, which corresponded to 48 hours post-injection. 
The retinol level in control and bisdiamine-treated embryos was 
summarized in Table 3.18 and illustrated in Graph 3.10. As the precursor of RA in 
the RA synthesis pathway, it was speculated that the level of retinol in embryos 
would change following bisdiamine treatment. Indeed, the amount of retinol in 
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bisdiamine-treated embryos was consistently higher than that in the control by 
approximately 10-20% throughout the 4 time points studied, with the difference 
between them reaching a statistically significant level at Ell.O {p < 0.05) and 
E12.0 (p < 0.05), which corresponded to 24 and 48 hours post-injection. 
Table 3.18 Endogenous retinol levels in control and bisdiamine-treated 
embryos at different time points after injection at ElO.O. 
Amount of retinol /7-value of 
Developmental Treatment Number 
(ng/mg protein) control vs. 
stages groups of litters . . . 各 s P 土 SEM bisdiamine 
C o n t r o l 4 2.282 ±0.145 
E10.25 0.121 
Bisdiamine 4 2.750 ±0.277 
Control 4 2.593 ±0.212 
E10.5 0.335 
Bisdiamine 3 2.895 ±0.137 
Control 4 2.173 ±0.118 ^ � + 
Ell.O 0.048* 
Bisdiamine 4 2.582 ± 0.086 
Control 3 2.672 ±0.051 _ 
E12.0 0.023* 
Bisdiamine 3 3.186 ±0.112 
* Statistically significant (Independent Sample ^-test). 
3.4.3.2 Comparison of RA signaling patterns in control and 
bisdiamine-treated embryos at different time points after 
treatment 
In addition to quantification of RA levels by HPLC, the pattern of RA 
signaling was also studied in RARE-hsp-LacZ embryos {RARE-hsp-LacZ male 
mated with ICR female) at E10.25, E10.5, Ell.O and E12.0 that were maternally 
exposed to bisdiamine or vehicle at ElO.O. 
- 9 0 -
Chapter 3: Bisdiamine-induced Renal Malformations 
In the control embryo at E10.25 (Figure 3.7A), RA signaling, 
represented by the presence of the blue colored product of X-gal, was observed at 
multiple sites. In the head, staining was obvious in the telencephalic vesicle, optic 
vesicle, periocular tissues and nasolacrimal groove. Staining was prominent 
throughout the trunk region, including the heart, lateral ridge along the body wall 
and along the neural tube, while staining was not observed in the limb bud and tail. 
For the bisdiamine-treated embryo (Figure 3.7B), staining was observed at similar 
sites. There was no observable difference between the staining intensity of control 
and bisdiamine-treated embryos at El0.25. This was in contrast to the HPLC data 
which showed that the amount of RA in bisdiamine-treated embryos was reduced 
by 31.4% at El0.25. The difference could be explained by the turnover rate of 
P-galactosidase in that the existing LacZ gene product might not yet been 
degraded by 6 hours after treatment. This resulted in a time gap between the RA 
signaling pattern observed in RARE-hsp-LacZ embryos and the actual RA level. 
The control embryo at E10.5 (Figure 3.8A) showed similar pattern of 
staining when compared to the control embryo at El0.25 (Figure 3.7A). However, 
reduction of staining intensity was observed at multiple sites in the El0.5 
bisdiamine-treated embryo. Prominent reduction in staining intensity was 
observed at the telencephalic vesicle, the dorsal and ventral halves of the optic 
vesicle, the periocular tissues and the nasolacrimal groove (Figure 3.8C for 
control and Figure 3.8D for bisdiamine-treated embryo). In the trunk region, 
decrease in staining intensity was observed at the heart, lateral ridge along the 
body wall, neural tube and genital ridge (Figure 3.8E for control and Figure 3.8F 
for bisdiamine-treated embryo). Despite the time gap between RA signaling and 
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RA-controlled P-galactosidase expression, this result was in agreement to the 
HPLC data that the RA level was reduced by 65.6% in bisdiamine-treated 
embryos at El0.5. 
At Ell .0, the RA signaling pattern in the control embryo (Figure 3.9A) 
became more localized, but the sites of expression were still similar to that in the 
El0.5 control embryo (Figure 3.8A). It should be noted that signal was observed 
at the first brachial cleft of the Ell.O control embryo, which was not observed in 
the control embryo at earlier stages. For the bisdiamine-treated embryo, prominent 
reduction or even absence of staining was observed at multiples sites (Figure 
3.9B). In the head region, significant reduction in staining intensity was observed 
at the nasolacrimal groove, the dorsal and ventral halves of the optic vesicle and 
the periocular tissues (Figure 3.9C for control; Figure 3.9D for bisdiamine-treated 
embryo). There was no staining at the first branchial cleft. In the trunk region, 
decrease in RA signaling was observed at the heart, lateral ridge along the body 
wall, neural tube and the genital ridge (Figure 3.9E for control; Figure 3.9F for 
bisdiamine-treated embryo). 
The El2.0 control embryo (Figure 3.1 OA) showed even more restricted 
and localized staining patterns than that observed in the Ell.O control embryo 
(Figure 3.9A). However, the sites of P-galactosidase expression were still similar 
to control embryos at earlier stages. In the El2.0 bisdiamine-treated embryo, 
prominent reduction or absence of RA signaling was again observed (Figure 
3.1 OB). Distinctive decline in staining intensity was observed at the dorsal and 
ventral halves of the optic vesicle (Figure 3. IOC for control and Figure 3.10D for 
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bisdiamine-treated embryo). Staining at the nasolacrimal groove and first 
branchial cleft was completely absent. In the trunk region, reduction in staining 
intensity was observed at the neural tube. Signal was abolished at the lateral ridge 
along the body wall and genital ridge (Figure 3.10E for control and Figure 3.1 OF 
for bisdiamine-treated embryo). According to the HPLC data, the difference in RA 
levels between control and bisdiamine-treated embryos was found to be reduced 
from 69.1% at Ell.O to 30.8% at E12.0. However, in the X-gal staining of E12.0 
RARE-hsp-LacZ embryo, the difference in staining intensity between control and 
bisdiamine-treated embryos appeared to be the greatest. This could again be 
explained by the turnover rate of P-galactosidase in that the pattern observed at 
El 2.0 might actually represent RA levels at earlier stage of development when RA 
deficiency was prominent. 
3.4.3.3 Comparison of endogenous RA levels in control and 
bisdiamine-treated metanephroi at different time points after 
treatment 
Results of HPLC and X-gal staining of RARE-hsp-LacZ embryos 
showed that RA deficiency and disruption of RA signaling took place in the whole 
embryo level following bisdiamine treatment. To further determine whether RA 
deficiency occurred in the early metanephros, metanephroi were isolated from 
control and bisdiamine-treated embryos at Ell.O and El2.0 for morphological 
analysis and quantification of RA levels by the RA-responsive cell line. 
The morphology of representative control and bisdiamine-treated 
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Ell.O and E12.0 metanephroi was shown in Figure 3.11. In the Ell.O control 
metanephros, the ureteric bud (UB) had already penetrated into the metanephric 
mesenchyme (MM). In majority of control metanephroi at this stage, the UB had 
undergone the first dichotomous branching to form a "T-shape". Although the UB 
of the bisdiamine-treated metanephros had also penetrated into the MM by Ell.O, 
no branching was observed in all treated metanephroi. At El2.0, the UB of the 
control metanephros showed multiple branches. However, the UB of the 
bisdiamine-treated metanephros had just undergone the first dichotomous 
branching. These results showed that the metanephros was formed following 
bisdiamine treatment, but its development was severely disrupted. 
The endogenous RA level in control and bisdiamine-treated 
metanephroi was summarized in Table 3.19 and illustrated in Graph 3.11. At 
Ell.O, control metanephroi had 8.583 pg of RA per \ig of protein while the RA 
content in bisdiamine-treated metanephroi was below the detection threshold at 
1.056 pg per |ig of protein. This implied that the amount of endogenous RA in the 
Ell.O bisdiamine-treated metanephros was reduced by at least 8-fold. At El2.0, 
the control metanephros had similar amount of RA when compared to the control 
metanephros at Ell.O. Although the amount of RA in bisdiamine-treated 
metanephroi at El 2.0 was restored to 4.485 pg per jig of protein, this amount was 
still significantly (p < 0.001) reduced by 51.3% when compared to that of the 
control at the same stage. These results confirmed that RA deficiency was induced 
in the early metanephros of the bisdiamine-treated embryo. 
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Table 3.19 Endogenous RA levels in the metanephros of control and 
bisdiamine-treated embryos at different time points after 
injection at ElO.O. 
Amount of RA /7-value of 
Developmental Treatment Sample 
(pg/fig protein) control vs. 
Stages Groups Size 士 SEM bisdiamine 
C o n t r o l 9 8.583 ± 0 . 7 9 5 “ 
Ell.O N/A 
Bisdiamine 5 < 1.056# 
Control 11 9.205 ± 0.459 
E12.0 <0.001* 
Bisdiamine 10 4.485 ± 0.386 
Detection threshold. 
* Statistically significant (Independent Sample /-test). 
3.4.4 Increase in the number of apoptotic nuclei in the metanephros 
after bisdiamine treatment 
In the above experiments, it was confirmed that administration of 3 
g/kg bisdiamine at ElO.O caused RA deficiency in the whole embryo and the 
metanephros. To study whether there was an increase in apoptosis in the 
metanephros under RA deficiency, TUNEL staining was performed in the 
metanephric region of El 2.0 control and bisdiamine-treated embryos. The number 
of apoptotic nuclei in the metanephros of each treatment group was summarized 
in Table 3.20 and illustrated in Graph 3.12, while pictures showing TUNEL 
staining of paraffin sections were shown in Figure 3.12. 
The metanephros of El2.0 control embryos had an average of 239 
2 
apoptotic nuclei per mm while the number surged up by 2.5 times to 607 per 
mm (p < 0.001) in the bisdiamine-treated metanephros. In the control 
metanephros, apoptotic nuclei were mainly found in the MM lying adjacent to the 
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multiple branches of the UB (Figure 3.12C). In the same region of the control 
metanephros (Figure 3.12C), the sectional area of the bisdiamine-treated 
metanephros was prominently reduced (Figure 3.12D). Only a single UB branch 
was observed in this region, but there was comparable number of apoptotic nuclei 
in the MM lying next to the UB (Figure 3.12D). Apoptosis was rarely observed at 
the cranial (Figure 3.12A) and caudal ends (Figure 3.12E) of the control 
metanephros. In contrast, fulminant apoptosis was found at the cranial end (Figure 
3.12B) while a few apoptotic nuclei were observed at the caudal end of the 
bisdiamine-treated metanephros (Figure 3.12F). Taken together, results showed 
that concomitant with a reduction in RA levels, there was an increase in apoptosis 
in the bisdiamine-treated metanephros. 
Table 3.20 Number of apoptotic nuclei in the metanephros of El2.0 control 
and bisdiamine-treated embryos after injection at ElO.O. 
Treatment groups Control Bisdiamine 
Number of metanephroi examined 6 8 
Number of apoptotic nuclei per mm 239.25 607.30 
士 SEM 士 18.74 ± 66.33 
/7-values of control vs. bisdiamine < 0.001* 
* Statistically significant (Independent Sample Mest). 
3.4.5 Alteration of genes expression in the metanephros after bisdiamine 
treatment 
As mentioned in section 1.1.1.2, c-Ret and Gdnf are genes important 
for early metanephric development. As it was shown that fetuses treated with 3 
g/kg bisdiamine at ElO.O demonstrated severe renal malformations, including 
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renal agenesis and ectopic hypodysplastic kidneys, it was speculated that 
expression of these genes might be disrupted. Thus, the mRNA expression levels 
of c-Ret and Gdnf in the metanephros of control and bisdiamine-treated embryos 
at Ell.O and El2.0 were quantified. Results were summarized in Table 3.21 and 
illustrated in Graphs 3.13 and 3.14. 
At Ell.O, the relative expression level of c-Ret in the 
bisdiamine-treated metanephros was significantly decreased (p < 0.001) by 78.9% 
when compared to the control (Graph 3.13). The downregulation was further 
aggravated to 89.6% at E12.0 {p < 0.001). 
For Gdnf (Graph 3.14), its expression level in the control metanephros 
at El2.0 was approximately 30% lower than that at Ell.O. With bisdiamine 
treatment, a significant upregulation (p < 0.01) of Gdnfhy 19.3% was observed at 
Ell.O. However, no significant difference in the expression level was found 
between the control and bisdiamine-treated groups at El2.0. 
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Table 3.21 Relative expression levels of c-Ret and Gdnf in the metanephros 
of Ell.O and E12.0 control and bisdiamine-treated embryos after 
injection at ElO.O. 
Developmental stages Ell.O E12.0 
Treatment groups Control Bisdiamine Control Bisdiamine 
Number of litters 3 4 5 5 
Expression levels of 0.0058 0.0014 0.0048 0.0005 
c-Ret 旧-actin±SEM ±0.0006 ± 0.0002 士 0.0002 =b 0.0001 
o-values of control vs. 
P <0.001* <0.001* 
bisdiamine 
Expression levels of 0.0109 0.0130 0.0071 0.0073 
Gdnf 旧-actin±SEM 士 0.0001 ±0.0004 ±0.0001 ± 0.0003 
p-values of control vs. 
^ 0.006* 0.574 
bisdiamine 
* Statistically significant (Independent Sample Mest). 
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3.5 DISCUSSION 
In this chapter, it was shown that administration of different dosages of 
bisdiamine at various time points resulted in varying frequency and severity of 
renal and non-renal malformations in mouse fetuses. In particular, injection of 3 
g/kg bisdiamine to pregnant ICR mice at ElO.O induced the most frequent and 
severe types of renal malformations, with nearly 40% of fetuses suffered from 
bilateral renal agenesis. The amount of RA in bisdiamine-treated embryos was 
reduced as early as 6 hours post-treatment. The reduction of endogenous RA was 
most prominent at Ell.O, but had started to be restored by E12.0. In 
bisdiamine-treated embryos, the metanephroi was formed at Ell.O with the UB 
penetrated into the MM but without undergoing the first dichotomous branching. 
Severe RA deficiency was found in the metanephros at Ell.O and El2.0 with 
fulminant apoptosis occurred at E12.0. Concurrently, the mRNA expression of 
c-Ret was drastically downregulated while the expression of Gdnf expression was 
significantly increased at Ell.O but not at El2.0. 
In the first part of the study, bisdiamine was found to cause resorption 
in a time- and dose-dependent manner. In particular, the frequency of resorption 
gradually decreased from 74% to 6% when the time of administration shifted from 
E9.0 to Ell.O. Bisdiamine has long been regarded as an abortifant. In rats, 
administration of two doses of 200 mg bisdiamine at ElO.O and Ell.O, which 
correspond to E8.0 and E9.0 in mice, was able to cause 100% resorption (Oster et 
al., 1974). This sensitive period coincides with the time of heart formation, which 
starts at E8.0 in mice. In this study, bisdiamine-induced heart malformations were 
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not determined since histological examination was required. However, previous 
studies showed that bisdiamine could induce a range of cardiovascular defects, 
including malformations of the septum and great vessels (Momma et al., 1990a; 
Momma et al., 1990b; Tasaka et al., 1991; Kuribayashi & Roberts, 1993; 
Nishijima et al., 2000; Kise et al., 2005; Hanato et al., 2010). Thus, it is possible 
that resorption of bisdiamine-treated embryos was caused by lethal heart 
malformations as in the Raldh2 knockout mutant (Niederreither et al., 1999). 
In agreement to previous studies (Taleporos et al., 1978), bisdiamine 
reduced overall growth in the live fetus, in terms of weight, head length and 
crown-rump length. In addition to renal defects, malformations were observed in 
13 other organs that were examined. Similar to the finding by Taleporos et al 
(1978), most of these malformations occurred in a time- and dose-dependent 
manner. As a potent teratogen when administered at the stage of organogenesis, 
bisdiamine had very little effect on adult animals. The median lethal dose (LD50) 
was as high as 16 g/kg in mice (Coulston et al., 1960). Other than suppression of 
spermatogenesis, bisdiamine did not demonstrate any toxic effect in adult cats as 
illustrated by tests on hematopoiesis, liver and kidney functions (Munson et al., 
2004). More recently, it was discovered that the inhibitory effect of bisdiamine on 
spermatogenesis was mediated by RA deficiency (Amory et al., 2011; Hogarth et 
al., 2011). Interestingly, all of the malformations observed in the present and 
previous studies (Taleporos et al., 1978) were also found in fetuses with vitamin 
A-deficient syndrome (Clagett-Dame & DeLuca, 2002). In particular, 
bisdiamine-treated rat fetuses were shown to suffer from DiGeorge syndrome, 
which involved a spectrum of anomalies of the cardiovascular system, parathyroid, 
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thyroid and spleen (Oster et al,, 1983). This syndrome was also observed in 
mouse fetuses with a hypomorphic Raldh2 allele, which suffered from reduced 
RA synthesis (Vermot et al., 2003). These findings therefore lead to the 
speculation that the teratogenicity of bisdiamine is mediated via disruption of RA 
synthesis. 
Indeed, Mey et al (2003) and Amory et al (2011) have showed that 
bisdiamine inhibited the RA synthesizing activity of RALDH2 in vitro. Although 
the RA synthesizing activity in tissues of bisdiamine-treated embryos has not been 
examined in the present study, prominent reduction of endogenous RA levels was 
found in the embryo from El0.25 to El2.0’ which corresponded to 6-48 hours 
post bisdiamine treatment. In contrast, retinol, the precursor of RA, was found to 
accumulate in bisdiamine-treated embryos, probably due to inhibition of RA 
synthesis. So far, this is the first direct evidence which showed that bisdiamine 
induced RA deficiency in the embryo in vivo. In addition, the effect of bisdiamine 
on RA-mediated gene expression was studied with the RARE-hsp-LacZ embryo. 
In agreement to the HPLC result, disruption of RA signaling was observed at 
multiple sites of the embryo as revealed by X-gal staining. However, a general 
delay in reduction of staining intensity was observed when the staining pattern 
was compared to the time of occurrence of RA deficiency. For instance, while the 
amount of RA found to be reduced by 31.4% as early as 6 hours post-treatment, 
no observable reduction in staining intensity was observed in the RARE-hsp-LacZ 
embryo at the same time point. Moreover, while RA deficiency was most 
significant at Ell.O and had started to be restored by El2.0，most prominent 
reduction of staining intensity was observed at El 2.0. As mentioned in the result, 
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the delay in reduction of staining intensity at ElO.O might be caused by the 
presence of p-galactosidase that existed before treatment and had not yet been 
degraded. However, the discrepancy at El2.0 might suggest a genuine delay in 
change of RA signaling patterns in response to RA deficiency. Upon change of RA 
levels, a series of events, including transcription and translation, have to be 
carried out before any change of protein expression can be observed. In support of 
this, the same delay was observed in the metanephros. While RA deficiency was 
most severe at Ell.O and had started to be restored at El2.0, the expression of 
c-Ret, a RA-responsive gene, was found to be most significantly downregulated at 
El2.0. Another observation of the RARE-hsp-LacZ embryo was that the RA 
staining pattern largely coincided with the expression sites of Raldhl, Raldh2 and 
Raldh3 as described in section 1.2.1 (Niederreither et al., 2002; Dupe et al., 2003; 
Matt et al., 2005). After bisdiamine treatment, reduction of RA-induced 
3-galactosidase expression was observed in expression sites of all three subtypes 
of RA synthesizing genes. For instance, decreased intensity was noted at the 
dorsal and ventral halves of the optic vesicle, which correspond to expression sites 
of Raldhl and RaldhS respectively. Reduction was also observed at the heart, 
lateral ridge along the body wall and genital ridge, where Raldh2 is expressed. 
This suggested that bisdiamine could suppress the RA synthesizing activity of 
RALDHl and RALDH3, in addition to RALDH2 which had previously been 
shown (Mey et al., 2003). The inhibition was so significant that staining was 
totally abolished at some sites, such as the first branchial cleft and the 
nasolacrimal groove. Taken together, these findings clearly suggest that 
bisdiamine can induce RA deficiency through inhibition of RALDHs activity. 
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As discussed in section 1.2.2.1, homozygous RARcfJy and RARa/RXRa 
compound knockout mutants exhibited renal agenesis while RARa//32 mutants had 
ectopic hypoplastic kidneys (Mendelsohn et al., 1994; Kastner et aL, 1997). In the 
present study, bisdiamine treatment at ElO.O was found to induce renal agenesis 
and ectopic hypodysplastic kidney in the fetus. This similarity led to the 
speculation that bisdiamine-induced renal malformations were caused by 
interruption of RA signaling. Indeed, severe RA deficiency and disruption of RA 
signaling occurred during early kidney development in embryos treated with 
bisdiamine. This might be associated with the drastic downregulation of c-Ret in 
the metanephros. As mentioned earlier, c-Ret is shown to be a RA-responsive gene 
expressed in the UB. Its downregulation in RARa旧2 knockout mutant led to 
formation of hypoplastic kidney (Batourina et al., 2001). Similarly, the severe 
downregulation of c-Ret observed in the metanephros of bisdiamine-treated 
embryos was most likely caused by the RA deficiency. So far, the expression of 
Gdnf, has not been shown to be responsive to changes in RA levels. Encoding the 
ligand of Ret, the slight increase in Gdnf expression in bisdiamine-treated 
metanephroi at Ell.O might involve a feedback mechanism in response to the 
reduction of c-Ret expression. However, the slight and temporary upregulation of 
Gdnf was probably not enough to restore GDNF/Ret signaling as shown by the 
occurrence of ectopic hypodysplastic kidneys at El 8.0. 
The outstanding question in the pathogenic mechanism of renal 
agenesis in bisdiamine-treated fetuses was whether the absence of kidney was 
solely caused by c-Ret downregulation. In the knockout mutant of c-Ret, over 
50% of the fetuses exhibited renal agenesis (Schu chard t et a I., 1994; Schuchardt 
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et al., 1996). However, the cause of renal agenesis in this mutant was failure of 
formation of the UB. In some mutant fetuses in which the UB had penetrated into 
the MM, hypodysplastic kidney was resulted. Furthermore, c-Ret has not been 
shown to affect apoptosis in the metanephros that was formed. In all 
bisdiamine-treated metanephroi, the UB had penetrated into the MM. The 
metanephric rudiment either later degenerated (resulting in agenesis) or developed 
into hypodysplastic kidneys. If downregulation of c-Ret was the only effect 
exerted by bisdiamine, all bisdiamine-treated metanephric rudiment should 
develop into hypodysplastic kidney as in the case of c-Ret mutants since the UB 
had penetrated into the MM. Thus, downregulation of c-Ret alone should not be 
sufficient to result in renal agenesis in bisdiamine-treated fetuses. Fulminant 
apoptosis is believed to play a role in the involution of the organ. Downregulation 
of c-Ret, which caused reduced growth and differentiation, together with 
fulminant apoptosis in the bisdiamine-treated metanephros is suspected to lead to 
the occurrence of renal agenesis. Before going into detailed discussion about the 
relationship of RA deficiency, apoptosis and renal agenesis, it is necessary to 
confirm whether it was RA deficiency which perturbed kidney development in 
bisdiamine-treated embryos. Thus, in the next chapter, attempts were made to 
correct RA deficiency in bisdiamine-treated metanephroi to test whether renal 
development could be restored along with suppression of apoptosis and 
normalization of c-Ret expression. 
In summary, a bisdiamine-induced renal agenesis mouse model was 
established in this chapter. The findings strongly suggested that the renal and 
non-renal malformations resulted were due to bisdiamine-induced RA deficiency 
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from around El0.25 to at least E12.0. In particular, downregulation of c-Ret and 
fulminant apoptosis were believed to be the causes of renal defects, including 
agenesis and ectopic hypodysplasia. 
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Figure 3.1 External morphology of E18.0 mouse fetuses treated with 3 g/kg 
bisdiamine or vehicle (control) at different time points. 
A. El8.0 fetus treated with vehicle (control) at ElO.O with normal external 
morphology. 
B. El8.0 fetus treated with bisdiamine at E9.0. When compared to the control, the 
fetus showed prominent reduction in size. Blunt snout and shortened body axis 
were some obvious external defects. 
C. El8.0 fetus treated with bisdiamine at ElO.O. The fetus was prominently reduced 
in size and exhibited open eye. 
D. El8.0 fetus treated with bisdiamine at Ell.O. The fetus showed prominent 
reduction in size and had open eye. 
Scale bar: A-D 1 cm 
Control (E10.0) Bisdiamine (E9.0) 
Bisdiamine at (E10.0) Bisdiamine (E11.0) 
0 0 
Figure 3.2 Measurement of various growth parameters in E18.0 fetus. 
A. Crown-rump length (CRL). The length from the top of the head (crown) to the 
bottom of the buttock (rump). 
B. Head length (HL). The length from the tip of the nose to the hindbrain. 
Labels: CRL crown-rump length 
HL head length 
Scale bar: A-B 1 cm 

Figure 3.3 Examples of bisdiamine-induced urogenital malformations in E18.0 
mouse fetuses. 
A: Control fetus treated with vehicle 
B and C: Fetuses treated with bisdiamine 
A. Two normal kidneys and testes. A pair of adrenal glands (yellow arrowhead) was 
lying on top of the bean-shape normal kidney (K). A pair of testes (T) was 
located at the pelvic region. 
B. Bilateral renal agenesis with undescended testes. Both kidneys were missing 
while a pair of adrenal glands was still present. The testes failed to descend from 
the abdominal region into the pelvic region. 
C. Bilateral ectopic hypodysplastic kidneys with undescended testes. Both kidneys 
were distorted in shape and reduced in size. They failed to ascend from the pelvic 
region to the lumbar region. The testes were undescended. 
Labels: K kidney 
T testis 
Symbol: Yellow arrowhead adrenal gland 




Figure 3.4 Examples of bisdiamine-induced malformations in E18.0 mouse 
fetuses. (1) 
A, C, E and G: Control fetuses treated with vehicle 
B, D, F and H: Fetuses treated with bisdiamine 
A. Normal fetus with the eye (yellow arrowhead) covered by the eyelid. 
B. Malformed fetus with open eye. 
C. Fetus with normal lower and upper jaws. 
D. Malformed fetus with bilateral cleft lips (green arrowheads). 
E. Abdomen of normal fetus. 
F. Malformed fetus with omphalocele (blue arrowhead) in which the intestine 
remained outside of the abdomen. 
G. Normal fetus with an anal opening (orange arrowhead) near the base of the tail. 
H. Malformed fetus with imperforate anus in which the anus was closed. 
Symbols: Blue arrowhead omphalocele 
Green arrowhead cleft lip 
Orange arrowhead anus 
Yellow arrowhead eye 
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Figure 3.5 Examples of bisdiamine-induced malformations in E18.0 mouse 
fetuses. (2) 
A, C, E and G: Control fetuses treated with vehicle 
B, D, F and H: Fetuses treated with bisdiamine 
A. Normal fetus with a pair of thymus (T) located above the heart (H). 
B. Malformed fetus with bilateral thymic agenesis. 
C. Fetus with normal lung (L). 
D. Malformed fetus with bilateral hypoplastic lung. 
E. Normal fetus with a diaphragm (yellow arrowheads) separating the abdomen and 
the thorax. 
F. Malformed fetus with bilateral diaphragmatic hernia, in which a large hole was 
observed in both sides of the diaphragm. 
G. Fetus with normal rib cage (green arrowheads). 
H. Malformed fetus with small rib cage. 
Labels: H heart 
L lung 
T thymus 
Symbols Green arrowhead rib cage 
Yellow arrowhead diaphragm 
Normal Malformed 
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Figure 3.6 External morphology of El8.0 mouse fetuses treated with various 
dosages of bisdiamine or vehicle (control) at ElO.O. 
A. El 8.0 fetus treated with vehicle (control) with normal external morphology. 
B. El8.0 fetus treated with 1 g/kg bisdiamine. When compared to the control, the 
fetus showed reduced size. Open eye and blunt snout were noticeable external 
defects. 
C. El8.0 fetus treated with 2 g/kg bisdiamine. When compared to the fetus treated 
with 1 g/kg bisdiamine, the fetus showed further reduction in size. Open eye, and 
blunt were observed. 
D. El8.0 fetus treated with 3 g/kg bisdiamine. The fetus showed prominent 
reduction in size, with open eye and blunt snout as noticeable external defects. 
E. El8.0 fetus treated with 4 g/kg bisdiamine. Similar to 2 g/kg and 3 g/kg 
bisdiamine-treated fetuses, the fetus showed prominent reduction in size, with 
open eye and blunt snout as noticeable external defects. 
Scale bar: A-E 1 cm 
Control 
1 g/kg Bisdiamine 2 g/kg Bisdiamine 
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3 g/kg Bisdiamine 4 g/kg Bisdiamine mmmm 
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Figure 3.7 X-gal staining of E10.25 (6 hours after treatment) RARE-hsp-lacZ 
embryos treated with 3 g/kg bisdiamine or vehicle (control) at ElO.O. 
A. El0.25 vehicle-treated (control) embryo. Staining was observed at multiple sites. 
In the head, staining was obvious in the telencephalic vesicle (Te)，optic vesicle 
(Op), periocular tissues and nasolacrimal groove (Na). Blue signal was prominent 
throughout the trunk region, including the heart (He), lateral ridge along the body 
wall (La) and along the neural tube (Ne). No staining was observed in the limb 
bud (Li) and tail (behind the heart). 
B. El0.25 bisdiamine-treated embryo. The staining pattern and intensity were 
similar to those observed in the control embryo at the same stage. 
Labels: He heart 
La lateral ridge along the body wall 
Li limb bud 
Na nasolacrimal groove 
Op optic vesicle 
Ne neural tube 
Te telencephalic vesicle 
Scale bars: A-B 1 mm 
E10.25 (6 hours after treatment) 
Control Bisdiamine 
A B 
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Figure 3.8 X-gal staining of E10.5 (12 hours after treatment) RARE-hsp-lacZ 
embryos treated with 3 g/kg bisdiamine or vehicle (control) at ElO.O. 
A. El0.5 vehicle-treated (control) embryo. The staining pattern was similar to that 
observed in the El0.25 control embryo. Staining was observed in the 
telencephalic vesicle (Te), optic vesicle (Op), periocular tissues, nasolacrimal 
groove (Na), heart (He), lateral ridge along the body wall (La), neural tube (Ne) 
and genital ridge (Ge). 
B. El 0.5 bisdiamine-treated embryo. Reduction of staining intensity was observable 
at multiple sites. 
C. Higher magnification of the head region of the El 0.5 control embryo. 
D. Higher magnification of the head region of the El 0.5 bisdiamine-treated embryo. 
Prominent reduction in staining intensity was observed at the telencephalic 
vesicle (yellow arrowhead), the nasolacrimal groove (green arrowhead), the 
dorsal (blue arrowhead) and ventral (black arrowhead) halves of the optic vesicle 
and the periocular tissues. 
E. Higher magnification of the trunk region of the El 0.5 control embryo. 
F. Higher magnification of the trunk region of the El 0.5 bisdiamine-treated embryo. 
Prominent reduction in staining intensity was observed at the heart (orange 
arrowhead), lateral ridge along the body wall (grey arrowhead), neural tube (pink 
arrowhead) and genital ridge (brown arrowhead). 
Labels: Ge genital ridge 
He heart 
La lateral ridge along the body wall 
Na nasolacrimal groove 
Op optic vesicle 
Ne neural tube 
Te telencephalic vesicle 
Symbols: Black arrowhead ventral half of the optic vesicle 
Blue arrowhead dorsal half of the optic vesicle 
Brown arrowhead genital ridge 
Green arrowhead nasolacrimal groove 
Grey arrowhead lateral ridge along the body wall 
Orange arrowhead heart 
Pink arrowhead neural tube 
Yellow arrowhead telencephalic vesicle 
Scale bars: A-B 1 mm 
C-D 0.5 mm 
E-F 0.74 mm 
E10.5 (12 hours after treatment) 
Control Bisdiamine 
A B 





Figure 3.9 X-gal staining of Ell.O (24 hours after treatment) RARE-hsp-lacZ 
embryos treated with 3 g/kg bisdiamine or vehicle (control) at ElO.O. 
A. Ell.O vehicle-treated (control) embryo. The staining pattern, though more 
restricted, was similar to that observed in the El0.5 control whole embryo. Blue 
signal appeared in the first brachial cleft (Fb) which was not observed in control 
embryos at earlier stages. 
B. El 1.0 bisdiamine-treated embryo. Prominent reduction or absence of staining 
signal was observable at multiple sites. 
C. Higher magnification of the head region of the E l l .0 control embryo. 
D. Higher magnification of the head region of the Ell.O bisdiamine-treated embryo. 
Prominent reduction in staining intensity was observed at the nasolacrimal 
groove (green arrowhead), the dorsal (blue arrowhead) and ventral (black 
arrowhead) halves of the optic vesicle. The optic vesicle was obviously smaller 
in size than that of the control. Staining at the first branchial cleft was (yellow 
arrowhead) completely absent. 
E. Higher magnification of the trunk region of the El 1.0 control embryo. 
F. Higher magnification of the trunk region region of the Ell.O bisdiamine-treated 
embryo. Prominent reduction in staining intensity was observed at the heart 
(orange arrowhead) and neural tube (pink arrowhead), lateral ridge along the 
body wall (grey arrowhead) and genital ridge (brown arrowhead). 
Labels: Fb first branchial cleft 
Ge genital ridge 
He heart 
La lateral ridge along the body wall 
Na nasolacrimal groove 
Op optic vesicle 
Ne neural tube 
Te telencephalic vesicle 
Symbols Black arrowhead ventral half of the optic vesicle 
Blue arrowhead dorsal half of the optic vesicle 
Brown arrowhead genital ridge 
Green arrowhead nasolacrimal groove 
Grey arrowhead lateral ridge along the body wall 
Orange arrowhead heart 
Pink arrowhead neural tube 
Yellow arrowhead first branchial cleft 
Scale bar: A-B 2 mm 
C-D 1 mm 
E-F 1.46 mm 
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Figure 3.10 X-gal staining of E12.0 (48 hours after treatment) RARE-hsp-lacZ 
embryos treated with 3 g/kg bisdiamine or vehicle (control) at ElO.O. 
A. El2.0 vehicle-treated (control) embryo. The staining pattern, though more 
restricted, was similar to that observed in the El 1.0 control whole embryo. 
B. El2.0 bisdiamine-treated embryo. Prominent reduction or absence of staining 
signal was observable at multiple sites. 
C. Higher magnification of the head region of the El 2.0 control embryo. 
D. Higher magnification of the head region of the El 2.0 bisdiamine-treated embryo. 
Prominent reduction in staining intensity was observed at the dorsal (blue 
arrowhead) and ventral (black arrowhead) halves of the optic vesicle. Staining at 
the nasolacrimal groove (green arrowhead) and the first branchial cleft was 
completely absent (yellow arrowhead). 
E. Higher magnification of the trunk region of the El 2.0 control embryo. 
F. Higher magnification of the trunk region of El2.0 bisdiamine-treated embryo. 
Prominent reduction in staining intensity was observed at the neural tube (pink 
arrowhead). No signal was observed at the lateral ridge along the body wall (grey 
arrowhead) and genital ridge (brown arrowhead). 
Labels: Fb first branchial cleft 
Ge genital ridge 
La lateral ridge along the body wall 
Na nasolacrimal groove 
Op optic vesicle 
Ne neural tube 
Te telencephalic vesicle 
Labels: Black arrowhead ventral half of the optic vesicle 
Blue arrowhead dorsal half of the optic vesicle 
Brown arrowhead genital ridge 
Green arrowhead nasolacrimal groove 
Grey arrowhead lateral ridge along the body wall 
Pink arrowhead neural tube 
Yellow arrowhead first branchial cleft 
Scale bar: A-B 2 mm 
C-D 0.89 mm 
E-F 1.48 mm 
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Figure 3.11 Morphology of Ell.O and E12.0 metanephroi of embryos treated 
with 3 g/kg bisdiamine or vehicle (control) at ElO.O. 
A. Vehicle-treated (control) metanephros dissected out at Ell.O. The ureteric bud 
(UB) had penetrated into the metanephric mesenchyme (MM) and undergone the 
first dichotomous branching to form a “T-shape”. 
B. Bisdiamine-treated metanephros dissected out at El 1.0. The UB had penetrated 
into the MM but no branching was observed. 
C. Vehicle-treated (control) metanephros dissected out at El2.0. The UB had 
undergone repeated branching, resulting in formation of multiple UB tips. 
D. Bisdiamine-treated metanephros taken out at El2.0. The UB had just undergone 
the first dichotomous branching. 
Labels: MM metanephric mesenchyme 
UB ureteric bud 
Scale bar: A-D 0.5 mm 
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Figure 3.12 TUNEL staining showing apoptotic nuclei and morphology of the 
metanephros of paraffin-sectioned E12.0 embryos treated with 3 
g/kg bisdiamine or vehicle (control) at ElO.O. 
All figures were transverse sections of the metanephros. 
A. The cranial end of the metanephros of the vehicle-treated (control) embryo. 
Apoptotic nuclei were hardly observed at the cranial region of the metanephros 
(circled) of the control embryo. 
B. The cranial end of the metanephros of the bisdiamine-treated embryo. Apoptotic 
nuclei were indicated by yellow arrowheads. In contrast to the control (A), 
fulminant apoptosis was observed at the cranial region of the condensed 
metanephric mesenchyme (MM) of the bisdiamine-treated embryo. 
C. The mid-region of the metanephros of the control embryo. Multiple sections of 
ureteric bud (UB) were observed. A few apoptotic nuclei were found in the 
metanephric mesenchyme next to the UB. 
D. The mid-region of the metanephros of bisdiamine-treated embryo. In contrast to 
the presence of multiple UB sections observed in the control (C) of the same 
region, only a couple of UB sections were found in the bisdiamine-treated one. 
The sectional area of the bisdiamine-treated metanephros was prominently 
reduced. There was comparable amount of apoptotic nuclei in the metanephric 
mesenchyme next to the UB in the bisdiamine-treated metanephros as in that of 
the control (C). 
E. The caudal end of the metanephros of the control embryo. Apoptotic nuclei were 
hardly found in this region. 
F. The caudal end of the metanephros of bisdiamine-treated embryo. A few 
apoptotic nuclei were observed. 
Label: UB ureteric bud 
Symbols: Circle outline of the metanephros 
Yellow arrowhead apoptotic nuclei 
Scale bar: A-B; E-F 0.1 mm 
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Graph 3.1 Frequency of resorption at E18.0 in litters of mice treated with 3 
g/kg bisdiamine (Bis) or vehicle (Control) at different time points. 
100 r c 
0 
a 
g 80 - # 
I m I 1 
c 
? 60 -Q) 
1 
w 
£ 40 -.2 
S c (0 
Q. 20 _ 
a B 
o 
^ 0 I I I J 1 I I- I I 
(67) (74) (81) (72) 
Control Bis Bis Bis 
E10.0 E9.0 E10.0 E11.0 
Time of injection 
The number in parentheses represents sample size, which refers to the number of 
implantations examined. 
Data were analyzed by Chi-square test. 
#p < 0.001 vs. Control (ElO.O) 
a；? <0.001 vs. Bis (E9.0) 
Pp < 0.001 vs. Bis (ElO.O) 
Graph 3.2 Weight (A), crown-rump length (B), head length (C) and head 
length/crown-rump length ratio (D) in E18.0 fetuses treated with 3 
g/kg bisdiamine (Bis) or vehicle (Control) at different time points. 
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Sample size, which refers to the number of live fetuses examined, for Graphs A-D: 
Control (ElO.O) 二 65; Bis (E9.0) = 19; Bis (ElO.O) = 43; Bis (El 1.0) = 68 
Data were analyzed by one-way ANOVA followed by Bonferroni test. 
� < 0.001 vs. Control (ElO.O) 
ap< 0.01; P p < 0.001 vs. Bis (E9.0) 
> < 0 . 0 5 vs. Bis (ElO.O) 
Graph 3.3 Frequency of renal malformations in E18.0 fetuses treated with 
3 g/kg bisdiamine (Bis) or vehicle (Control) at different time points. 
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The number in parentheses represents sample size, which refers to the number of live 
fetuses examined. 
Data were analyzed by Jonckheere-Terpstra test. 
林p < 0.001 vs. Control (ElO.O) 
ap < 0.05 vs. Bis (E9.0) 
Pp< 0.005 vs. Bis (ElO.O) 
Graph 3.4 Frequency of eye malformations (A), blunt snout (B), cleft palate 
(C), cleft lip (D), omphalocele (E) and imperforate anus (F) in 
El8.0 fetuses treated with 3 g/kg bisdiamine (Bis) or vehicle 
(Control) at different time points. 
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Sample size, which refers to the number of live fetuses examined, for Graphs A-F: 
Control (ElO.O) = 65; Bis (E9.0) = 19; Bis (ElO.O) 二 43; Bis (El 1.0) = 68 
Data were analyzed by Chi-square test. 
料p < 0.005; < 0.001 vs. Control (ElO.O) 
Pp < 0.05; Yp < 0.005; sp < 0.001 vs. Bis (E9.0) 
V < 0.01; 0.001 vs. Bis (ElO.O) 
Graph 3.4 Frequency of thymus malformations (G), lung malformations (H), 
diaphragmatic hernia (I), hypoplastic spleen (J), undescended 
testes (K) and small rib cage (L) in E18.0 fetuses treated with 
3 g/kg bisdiamine (Bis) or vehicle (Control) at different time points. 
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Sample size, which refers to the number of live fetuses examined, for Graphs G-J & L: 
Control (ElO.O) = 65; Bis (E9.0) 二 19; Bis (ElO.O) = 43; Bis (El 1.0) = 68 
Sample size, which refers to the number of male fetuses examined, for Graph K: 
Control (ElO.O) = 31; Bis (E9.0) - 9; Bis (ElO.O)-27; Bis (El 1 .0 ) -32 
Data were analyzed by Chi-square test. 
林 P < 0.001 vs. Control (ElO.O) < 0.05; 0.01; 丫 尸 < 0.001 vs. Bis (E9.0) 
'•p < 0.001 vs. Bis (ElO.O) 
Graph 3.5 Frequency of resorption at E18.0 in litters of mice treated with 
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The number in parentheses represents sample size, which refers to the number of 
implantations examined. 
Data were analyzed by Chi-square test. 
林p < 0.05; < 0.001 vs. Control 
Pp < 0.005; Yp < 0.001 vs. 1 g/kg 
<0.001 vs. 2 g/kg 
石p < 0.005 vs. 3 g/kg 
Graph 3.6 Weight (A), crown-rump length (B), head length (C) and head 
length/crown-rump length ratio (D) of E18.0 fetuses treated with 
various dosages of bisdiamine or vehicle (Control) at ElO.O. 
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Sample size, which refers to the number of live fetuses examined, for Graphs A-D: 
Control = 65; 1 g/kg = 58; 2 g/kg = 37; 3 g/kg = 43; 4 g/kg = 19 
Data were analyzed by one-way ANOVA followed by Bonferroni test. 
< 0.001 vs. Control 
«p <0.05; Pp <0.01; Yp <0.005; <0.001 vs. 1 g/kg 
V = 0.001; V < 0.001 vs. 2 g/kg 
""<0.005 vs. 3 s/kii 
Graph 3.7 Frequency of renal malformations in E18.0 fetuses treated with 
various dosages of bisdiamine or vehicle (Control) at ElO.O. 
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The number in parentheses represents sample size, which refers to the number of live 
fetuses examined. 
Data were analyzed by Jonckheere-Terpstra test and Spearman's rank correlation. 
林p < 0.001 vs. Control < 0.001 vs. 1 g/kg 
Pp < 0.001 vs. 2 g/kg ^p = 0.01 vs. 3 g/kg 
Graph 3.8 Frequency of eye malformations (A), blunt snout (B), cleft lip (C), 
omphalocele (D), imperforate anus (E) and thymus malformations 
(F) in E18.0 fetuses treated with various dosages of bisdiamine or 
vehicle (Control) at ElO.O. 
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Sample size, which refers to the number of live fetuses examined, for Graphs A-F: 
Control = 65; 1 g/kg = 58; 2 g/kg = 37; 3 g/kg = 43; 4 g/kg = 19 
Data were analyzed by Chi-square test. 
0.05; a；? < 0.01 0.001 vs. Control ^p < 0.05; ^p < 0.005; ^p < 0.001 vs. 1 g/kg 
V < 0.05; V < 0.001 vs. 2 g/kg V < 0.001 vs. 3 g/kg 
Graph 3.8 Frequency of lung malformations (G), diaphragmatic hernia (H), 
hypoplastic spleen (I), undescended testes (J) and small rib cage (K) 
in E18.0 fetuses treated with various dosages of bisdiamine or 
vehicle (Control) at ElO.O. 
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Sample size, which refers to the number of live fetuses examined, for Graphs G-I & K: 
Control = 65; 1 g/kg = 58; 2 g/kg = 37; 3 g/kg = 43; 4 g/kg = 19 
Sample size, which refers to the number of male fetuses examined, for Graph J: 
Control = 31; 1 g/kg - 2 8 ; 2 g/kg = 18; 3 g/kg = 27; 4 g/kg = 7 
Data were analyzed by Chi-square test. 
V < 0.05;以p < 0.01; P p < 0.001 vs. Control 
V < 0.05; ^p < 0.005; c p < 0.001 vs. 1 g/kg 
Graph 3.9 Endogenous RA levels in embryos at different time points after 
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The number in parentheses represents sample size, which refers to the number of litters 
of embryos. 
Data were analyzed by Independent Sample /-test. 
< 0.05; ap < 0,005; P/? < 0.001 vs. Control at the same developmental stage 
Graph 3.10 Endogenous retinol levels in embryos at different time points after 
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The number in parentheses represents sample size, which refers to the number of litters 
of embryos. 
Data were analyzed by Independent Sample /-test. 
林p < 0.05 vs. Control at the same developmental stage 
Graph 3.11 Endogenous RA levels in the metanephros of Ell.O and E12.0 
embryos treated with 3 g/kg bisdiamine (Bis) or vehicle (Control) 
at ElO.O. 
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The number in parentheses represents sample size, which refers to the number of 
metanephroi samples (every 8 metanephroi of the same treatment group were pooled as 
one sample). 
Dashed line represents RA detection threshold at 1.06 pg/|ag protein. 
Data were analyzed by Independent Sample /-test. 
甘p < 0.001 vs. Control at the same developmental stage 
Graph 3.12 Number of apoptotic nuclei in the metanephros of E12.0 embryos 
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The number in parentheses represents sample size, which refers to the number of 
metanephroi analyzed. 
Data were analyzed by Independent Sample 广-test. 
#；? < 0 . 0 0 1 vs. Control 
Graph 3.13 Relative expression levels of c-Ret in the metanephros of Ell.O and 
E12.0 embryos treated with 3 g/kg bisdiamine (Bis) or vehicle-
(Control) at ElO.O. 
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The number in parentheses represents sample size, which refers to the number of litters 
of metanephroi. 
Data were analyzed by Independent Sample 广-test. 
林p < 0.001 vs. Control at the same developmental stage 
Graph 3.14 Relative expression levels of Gdnf in the metanephros of Ell.O and 
E12.0 embryos treated with 3 g/kg bisdiamine (Bis) or vehicle-
(Control) at ElO.O. 
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The number in parentheses represents sample size, which refers to the number of litters 
of metanephroi. 
Data were analyzed by Independent Sample f-test. 
林p < 0.01 vs. Control at the same developmental stage 
Chapter 4 
Rescuing Bisdiamine-treated 
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4.1 INTRODUCTION 
4.1.1 Embryonic kidney culture 
Embryonic kidney development is commonly used as a model system 
to study organogenesis as the process involves many fundamental mechanisms of 
development, including epithelial branching morphogenesis, inductive tissue 
interactions, differentiation, cell polarization, mesenchymal-to-epithelial 
transformation and pattern formation (Vainio & Lin, 2002). Since the introduction 
of mammalian metanephros culture in the 1950s, our understanding on the 
mechanisms of the above events has been greatly improved by using the in vitro 
system. The embryonic kidney is grown on a porous membrane at the air-medium 
interface with hormonally-defined medium (Grobstein, 1953; Avner et al., 1982; 
Saxen & Lehtonen, 1987). The epithelial- and mesenchymal-derived tissues 
particularly develop well in organ culture. Nephrogenesis, i.e. the formation of 
nephron, can occur within a few days of culture in a timely manner. In fact, 
development of the metanephros in vitro is found to closely resemble the 
development in vivo. For instance, the temporal and spatial expression patterns of 
Wtl in the mouse metanephric explant was shown to be similar to that in the 
metanephros of the corresponding stage developed in vivo (Yeger et al., 1996). 
One of the advantages of in vitro kidney culture over in vivo study is 
that it allows temporal and spatial observation of the inductive events that occur in 
nephrogenesis. Development of the metanephric explant can be assessed daily in 
terms of overall morphology and the extent of UB branching. Moreover, the 
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system provides easy access for experiments that use drugs (Fisher et al., 2001), 
blocking antibodies (Vega et al., 1996), exogenous growth factors (Hammerman 
et al., 1992), short interfering RNAs (Davies et al., 2004) and retroviral infection 
with DNA constructs (Koseki et al., 1992). In particular, the concenrtation of 
agents that is required to promote or perturb renal development can be precisely 
determined. Thus, embryonic metanephros culture provides a quicker and more 
convenient way to study developmental events and mechanisms than in vivo 
study. 
Metanephric development in vitro can be assessed by the extent of UB 
branching morphogenesis and nephron formation. Whole-mount 
immunohistochemical staining of corresponding structures in the cultured kidney 
is a popular technique to monitor renal development (Barak & Boyle, 2011). For 
instance, immunohisto chemical staining of protein markers of the ureteric 
epithelium, such as Cytokeratin 8 and Calbindin-DisK, can reveal branching 
morphogenesis. On the other hand, nephrogenesis can be examined through 
staining of nephron structures, such as the mature proximal tubules by 
fluorescence-conjugated Lotus tetmgonolohus (LT) lectin. Whole-mount 
immunohisto chemical staining of these structures not only allows visualization, 
but also proper quantification to assess the degree of kidney development. 
4.1.2 In vitro culture of the RA-treated metanephros 
As described in section 1.2.3.2, the metanephros of the RA-induced 
renal agenesis mouse model demonstrated fulminant apoptosis at Ell.O and 
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completely regressed by El6.25 in vivo. To determine whether the defect is 
intrinsic to the RA-treated metanephros or due to the influence of surrounding 
tissues, in vitro embryonic kidney culture was performed. In the experiment, 
control (vehicle-treated) and RA-treated Ell.25 metanephroi were cultured in 
hormonally defined serum-free medium for 5 days (Tse et al., 2005). While the 
control metanephric explant underwent comprehensive UB branching and 
nephron formation, the RA-treated explant failed to grow but degenerated. This 
illustrated that the renal defect was autonomous. Surprisingly, development of the 
RA-treated metanephros could be rescued when the culture medium was 
supplemented with fetal bovine serum. With 20% serum supplementation, Ell .25 
and El2.25 RA-treated metanephroi showed repeated UB branching and 
nephrogenesis. Fetal bovine serum contains various factors, including growth 
factors, hormones, cytokines and retinoids. It is not known which of these factors 
rescued the development of the RA-treated metanephros. However, this 
experiment revealed that perturbation of renal development induced by RA could 
be reversed if treatment was carried out at an early stage of kidney development. 
4.1.3 Effect of exogenous retinoic acid on in vitro development of 
metanephros 
As discussed in section 1.2.2.1, retinoids play indispensable roles in 
renal development. RA regulates UB branching morphogenesis and nephrogenesis 
through c-Ret expression. The number of nephrons in the fetus closely correlates 
with fetal circulating vitamin A levels. Significant reduction in nephrons number 
was found in near-term rat fetuses with mild vitamin A deficiency 
-109 -
Chapter 4: Rescuing Bisdiamine-treated Metanephroi 
(Lelievre-Pegorier et al., 1998). Previous studies on supplementing exogenous RA 
to metanephroi in vitro also suggest that RA stimulates nephrogenesis. 
Specifically, it was found that the number of glomeruli in metanephric explants 
isolated from E13.0 and E14.0 rat embryos (corresponding to Ell.O and E12.0 
mouse embryos respectively) was significantly increased when cultured for 6 days 
in the presence of 10"'° to 10'^  M (0.1 to 1000 nM) RA (Vilar et al., 1996). 
Subsequent studies revealed that exogenous RA stimulated c-Ret expression to 
promote nephrogenesis in the RA-supplemented metanephric explant culture 
(Moreaue^ al, 1998). 
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4 .2 EXPERIMENTAL DESIGN 
In Chapter 3, it was found that administration of 3 g/kg bisdiamine at 
ElO.O could induce renal malformations, including renal agenesis, in mouse 
fetuses. Concomitant with RA deficiency and disruption of RA signaling, there 
was fulminant apoptosis and reduction of c-Ret expression in bisdiamine-treated 
metanephroi. 
In this chapter, to test whether perturbation of renal development was 
indeed caused by bisdiamine-induced RA deficiency, it was attempted to correct 
the RA deficit in bisdiamine-treated metanephroi. Low concentrations of RA (0.1, 
0.5 and 1 nM) were added to the culture medium to compensate for the RA 
deficiency in Ell .25 bisdiamine-treated metanephric explants. Development of 
vehicle- and bisdiamine-treated explants under various concentrations of RA was 
monitored daily over a 6-day culture period by a morphological grading system of 
the number of UB tips (refer to section 4.3.1.2). Towards the end of culture, 
metanephric explants of various treatment groups were subjected to whole-mount 
immunohistochemical staining of ureteric epithelium and mature proximal tubules 
for morphological analysis and proper quantification of UB tips and nephrons. 
The concentration of RA found to be most effective in rescuing the development 
of bisdiamine-treated metanephric explants was chosen for subsequent 
experiments. 
After proving that low concentrations of RA supplementation could 
rescue the development of bisdiamine-treated metanephric explants, experiments 
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were carried out to determine if the rescue effect was mediated via reduction of 
apoptosis and restoration of gene expression. TUNEL staining was performed to 
reveal the number of apoptotic nuclei in vehicle- and bisdiamine-treated 
metanephric explants cultured for two days under the optimum concentration of 
RA. The expression level of c-Ret and Gdnf was also quantified by real-time 
RT-PCR at the same time point. 
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4 .3 MATERIALS AND METHODS 
4.3.1 Supplementation of low concentrations of RA to metanephric 
explant culture 
4.3.1.1 Preparation of culture medium supplemented with low 
concentrations of RA 
To prepare metanephric explant culture medium supplemented with 
low concentrations of RA, 100 mM RA stock (10' M), prepared using the method 
described in section 2.3, was subjected to 10-fold serial dilution down to 10'^  M 
with DMSO under sterile conditions in the dark. The 10'^  M RA stock was then 
diluted 1-fold to 5x10—7 m, followed by further dilution by 5-fold to 10"^  M. The 
working RA stock solutions of 10"^  M, 5x10"^ M and 10"^  M were then added to 
the metanephric explant culture medium. The hormonally-defined serum-free 
kidney culture medium consisted of Dulbecco's Modified Eagle Medium: Nutrient 
Mixture F-12 (DMEM/F12) (Gibco) supplemented with ITS Liquid Media 
Supplement (Sigma) (100:1, v/v). The working RA stock solutions of 10'^  M (0.1 
pM), 5x10.7 M (0.5 |iM) and 10"^  M (1 i^M) were transferred to the 
hormonally-defined serum-free medium at a ratio of 1:1000 (v/v) to make up 
culture medium with final RA concentrations at 0.1, 0.5 and 1 nM respectively. 
Control medium (no RA supplementation) was prepared by adding equivalent 
volume of solvent (DMSO) to the hormonally-defined serum-free medium. The 
DMSO concentration was kept at 0.1 % of total volume of the culture medium to 
prevent cytotoxic effect on the metanephric explant development. Subsequently, 
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1.1 ml of medium supplemented with 0.1, 0.5 or 1 nM RA or 0.1% DMSO 
(control) was added to each well of a 6-well culture plate (Coming). Milli Cell 
Culture Insert with hydrophilic Teflon (PTFE) membrane of 0.4 |im pore size 
(MilUpore) was placed into each well. The culture plate was loosely covered with 
aluminum foil to prevent photoisomerization of RA and pre-equilibrated at 37°C 
in a 5% CO2 incubator for 1 hour. 
4.3.1.2 Metanephric explant culture 
At ElO.O, 3 g/kg of bisdiamine (150 mg/ml stock suspension) or 
equivalent volume of peanut oil (vehicle) was injected intraperitoneally into 
pregnant ICR mice. At Ell.25, vehicle-treated and bisdiamine-treated mice were 
sacrificed and embryos were dissected out in ice-cold L-15 medium as described 
in section 2.4. The metanephros was excised using a pair of 1 ml syringes fitted 
with 30G needle, and then washed thoroughly in fresh L-15 medium to remove 
any residual bisdiamine or vehicle. Each litter of vehicle- or bisdiamine-treated 
metanephroi was randomly separated into 4 groups and transferred onto the 
culture insert immersed with medium supplemented with 0.1, 0.5 or 1 nM RA or 
0.1% DMSO as the control in the dark under dim yellow light. The metanephric 
explants were cultured in the 6-well culture plate, loosely covered by aluminum 
foil, at the air-medium interface at 37°C in a 5% CO2 incubator for 6 days. The 
first day of culture was designated as "Day 0”. The culture medium was refreshed 
daily with freshly-prepared RA-supplemented or DMSO-supplemented medium. 
Prior to refreshment of the medium, the morphology of each metanephric explant 
was monitored daily under an inverted microscope (Axiovert 40 CFL, Zeiss). 
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Development of each explant was assessed in terms of the number of UB tips 
according to a morphological grading system as listed in Table 4.1. 
Table 4.1 Morphological grading system of the number of UB tips. 
• • , , __•• I - •' _. —————— 
Morphological grade I II III [ IV V 
Number of UB tips 1 2 3-6 7-10 >10 
4.3.2 Whole-mount immunohistochemical staining of ureteric 
epithelium and nephric tubules in metanephric explants 
Subsequent to culture in RA-supplemented medium, metanephric 
explants of various treatment groups were subjected to whole-mount 
immunohistochemical staining of ureteric epithelium and mature proximal tubules 
for assessment of UB branching morphogenesis and nephrogenesis. At day 6 of 
culture, metanephric explants growing on the culture insert were washed in 
ice-cold PBS once and fixed in methanol (prechilled to -20°C) for 15 minutes at 
-20�C. After fixation, the metanephros was washed thoroughly in PBS twice. The 
PTFE membrane with metanephric explants on it was cut out from the plastic 
holder of the culture insert using a pair of 1 ml syringes fitted with 30G needle. 
Metanephric explants attached to the membrane were incubated with blocking 
solution consisting of 10% fetal bovine serum and 1% bovine serum albumin in 
PBS for 1 hour at room temperature to block the non-specific binding site. After 
that, they were incubated with monoclonal mouse anti-Calbindin-D28K antibody 
(C9848, Sigma) in blocking solution (1:2000, v/v) at 4°C overnight. The 
metanephric explants were then washed in PBS twice, each for 15 minutes, with 
gentle shaking. Subsequently, Alexa Fluor 488-labeled goat anti-mouse IgG 
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antibody (A-11001, Invitrogen) (1:1000) and Fluorescein-labeled Lotus 
tetragonolobus (LT) lectin (FL-1321, Vector Laboratories) (1:400) in PBS were 
added to the explants and incubated at room temperature in the dark for 1 hour. 
After washing with PBS for 5 times (5 minutes each) with gentle shaking in the 
dark, the membrane with metanephric explants attached on it was transferred to a 
glass slide and mounted with PBS. Metanephric explants were examined by using 
an inverted microscope (Axiophot 2, Zesis) under Filter Set 09 (excitation: 
450-490 nm; emission: 520 nm) and Filter Set 15 (excitation: 546/12 nm; 
emission: 590 nm) for viewing nephric tubules and ureteric epithelium 
respectively. Images were taken with a SPOT digital camera {SPOT Imaging 
Solutions). The number of Calbindin-D28K-stamed UB tips and LT lectin-stained 
mature proximal tubules in each explant was quantified. 
4.3.3 TUNEL staining of metanephric explants 
Forty-eight hours after cultured in medium supplemented with various 
concentrations of RA or 0.1% DMSO, vehicle-treated and bisdiamine-treated 
metanephric explants were fixed, dehydrated, wax infiltrated and sectioned as 
described in sections 2.6.1 and 2.6.2. Serially sectioned metanephric explants on 
glass slides were subjected to TUNEL staining according to the procedure 
described in section 2.6.3. The number of apoptotic nuclei per sectioned area of 
each metanephric explant was counted according to the method described in 
section 2.6.3. For each treatment group, apoptotic nuclei in 5-8 metanephric 
explants were quantified. 
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4.3.4 Real-time quantitative RT-PCR 
Forty-eight hours after cultured in medium supplemented with various 
concentrations of RA or 0.1 % DMSO, metanephric explants attached to the 
culture insert were washed with DEPC-treated ice-cold PBS. Metanephric 
explants isolated from the same litter of embryos and cultured under the same 
concentration of RA were collected and pooled as one sample. Samples were 
stored in RNAlater RNA stabilization reagent as described in section 2.5.1. The 
metanephric explant sample was subjected to total RNA extraction, reverse 
transcription and real-time quantitative RT-PCR of c-Ret and Gdnf mRNA 
expression according to the protocol described in sections 2.5.2, 2.5.3, 2.5.4 and 
2.5.5. P-actin was used as the internal control for normalization of c-Ret and Gdnf 
expression. Information of primer pairs for various target genes was listed in 
Table 3.3. Gene expression in 4 samples was examined for each treatment group. 
4.3.5 Statistical analysis 
As described in section 4.3.1.2, development of the metanephric 
explant was monitored daily by a morphological grading system of the number of 
UB tips. To compare the development between explants of different treatment 
groups, the morphological grade was ranked as listed in Table 4.2. 
Jonckheere-Terpstra test was then employed to compare the development of 
different treatment groups at each day of culture in terms of the ranking of the 
morphological grade. Using the same ranking system, correlation between the 
concentration of supplemented RA and the morphological grade of UB tips in 
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vehicle- or bisdiamine-treated metanephric explants at day 6 of culture was 
determined by Spearman's rank correlation, a non-parametric correlation test 
described in section 3.3.7. 
Next, the number of UB tips and nephric tubules, as revealed by 
whole-mount immunohistochemical staining, in metanephric explants of different 
treatment groups were compared by Independent Sample /-test. The number of 
apoptotic nuclei and the relative expression level of c-ret and Gdnf in vehicle- and 
bisdiamine-treated metanephric explants cultured for 2 days with or without RA 
supplementation were analyzed by One-way ANOVA followed by Bonferroni test. 
All statistical analyses were performed with SPSS 13.0 software (IBM). The 
statistical significance level was set at p < 0.05. 
Table 4.2 Ranking system of the morphological grade of the number of UB 
tips. 
Morphological grade I II III IV V 
__ ‘ -_-• , , ！ ‘ ” •"丨 ‘ { I I • ， 一 … ， . . 」 . 一 ' , ' . . , „ , . , 
Number of UB tips 1 2 3-6 7-10 >10 
Rank 1 2 3 4 5 
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4 .4 RESULTS 
4.4.1 Rescue of bisdiamine-treated metanephric explants by in vitro 
culture in medium supplemented with low concentrations of RA 
The aim of this chapter was to rescue the development of 
bisdiamine-treated metanephroi by correcting RA deficiency through 
supplementation of low concentrations of RA. First, the development of vehicle-
and bisdiamine-treated metanephric explants was monitored daily over a 6-day 
culture period by the morphological grading system of UB tips. At the end of 
culture, the number of UB tips and nephric tubules in the explant was quantified. 
4.4.1.1 Assessment of metanephric development under various 
concentrations of RA by morphological grading of UB tips at 
different day of culture 
Figure 4.1 demonstrated the morphology of metanephric explants with 
various number of UB tips. Under an inverted microscope, the extent of UB 
branching (up to 10 branches) in the metanephric explant cultured on the 
membrane could be clearly visualized. A grade, based on the number of UB tips as 
listed in Table 4.1, was given to each explant daily over the 6-day culture period. 
Results of UB tips grading in vehicle- and bisdiamine-treated metanephric 
explants cultured under various concentrations of RA at different day of culture 
were summarized in Table 4.3 and Graph 4.1. Results of statistical analyses were 
shown in Tables 4.4 and 4.5. 
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Table 4.4 Statistical analysis of the morphological grading of UB tips in 
vehicle- and bisdiamine-treated metanephric explants cultured 
under various concentrations of RA at different day of culture. 
Treatment at ElO.O Vehicle Bisdiamine 
Concentrations of RA (nM) 0.1 0.5 1 0 0.1 0.5 1 
/7-value vs. 
vehicle 0.752 0.658 1.000 0.071 0.090 0.056 0.071 
八 without RA 
Day 0 ： 
j9-value vs. 
bisdiamine - 0.925 0.929 1.000 
without RA 
/7-value vs. 
vehicle 0.485 0.732 0.985 < 0.001*< 0.001*< 0.001* 0.004* 
n 1 without RA 
Day 1 ： 
/>-value vs. 
bisdiamine - 0.690 0.391 0.059 
without RA 
/?-value vs. 
vehicle 0.951 0.876 0.477 < 0.001*< 0.001*< 0.001*< 0.001* 
， without RA 
Day 2 ： 
/?-value vs. 
bisdiamine - 0.545 0.006* <0.001* 
without RA 
p-value vs. 
vehicle 0.553 0.175 0.317 < 0.001*< 0.001*< 0.001* 0.001* 
n ^ without RA 
Day 3 ： 
/7-value vs. 
bisdiamine - 0.518 0.002* <0.001* 
without RA 
/7-value vs. 
vehicle N/A N/A N/A < 0.001*< 0.001*< 0.001* 0.025* 
n . without RA 
Day 4 ： 
；?-value vs. 
bisdiamine - 0.719 < 0.001*< 0.001* 
without RA 
p-value vs. 
vehicle N/A N/A N/A < 0.001*< 0.001*< 0.001* 0.048* 
n . without RA 
Day 5 ： 
/7-value vs. 
bisdiamine - 0.588 < 0.001*< 0.001* 
without RA 
p-value vs. 
vehicle N/A N/A N/A < 0.001* <0.001* 0.002* 0.048* 
„ . without RA 
Day 6 ： 
/?-value vs. 
bisdiamine - - - - 0.125 < 0.001* < 0.001* 
without RA I I I I I I I 
* Statistically significant (Jonckheere-Terpstra test) 
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Table 4.5 Spearman's rank correlation between the concentrations of RA 
supplemented and the morphological grades of UB tips in 
bisdiamine-treated metanephric explants at different day of 
culture. 
，•.上 .. .. , - ， • "• •二 二“ • •• 
Treatment at ElO.O Bisdiamine 
Concentration of RA (nM) 0 0.1 0.5 1 
‘ ---._-，=••,__--••.- _•_•- ‘ — •••-' ‘ ‘ I • . ‘ ••“‘ 丨丨 ，".- i•上f ‘ ‘ ‘ 
Spearman's rank correlation coefficient � +0.232 
Day 1 
/?-value of Spearman's rank correlation 0.030* 
Spearman's rank correlation coefficient (r^) +0.487 
Day 2 
/?-value of Spearman's rank correlation < 0.001 * 
Spearman's rank correlation coefficient � +0.562 
Day 3 
p-value of Spearman's rank correlation < 0.001* 
D 4 Spearman's rank correlation coefficient (r^) +0.642 
/?-value of Spearman's rank correlation < 0.001* 
Spearman's rank correlation coefficient (r^) +0.675 
p-value of Spearman's rank correlation < 0.001 * 
Spearman's rank correlation coefficient (r^) +0.722 
Day 6 
p-value of Spearman's rank correlation < 0.001 * 
* Statistically significant (Spearman's rank correlation). 
The vehicle-treated metanephric explant cultured without RA 
supplementation (but supplemented with 0.1 % DMSO) was referred as “control” 
for simplicity. When vehicle-treated metanephroi were dissected out at Ell .25 
(day 0), the UB in approximately 55-62% of them had undergone the 
first-dichotomous branching to form a T-shape with 2 UB tips (Grade II, Figure 
4.IB). In the absence of RA, the UB continued to branch as culture proceeded 
(Graph 4.1 A). At day 1, 75% of metanephric explants had 3-6 UB tips (Grade III, 
Figure 4.1C) while 10% of them had already got 7-10 UB tips (Grade IV, Figure 
4. ID). Nearly half of the explants showed over 10 UB tips (Grade V, Figure 4. IE) 
by day 2 of culture while the figure reached 95% at day 3 of culture. At day 4 and 
beyond, all metanephroi cultured without RA supplementation were classified as 
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Grade V. For vehicle-treated metanephric explants cultured with 0.1, 0.5 and 1 nM 
of RA (Graph 4.1B-D), the trend of development was similar to that of the control. 
There was no significant difference between the control and the vehicle-treated 
explant cultured under various concentrations of RA at each corresponding day of 
culture (Table 4.3). Although it was difficult to count the extent of UB branching 
beyond day 3 of culture (when all explants were classified as Grade V), the above 
results suggested that the concentrations of RA supplemented did not significantly 
enhance UB branching in vehicle-treated metanephroi at least during the first 
three days of culture. 
In contrast to vehicle-treated metanephroi, less than 30% of 
bisdiamine-treated metanephroi had undergone the first dichotomous branching 
when they were dissected out at Ell .25 (day 0). Majority of them only had a 
single UB tip (Grade 1, Figure 4.1 A). When cultured without RA (Graph 4.IE), 
bisdiamine-treated explants demonstrated significantly reduced UB branching 
when compared to the control throughout day 1-6 of culture (p < 0.001 vs. vehicle 
without RA at day 1 to 6). While majority of control explants had reached Grade 
III at day 1, over 90% of bisdiamine-treated explants were at Grade I and Grade II. 
While 54.5% of bisdiamine-treated explants did reach Grade III by day 2 of 
culture, majority of them did not develop further and 63.6% of the explants 
remained to have only 3-6 UB tips (Grade III) at day 6 of culture. In contrast to 
the control in which all explants had over 10 UB tips at day 6 of culture, only 
9.1% of bisdiamine-treated explants developed to Grade V. Even worse, about 
18% of bisdiamine-treated explants had 1 or 2 UB tips at the end of the culture 
period. These explants had never developed or had branched initially but later 
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underwent regression. Supplementation of 0.1 nM of RA to bisdiamine-treated 
explants did not rescue metanephric development (Graph 4.IF), as shown by the 
result that there was no significant difference in the extent of UB branching 
between bisdiamine-treated explants cultured without RA and with 0.1 nM RA 
throughout day 1-6 of culture (Table 4.5). When the concentration of RA was 
increased to 0.5 nM (Graph 4.1G), the extent of UB branching was found to be 
enhanced. While nearly half of the bisdiamine-treated explants without RA 
supplementation had only 1 or 2 UB tips (Grade I and II) at day 2 of culture, only 
17.4% of explants cultured with 0.5 nM RA remained at these low grades. Starting 
from day 2 of culture and beyond, the extent of UB branching was significantly 
enhanced in bisdiamine-treated explants supplemented with 0.5 nM RA when 
compared to those without RA supplementation {p < 0.01 at day 2; p < 0.005 at 
day 3; and p < 0.001 at day 4-6 vs. bisdiamine without RA). While less than 
one-tenth of bisdiamine-treated explants cultured without RA supplementation 
managed to reach Grade V by day 6, over 60% of bisdiamine-treated explants 
cultured with 0.5 nM RA were at Grade 5. When the concentration of RA 
supplementation was increased to 1 nM (Graph 4.1H), the extent of UB branching 
in bisdiamine-treated explants was further enhanced. At day 2 of culture and 
beyond, there were significantly more UB tips in bisdiamine-treated explants 
cultured with 1 nM RA when compared to those cultured without RA 
supplementation. About 10% of the explants even managed to reach Grade V as 
early as day 2. By day 6 of culture, all of the metanephroi supplemented with 1 
nM RA were above Grade III, with 81.8% of them at Grade 5. Although the extent 
of UB branching in bisdiamine-treated explants with either 0.5 or 1 iiM of RA 
supplementation was significantly lower than that in the control throughout day 
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1-6 of culture, results suggested that development of bisdiamine-treated 
metanephroi could at least be partially restored in vitro in the presence of low 
concentrations of RA. 
To determine whether there was a concentration-dependent effect of 
RA on the extent of UB branching in bisdiamine-treated explants, Spearman's 
rank correlation was used to analyze the results at each culture day as listed in 
Table 4.5. However, correlation in vehicle-treated explants was not determined 
since there was no statistically significant difference in the extent of UB 
branching between vehicle-treated explants supplemented with different 
concentrations of RA for all culture day. In the test, a correlation coefficient closer 
to +1 represents a strong positive correlation between the two variables while a 
value of 0 represents no correlation. As early as day 1, a weak but significant (p < 
0.05) positive correlation coefficient of +0.232 was observed. As culture 
proceeded, the correlation became stronger and stronger, reaching a coefficient of 
+0.722 at day 6 of culture (p < 0.001 for day 2-6 of culture). This result suggested 
that a concentration-dependent effect of RA on the extent of UB branching in 
bisdiamine-treated explants was present. The higher the concentration of RA 
supplemented, the greater the extent of UB branching in bisdiamine-treated 
explants. The concentration-dependent effect became more prominent with 
increasing time of culture. 
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4.4.1.2 Effect of various concentrations of RA on the number of UB tips 
and nephric tubules in metanephric explants at day 6 of culture 
In addition to daily assessment of the extent of UB branching 
throughout the 6 days of culture, the exact number of UB tips and nephric tubules 
in vehicle- and bisdiamine-treated metanephroi cultured under various 
concentrations of RA was determined at the end of the culture period by 
whole-mount immunohistochemical staining of ureteric epithelium and mature 
proximal tubules. The morphology of representative explants from each treatment 
group was shown in Figure 4.2. Ureteric epithelium was stained by Alexa Fluor 
488 (emits red fluorescence when excited) while the mature proximal tubules 
were labeled by Fluorescein (emits green fluorescence when excited). Results of 
quantification of UB tips were shown in Table 4.6 and Graph 4.2. Pearson 
correlation between the number of UB tips and the concentrations of RA 
supplemented was shown in Table 4.7. 
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Table 4.6 Number of UB tips in vehicle- and bisdiamine-treated 
metanephric explants at day 6 of culture under various 
concentrations of RA. 
Cone. No. of /7-value 
Treatment No. of UB tips 
of RA explants vs. vehicle vs. bisdiamine 
at ElO.O 土 SEM 
(nM) examined without RA without RA 
._•• • _  •_ ‘ - I • • . • I -. . , . , 丨 I •— ‘ — — • • • 
0 20 28.40 ± 1.80 - -
0.1 20 27.50 ± 1.76 0.722 -
Vehicle 
0.5 21 36.00 士 2.64 0.024* -
1 20 42.25 士 2.65 <0.001* -
0 22 5.14 ±0.77 <0.001* -
0.1 21 6.62 ±0.95 <0.001* 0.232 
Bisdiamine 
0.5 23 13.96 ±1.57 <0.001* <0.001* 
1 2 2 2 0 . 0 0 士 1 . 8 0 0 . 0 0 2 * < 0 . 0 0 1 * 
* Statistically significant (Independent Sample /-test) 
Table 4.7 Pearson correlation between the number of UB tips and the 
concentrations of RA supplemented to vehicle- or 
bisdiamine-treated metanephric explants. 
Treatment at ElO.O Vehicle Bisdiamine 
Concentration of RA (nM) 0 0.1 0.5 1 0 0.1 0.5 1 
Pearson correlation coefficient (r) +0.508* +0.687* 
p-vahie of Pearson correlation < 0.001 < 0.001 
* Statistically significant (Pearson correlation) 
After 6 days of culture, vehicle-treated metanephric explants cultured 
without RA supplementation (control) had undergone repeated branching to form 
a roughly symmetrical UB tree with an average of 28 UB tips (Figure 4.2A). 
There was no significant difference in the number of UB tips between 
vehicle-treated explants cultured with 0.1 nM RA (Figure 4.2B) and control 
explants. When the concentration of RA was increased to 0.5 nM, an average of 
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36 UB tips was found in vehicle-treated explants (Figure 4.2C). This represented a 
26.8% increase from the control (p < 0.05). The number of UB tips increased to 
42 with 1 nM RA supplementation (Figure 4.2D). Analysis by Pearson correlation 
(Table 4.7) showed a moderate but significant concentration-dependent increase in 
UB tips with increasing concentrations of RA in vehicle-treated explants (r = 
+0.508,;? <0.001). 
Without RA supplementation, bisdiamine-treated metanephric explants 
only had an average of 5 UB tips at day 6 of culture. UB branching 
morphogenesis in explants treated with bisdiamine was severely disrupted such 
that the value was 81.9% less than that of the control. While a few UB tips were 
still visible in majority of the bisdiamine-treated explants cultured without RA, 
the explant had actually undergone regression and the UB branching had shrunk 
(Figure 4.21). With supplementation of 0.1 nM RA, the degree of UB branching 
was similar to that without RA supplementation in bisdiamine-treated explants 
(Figure 4.2J). With supplementation of 0.5 nM RA, the number of UB tips 
increased significantly by almost 3-fold to approximately 14 (p < 0.001 vs. 
bisdiamine without RA), but the value was still significantly smaller than that of 
the control (p < 0.001 vs. vehicle without RA). While the size of the 
bisdiamine-treated explant was prominently larger than that without RA 
supplementation, the morphology of UB branching was distorted from the 
symmetrical pattern (Figure 4.2K). When the concentration of RA was further 
increased to 1 nM, 20 UB tips were observed in bisdiamine-treated explants, 
which was almost 4 times more than that in bisdiamine-treated explants without 
RA supplementation (p < 0.001 vs. bisdiamine without RA), although it was still 
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29.6% lower than that in the control (p < 0.005 vs. vehicle without RA). The 
branching morphology was found to be restored as shown in Figure 4.2L. 
Analysis by Pearson correlation (Table 4.7) showed a strong 
concentration-dependent increase in UB tips with increasing concentrations of RA 
in bisdiamine-treated explants (r = +0.687, < 0.001). 
In addition to the number of UB tips, results of quantification of 
nephric tubules at day 6 of culture were shown in Table 4.8 and Graph 4.3. 
Pearson correlation between the number of nephric tubules and the concentrations 
of RA supplemented was shown in Table 4.9. 
Table 4.8 Number of nephric tubules in vehicle- and bisdiamine-treated 
metanephric explants at day 6 of culture under various 
concentrations of RA. 
Cone. No. of No. of /7-value 
Treatment 
of RA explants nephric tubules vs. vehicle vs. bisdiamine 
at ElO.O 
(nM) examined 士 SEM without RA without RA 
0 20 7.20 士 1.14 - -
0.1 20 7.60 士 1.43 0.828 -
Vehicle 
0.5 21 7.14 ±0.91 0.969 -
1 20 8.20 ± 1.20 0.550 -
0 22 0.55 ±0.14 <0.001* -
0.1 21 0.38 ±0.11 <0.001* 0.368 
Bisdiamine 
0.5 23 1.22 ±0.32 <0.001* 0.066 
1 22 1.27 ±0.28 <0.001 0.026* 
* Statistically significant (Independent Sample "test) 
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Table 4.9 Pearson correlation between the number of nephric tubules and 
the concentrations of RA supplemented to vehicle- or 
bisdiamine-treated metanephric explants 
Treatment at ElO.O Vehicle Bisdiamine 
Concentration of RA(nM) 0 | 0.1 | 0.5 | 1 0 | 0.1 | 0.5 [ 1 
Pearson correlation coefficient (r) +0.057 +0.303 
/?-value of Pearson correlation 0.611 0.004# 
* Statistically significant (Pearson correlation) 
Without RA supplementation, vehicle-treated metanephric explants 
had undergone nephrogenesis and showed an average of 7 mature proximal 
tubules at day 6 of culture (Figure 4.2E). With increasing concentrations of 
supplemented RA from 0.1 to 1 nM (Figure 4.2 E to H), significant change in the 
number of nephric tubules was not observed in vehicle-treated explants (Table 
4.8). There was no statistical significance in the Pearson correlation (r = +0.057,p 
=0.611). This suggested that increasing RA concentrations from 0 to 1 nM did not 
affect nephrogenesis in vehicle-treated explants. 
Similar to UB branching morphogenesis, the process of nephrogenesis 
was severely disrupted in bisdiamine-treated metanephric explants such that an 
average of less than 1 nephric tubule was observed (Figure 4.2M). 
Supplementation of 0.1 nM RA did not affect the number of nephric tubules at all 
(Figure 4.2N). At the concentrations of 0.5 (Figure 4.20) and 1 nM RA (Figure 
4.2P), the average number of nephric tubules increased to 1.22 and 1.27 
respectively. Significant increase was only observed with 1 nM RA 
supplementation (p < 0.05 vs. bisdiamine without RA) while the number was still 
almost 6 times smaller than that in the control. A weak but significant positive 
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correlation (r = +0.303, p < 0.005) between the number of nephric tubules in 
bisdiamine-treated explants and the concentrations of RA supplementation was 
observed. 
Taken together, results of morphological grading of UB branching at 
each culture day and the quantification of UB tips and nephric tubules at the end 
of 6 days of culture suggested that in vitro development of bisdiamine-treated 
metanephric explants was severely disrupted. This was in agreement to the in vivo 
fate of bisdiamine-treated kidneys as studied in Chapter 3, in which renal agenesis 
and hypodysplastic kidneys were frequently observed. Supplementation of 0.1 nM 
RA had no observable effect in restoring metanephric development while 
concentrations of 0.5 and 1 nM showed increasing ability to do so. While the 
concentration of 1 nM RA increased the number of UB tips in vehicle-treated 
metanephric explants by 48.7% (when compared to the same group without RA 
supplementation), this concentration caused an increment by almost 4-fold in 
bisdiamine-treated metanephric explants. Although restoration of nephrogenesis in 
bisdiamine-treated metanephric explants was not as prominent, the concentration 
of 1 nM RA was regarded as the most effective concentration in rescuing 
bisdiamine-treated metanephroi. 
4.4.2 Effect of RA supplementation on apoptosis in bisdiamine-treated 
metanephric explants 
After confirming that the development of bisdiamine-treated 
metanephroi could be partially rescued by supplementation of 1 nM RA in vitro. 
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TUNEL staining was performed at day 2 of culture to determine if there was a 
reduction of apoptosis during early metanephric development. The number of 
apoptotic nuclei in metanephric explants of each treatment group was summarized 
in Table 4.10 and illustrated in Graph 4.4, while pictures showing TUNEL 
staining on paraffin sections were shown in Figure 4.3. 
Table 4.10 Number of apoptotic nuclei in vehicle- and bisdiamine-treated 
metanephric explants cultured for 2 days (48 hours) with or 
without 1 nM RA supplementation. 
Treatment at ElO.O Vehicle Bisdiamine 
Concentration of RA (nM) 0 1 0 1 
Number of explants examined 5 5 8 8 
Number of apoptotic nuclei per mm^ 395.06 309.04 1137.22 517.38 
士 SEM ±31.96 ±55.07 ± 177.65 ± 74.44 
/^-value vs. vehicle without RA - 1.000 0.002* 1.000 
；7-value vs. vehicle with 1 nM RA - - 0.001* 1.000 
/?-value vs. bisdiamine without RA - - - 0.004* 
* Statistically significant (One-way ANOVA followed by Bonferroni test). 
Vehicle-treated explants cultured without RA supplementation (control) 
showed an average of 396.06 apoptotic nuclei per mrrT. Apoptotic nuclei were 
mainly observed in the MM at the peripheral region of the explant, with a few in 
the inner part (Figure 4.3A). Apoptosis was rarely observed in the UB of the 
explant. With supplementation of 1 nM RA, although the average number of 
apoptotic nuclei was reduced to 309.04, it did not show any significant difference 
from the control. Similar to the control, apoptotic nuclei were observed at the 
periphery of the explant (Figure 4.3B). 
In comparison to the control, the number of apoptotic nuclei surged up 
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by nearly 3 times to an average of 1137.22 per mm^ (p < 0.005) in 
bisdiamine-treated metanephroi without RA supplementation. Fulminant 
apoptosis was observed throughout the metanephric mesenchyme in the whole 
explant (Figure 4.3C). The size of bisdiamine-treated explant without RA 
supplementation was generally smaller than that in the control. When the 
bisdiamine-treated explant was cultured with 1 nM RA, the number of apoptotic 
nuclei was significantly reduced by 54.5% to an average of 517.38. Though this 
amount seemed to be higher than that of the control, there was actually no 
significant difference between these two groups. Apoptotic nuclei were mainly 
observed in the edges, but some in the inner part of the explant (Figure 4.3D). The 
size of the explant was still smaller than that of the control, but was prominently 
increased when compared to bisdiamine-treated explants without RA 
supplementation. To conclude, RA supplementation could indeed ameliorate 
apoptosis in bisdiamine-treated metanephric explants by day 2 of culture. 
4.4.3 Effect of RA supplementation on genes expression in 
bisdiamine-treated metanephric explants 
To determine whether RA supplementation could normalize the 
expression of c-Ret and Gdnf that was found to be altered in the early 
metanephros of bisdiamine-treated embryos (section 3.4.5), mRNA expression 
levels of c-Ret and Gdnf in vehicle- and bisdiamine-treated metanephric explants 
were quantified at day 2 of culture. Results were summarized in Table 4.11 and 
illustrated in Graphs 4.5, 4.6 and 4.7. 
-133 -
Chapter 4: Rescuing Bisdiamine-treated Metanephroi 
Table 4.11 Relative expression levels of c-Ret and Gdnf in vehicle- and 
bisdiamine-treated metanephric explants cultured for 2 days (48 
hours) with or without 1 nM RA supplementation. 
Treatment at ElO.O Vehicle Bisdiamine 
Concentration of RA (nM) 0 1 0 1 
Sample size 4 4 4 4 
Expression levels of 0.0019 0.0022 0.0013 0.0019 
c-Ret ip-actin 士 SEM ± 0.0002 士 0.0001 ± 0.0001 ± 0.0001 
-value vs. vehicle without RA - 0.452 0.035* 1.000 
；?-value vs. vehicle with 1 nM RA - - 0.001* 0.779 
/7-value vs. bisdiamine without RA - - - 0.019* 
Expression levels of 0.0090 0.0086 0.0094 0.0096 
Gdnfip-actin 士 SEM 士 0.0008 ± 0.0005 士 0.0007 ±0.0011 
p-value vs. vehicle without RA - 1.000 1.000 1.000 
/7-value vs. vehicle with 1 nM RA - - 1.000 1.000 
p-value vs. bisdiamine without RA - - - 1.000 
* Statistically significant (One-way AN OVA followed by Bonferroni test). 
In vehicle-treated metanephric explants, supplementation of 1 nM RA 
did not cause any significant change in c-Ret expression at day 2 of culture when 
compared to vehicle-treated metanephric explants without RA supplementation 
(control) (Graph 4.5). In bisdiamine-treated metanephric explants, without RA 
supplementation, c-Ret expression was significantly reduced by 31.6% when 
compared to the control {p < 0.05 vs. vehicle without RA). When 1 nM RA was 
supplemented, the expression was significantly increased {p < 0.05 vs. 
bisdiamine-treated without RA) to a level similar to that in the control. The result 
showed that in vitro RA supplementation could indeed restore c-Ret expression in 
bisdiamine-treated metanephric explants. 
Similar to the result in Chapter 3, bisdianiinc-treatment did not alter 
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expressions of Gdnf (Graph 4.6) in metanephric explants. Supplementation of 1 
nM RA to vehicle and bisdiamine-treated metanephric explants did not change 
expression of this gene either. 
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4 . 5 DISCUSSION 
In this chapter, it was shown that the development of 
bisdiamine-treated metanephroi could be rescued by correcting the RA deficiency 
in vitro. In particular, branching morphogenesis was partially restored. 
Concurrently, there was significant amelioration of apoptosis and normalization of 
c-Ret expression. 
As discussed in Chapter 3, downregulation of c-Ret alone should not 
be sufficient to result in renal agenesis in bisdiamine-treated fetuses. Apoptosis is 
speculated to play a role in the pathogenic mechanism. The fact that the number of 
apoptotic nuclei in bisdiamine-treated metanephric explants could be significantly 
reduced by supplementation of 1 nM RA further suggested that RA deficiency was 
linked to fulminant apoptosis. Indeed, RA deficiency has been shown to increase 
apoptosis in organs of several animal models, both in adults and embryos. In adult 
vitamin A-deficient rats, degeneration of testes and crypt cells in the intestine was 
shown to be caused by enhanced apoptosis (Akmal et al,, 1998; Swartz-Basile et 
al., 2003). In Raldh2'^' embryos, increased apoptosis in the posterior 
rhombencephalic neural crest cells was associated with impaired branchial arch 
morphogenesis (Niederreither et aL, 2000). In embryos of vitamin A-deficient 
quail, enhanced apoptosis was noticeable in the endoderm cells associated with 
the presumptive myocardium during the process of heart tube formation, leading 
to heart tube morphogenetic defect (Ghatpande et aL, 2000). Importantly, 
exogenously applied RA was sufficient to rescue apoptosis and restore normal 
development. Another example was eye malformations induced by a RAR 
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antagonist in mouse embryos (Zhou & Kochhar, 2003). The number of apoptotic 
cells was significantly increased in the developing eye together with reduced 
expression of Activator Protein-2 {AP-2), which codes for a transcription factor 
related to eye development. These examples illustrate that apoptosis is a common 
pathogenic mechanism during development under RA deficiency. 
In fact, apoptosis is a normal event during kidney development. This is 
in agreement with the presence of apoptotic nuclei in vehicle-treated metanephroi 
in vivo and in vitro. It was shown that about 3% of cells in the nephrogenic zone 
in rat metanephroi had apoptotic morphology (Koseki et al., 1992; Coles et al., 
1993). Apoptosis is found to be necessary for both branching morphogenesis and 
nephrogenesis (Araki et al., 1999; Araki et al., 2003). It is possible that excessive 
apoptosis can result in renal malformations as observed in bisdiamine-treated 
fetuses, as well as fetuses of the RA-induced renal agenesis mouse model. In both 
models, RA deficiency, fulminant apoptosis and renal agenesis were observed. At 
this moment, it is not clear how RA deficiency can lead to enhanced apoptosis in 
the metanephros. There are quite a number of genes that regulate apoptosis in the 
developing kidney. Targeted disruption of genes, such as Emx2, Bd-2, AP-2, Salll, 
Bmp7 and Wtl, as well as over expression o f p 5 3 in mice resulted in excessive 
apoptosis and caused renal malformations, ranging from hypoplasia to agenesis 
(Kreidberg et al., 1993; Godley et al., 1996; Nagata et al., 1996; Dudley & 
Robertson, 1997; Miyamoto et al., 1997; Moser et al., 1997; Nishinakamura et al., 
2001). Expressions of some of these genes, such as Bcl-2, AP-2, Bmp7 and JVtJ, 
have been shown to be regulated by RA (Baimer & Blomhoff’ 2002). It is still 
possible that expression of other RA-regulated genes, such as AP-2 and Bcl-2, was 
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disrupted in the bisdiamine-treated kidneys. For instance, it has been shown that 
the expression of AP-2 was downregulated during interruption of RA signaling in 
the developing eye of mouse embryos (Zhou & Kochhar, 2003). AP-2 is a 
negative regulator of c-myc (Gaubatz et al., 1995), an inducer of apoptosis (Evan 
et al., 1992). Thus, if the expression of AP-2 is downregulated in the metanephros 
during RA deficiency, over expression of c-myc will be resulted and lead to 
excessive apoptosis. This is just an example of many possible pathways in which 
RA deficiency in the early metanephros can lead to excessive apoptosis and renal 
agenesis. Further examination in alteration of genes expression in 
bisdiamine-treated metanephroi has to be carried out to study the relationship 
between RA deficiency, apoptosis and renal agenesis. 
In the present study to rescue Ell .25 bisdiamine-treated metanephroi 
by low concentrations of RA added in vitro, development of UB branching 
morphogenesis could only be partially restored while rescue of nephrogenesis was 
rather ineffective. As illustrated in Figure 3.11, metanephroi treated with 
bisdiamine showed disrupted UB branching. All of the examined kidney 
rudiments failed to undergo the first dichotomous branching at Ell.O. It has been 
reported that early immature metanephroi, in which the UB just penetrated the 
MM, failed to undergo nephrogenesis in vitro (Vilar et al., 1996). Thus, the 
limited ability of the bisdiamine-treated metanephric explant to undergo 
nephrogenesis even under 1 nM RA supplementation could be due to immaturity 
of the MM tissue upon isolation of the bisdiamine-treated explant at Ell.25. 
Another explanation for the partial rescue could be due the stage in which the 
metanephroi were rescued. In the time-response study in Chapter 3, it was 
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demonstrated that administration of bisdiamine at ElO.O induced the highest 
frequency of renal agenesis, while injection at E9.0 and Ell.O was not as effective. 
On the other hand, with injection at ElO.O, RA deficiency was observed at El0.25, 
became most prominent at Ell.O and had started to be restored by E12.0. This 
finding suggested that the effect of a single dose of bisdiamine in suppressing RA 
synthesis could last for roughly 2 days. Taken together, it was implied that the 
occurrence of RA deficiency from roughly ElO to El2 was most effective in 
causing renal agenesis, while deprivation from El l to El3 (with injection at Ell.O) 
was not as effective. This highlighted the importance of the period of RA 
deficiency from ElO to E l l on induction of renal agenesis in bisdiamine-treated 
fetuses. This time window entails events of early kidney development, which 
includes condensation of mesenchymal cells to form the metanephric blastema at 
ElO.5, the formation of the UB from the wolffian duct and the invasion of the 
MM by the UB. It is currently not known how RA deficiency affects these early 
events, which could subsequently result in regression of the metanephros that 
initially formed at Ell.O. However, this may explain the partial rescue effect of 
RA supplementation on Ell .25 bisdiamine-treated metanephric explants. The 
incomplete rescue was likely to be caused by intrinsic defect(s) in the 
bisdiamine-treated metanephros which were imposed during the period of ElO.O 
to Ell .25 by RA deficiency. Due to limitations of the in vitro kidney culture 
system, El l was the earliest time that rescue by supplementation of RA could be 
carried out. To overcome this obstacle, in vivo rescue by oral feeding of low doses 
of RA to bisdiamine-treated pregnant mice can be performed in an attempt to 
compensate for the RA deficiency and restore kidney development to a better 
extent. 
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To sum up, results of this chapter supported that perturbation of kidney 
development in bisdiamine-treated embryos could be caused by RA deficiency. 
Bisdiamine-induced RA deficiency in the metanephros led to fulminant apoptosis 
and downregulation of c-Ret, which could be reversed by normalization of RA 
levels in vitro. 
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Figure 4.1 Morphological grading system of the number of ureteric bud (UB) 
tips in metanephric explants. 
A. Metanephric explant with 1 UB tip (Grade I). 
B. Metanephric explant with 2 UB tips (Grade II). 
C. Metanephric explant with 3-6 UB tips (Grade III). 
D. Metanephric explant with 7-10 UB tips (Grade IV). 
E. Metanephric explant with >10 UB tips (Grade V). 
Labels: UB ureteric bud 
MM metanephric mesenchyme 
Scale bar: A-E 0.5 mm 
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Figure 4.2 Whole-mount immunohistochemical staining of ureteric bud (UB) 
branching and nephric tubules in vehicle- and bisdiamine-treated 
metanephric explants cultured under various concentrations of RA 
for 6 days. 
A. Staining of UB branching in the vehicle-treated metanephric explant cultured 
without RA supplementation. Thirty UB tips were observed in this explant. 
B. Staining of UB branching in the vehicle-treated metanephric explant cultured 
with 0.1 nM RA. Thirty-one UB tips were observed in this explant. 
C. Staining of UB branching in the vehicle-treated metanephric explant cultured 
with 0.5 nM RA. Forty UB tips were observed in this explant. 
D. Staining of UB branching in the vehicle-treated metanephric explant cultured 
with 1.0 nM RA. Forty-eight UB tips were observed in this explant. 
E. Staining of nephric tubules in the vehicle-treated metanephric explant cultured 
without RA supplementation. Seven nephric tubules were observed in this 
explant. 
F. Staining of nephric tubules in the vehicle-treated metanephric explant cultured 
with 0.1 nM RA. Eight nephric tubules were observed in this explant. 
G. Staining of nephric tubules in the vehicle-treated metanephric explant cultured 
with 0.5 nM RA. Six nephric tubules were observed in this explant. 
H. Staining of nephric tubules in the vehicle-treated metanephric explant cultured 
with 1.0 nM RA. Seven nephric tubules were observed in this explant. 
I. Staining of UB branching in the bisdiamine-treated metanephric explant cultured 
without RA supplementation. This explant had regressed, but two UB tips was 
still visible. 
J. Staining of UB branching in the bisdiamine-treated metanephric explant cultured 
with 0.1 nM RA. Four UB tips were observed in this explant. 
K. Staining of UB branching in the bisdiamine-treated metanephric explant cultured 
with 0.5 nM RA. Thirteen UB tips were observed in this explant. 
L. Staining of UB branching in the bisdiamine-treated metanephric explant cultured 
with 1.0 nM RA. Twenty-five UB tips were observed in this explant. 
M. Staining of nephric tubules in the bisdiamine-treated metanephric explant 
cultured without RA supplementation. No nephric tubule was observed in this 
explant. 
N. Staining of nephric tubules in the bisdiamine-treated metanephric explant 
cultured with 0.1 nM RA. No nephric tubule was observed in this explant. 
O. Staining of nephric tubules in the bisdiamine-treated metanephric explant 
cultured with 0.5 nM RA. One nephric tubule was observed in this explant. 
P. Staining of nephric tubules in the bisdiamine-treated metanephric explant 
cultured with 1.0 nM RA. Three nephric tubules were observed in this explant. 
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Figure 4.3 TUNEL staining showing apoptotic nuclei in vehicle- and 
bisdiamine-treated metanephric explants cultured for 2 days (48 
hours) with or without 1 nM RA supplementation. 
All figures were transverse sections of the metanephric explant. 
A. Vehicle-treated metanephric explant cultured without RA supplementation 
(control). Apoptotic nuclei (arrows) were found mainly in the metanephric 
mesenchyme at the peripheral region, with a few in the inner part of the explant. 
Apoptosis was a rare event in the ureteric bud (UB). 
B. Vehicle-treated metanephric explant cultured with 1 nM RA. Similar to the 
control, apoptotic nuclei were mainly observed in the peripheral region of the 
explant. There was no obvious difference in the number of apoptotic nuclei 
between vehicle-treated explants cultured with or without RA (A). 
C. Bisdiamine-treated metanephric explant cultured without RA supplementation. 
Fulminant apoptosis was observed throughout the metanephric mesenchyme in 
the entire explant, but not in the UB. The number of apoptotic nuclei in this 
treatment group was prominently much more than that in the control (A). The 
size of the bisdiamine-treated explant cultured without RA was generally smaller 
than that of the control (A). 
D. Bisdiamine-treated metanephric explant cultured with 1 nM RA. Apoptotic 
nuclei were found mainly in the peripheral region, with a few in the inner part of 
the explant. The number of apoptotic nuclei was noticeably much less than that 
in bisdiamine-treated explant cultured without RA supplementation (C). 
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Scale bar: A-D 0.1 mm 
A UB 
_ � Z Z 
Vehicle V , � / 
(Without RA) . 卜 , ，：： -
g .UB , 
Vehicle : V ； � � , / 
(1 nM RA) , 入 
C U B \ / 
Bisdiamine � , i _ \ > . - *• • : � � ‘ ‘ ‘ , , 镇 L 二 卞 : ！ 遍 
(Without RA) 
^ . / U B / I 
Bisdiamine \ … ‘ .. 














































































































































































































































































































































































































































































































































































































































































































































































































































Graph 4.2 Number of ureteric bud (UB) tips in vehicle- and bisdiamine-
treated metanephric explants at day 6 of culture under 
concentrations of RA. 
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The number in parentheses represents sample size, which refers to the number of 
metanephric explants examined. 
Data were analyzed by Independent Sample 广-test and Pearson correlation. 
林p < 0.05; ap < 0.005; Pp < 0.001 vs. Vehicle without RA 
< 0.001 vs. Bisdiamine without RA 
Graph 4.3 Number of nephric tubules in vehicle- and bisdiamine-treated 
metanephric explants at day 6 of culture under various 
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Graph 4.4 Number of apoptotic nuclei in vehicle- and bisdiamine-treated 
metanephric explants cultured for 2 days (48 hours) with or 
without 1 nM RA supplementation. 
] W i t h o u t RA 
O 1 nM RA 
^ 1400「 # a 
LU T 
<0 
















•Q 200 - : : E ] z 
0 1 1 
(5) (5) (8) (8) 
Vehicle Bisdiamine 
The number in parentheses represents sample size, which refers to the number of 
metanephric explants analyzed. 
Data were analyzed by one-way ANOVA followed by Bonferroni test. 
林p < 0.005 vs. Vehicle without RA 
< 0.005 vs. Vehicle with 1 nM RA 
^p < 0.005 vs. Bisdiamine without RA 
Graph 4.5 Relative expression levels of c-Ret in vehicle- and bisdiamine-
treated metanephric explants cultured for 2 days (48 hours) with 
or without 1 nM RA supplementation. 
] W i t h o u t RA 





+1 0 .0025 -
0 .0020 - T 
Hw 工 










0.0000 ‘ ‘ 
(4) (4) (4) (4) 
Vehicle Bisdiamine 
The number in parentheses represents sample size, which refers to the number of litters 
of metanephric explants. 
Data were analyzed by one-way AN OVA followed by Bonferroni test. 
林p < 0.05 vs. Vehicle without RA 
0.005 vs. Vehicle with 1 nM RA 
^p < 0.05 vs. Bisdiamine without RA 
Graph 4.6 Relative expression levels of Gdnf in vehicle- and bisdiamine-
treated metanephric explants cultured for 2 days (48 hours) with 
or without 1 nM RA supplementation. 
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of metanephric explants. 
Data were analyzed by one-way ANOVA followed by Bonferroni test. 
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5.1 CONCLUSION AND FUTURE PERSPECTIVES 
In the RA-induced renal agenesis mouse model established in our 
laboratory, it was found that maternal administration of excess RA to mouse 
embryos at embryonic day (E) 9.0, a time point before formation of the 
metanephros, could perturb kidney development. The kidney of RA-treated 
embryos initially formed at Ell.O, but later underwent excessive apoptosis and 
then degenerated. It was found that excess RA administered at E9.0 led to 
prolonged downregulation of Raldhs expression so that there was a deficiency of 
endogenous RA during early metanephric development. Supplementation of low 
doses of RA to the embryo during the period of RA deficiency could ameliorate 
apoptosis and restored kidney development. Based on these findings, the aim of 
this project was to test whether temporary RA deficiency, caused by reduced RA 
synthesis at around ElO to El2 as observed in the RA-induced renal agenesis 
mouse model, could indeed cause renal agenesis. To achieve this aim, bisdiamine, 
an inhibitor of RA synthesizing enzymes, was used to induce RA deficiency at 
around mid-gestation to mimic the conditions in the RA-induced renal agenesis 
mouse model. 
To begin with, detailed time- and dose-response studies on the 
susceptibility of embryos to bisdiamine-induced renal and non-renal 
malformations were carried out in Chapter 3. It was found that bisdiamine caused 
malformations in 13 out of 17 organ systems that were examined. Most of these 
malformations occurred in a time- and dose-dependent manner. In particular, 
administration of 3 g/kg bisdiamine to pregnant ICR mice at ElO.O induced renal 
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malformations in all fetuses, with 40% being bilateral renal agenesis. This dosage 
was regarded as most effective in inducing renal agenesis and was used in 
subsequent experiments to study the pathogenic mechanism. Interestingly, all of 
the malformations observed in bisdiamine-treated fetuses coincided with those 
found in VAD syndrome (Clagett-Dame & DeLuca, 2002). Indeed, severe RA 
deficiency was observed in bisdiamine-treated embryos from El0.25 to at least 
El2.0. Disruption of RA signaling was observed at multiple sites of the 
bisdiamine-treated embryo from El0.5 to at least El2.0. Bisdiamine was 
speculated to inhibit the RA synthesizing activity of RALDHl, RALDH2 and 
RALDH3 based on the X-gal staining pattern in RARE-hsp-LacZ embryos. In 
bisdiamine-treated embryos, a pair of metanephric rudiments was formed at Ell.O 
with the UB penetrated into the MM but without undergoing the first dichotomous 
branching. Concurrent with severe RA deficiency from Ell.O to El2.0, reduction 
of c-Ret expression and fulminant apoptosis was observed in bisdiamine-treated 
metanephric rudiments. To prove that renal agenesis was caused by 
bisdiamine-induced RA deficiency, the RA deficit in bisdiamine-treated 
metanephroi was corrected in vitro in Chapter 4. Low concentrations of RA were 
supplemented to the culture medium to compensate for the RA deficiency in 
Ell .25 bisdiamine-treated metanephric explants. It was shown that the 
development of bisdiamine-treated metanephroi could be partially rescued with 1 
nM RA supplementation. The branching morphogenesis was partially restored 
while significant reduction of apoptosis and normalization of c-Ret expression 
were observed. These results demonstrated that RA deficiency could indeed lead 
to perturbation of metanephric development in bisdiamine-treated embryos. While 
downregulation of c-Ret was able to disrupt growth and differentiation of the 
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metanephros, bisdiamine-induced renal agenesis could not be solely caused by 
downregulation of c-Ret based on comparison with the c-Ret knockout mutants 
(section 3.5). Excessive apoptosis, caused by bisdiamine-induced RA deficiency, 
may also play a role in the disruption of development of the bisdiamine-treated 
metanephric rudiment. 
Taken together, a bisdiamine-induced renal malformations mouse 
model was established in this thesis. Results suggested that RA deficiency, 
induced by bisdiamine from about El0 to El2, could indeed cause renal agenesis. 
As the study in this thesis was based on the findings of the RA-induced 
renal agenesis mouse model, a comparison between the two models was made 
(Table 5.1). In the RA-induced renal agenesis mouse model (described in section 
1.2.3.2), intraperitoneal injection of 125 mg/kg RA at E9.0 resulted in bilateral 
renal agenesis in 77.5% of fetuses. RA-treated metanephroi indeed formed at 
Ell.O with the UB penetrated into the MM, but then halted in further development. 
Fulminant apoptosis occurred in the MM and the metanephric rudiment 
subsequently degenerated. RA deficiency was found in the embryo and the 
metanephros from ElO.O to E12.0. The deficiency was caused by prolonged 
downregulation of Raldhs expression following the teratogenic insult at E9.0. 
Correction of RA deficiency by maternal supplementation of low doses of RA 
could restore kidney development. In the rescued metanephroi, expression of 
c-Ret was restored and apoptosis was ameliorated. The bisdiamine-induced renal 
agenesis mouse model established in this thesis was indeed very similar to the 
RA-induced renal agenesis mouse model. Although RA deficiency was caused by 
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suppression of RALDHs activity by bisdiamine, the period of RA deficiency 
occurring in bisdiamine-treated embryos was comparable to that in RA-treated 
embryos. In both models, metanephric rudiments were formed but subsequently 
underwent regression, leading to renal agenesis in some of the fetuses. 
Normalization of RA deficiency in bisdiamine-treated metanephroi was able to 
restore kidney development in association with upregulation of c-Ret and 
reduction of apoptosis. The many similarities between these two models have 
provided support to the hypothesis that excess RA causes RA deficiency in the 
embryo and the metanephros, leading to renal agenesis in association with 
fulminant apoptosis. Interestingly, other than renal malformations, defects of the 
eye, anus, diaphragm, thymus and testis were observed in both models. It is 
possible that the proposed novel mechanism of RA teratogenicity may also be 
applicable to these organ systems. 
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Table 5.1 Comparisons between the RA-induced renal agenesis mouse 
model and the bisdiamine-induced renal agenesis mouse model. 
‘—• •  ‘ ‘ • _•_•.- —— —• • • “ •••• —— 
Bisdiamine-induced 
RA-induced renal 
renal agenesis mouse 
agenesis mouse model 
model 
Mouse strain ICR mouse ICR mouse 
Intraperitoneal injection Intraperitoneal injection 
Treatment of 125 mg/kg RA at of 3 g/kg bisdiamine at 
E9.0 ElO.O 
Frequency of bilateral renal 
^ 77.5% 39.5% 
agenesis in El8 fetuses 
The UB penetrated into The UB penetrated into 
Early renal phenotype 
the MM at Ell.O the MM at Ell.O 
Suppression of RA 
Reduced mRNA synthesizing activities of 
Cause of RA deficiency 
expression of Raldhs RALDHs 
(indirect evidences) 
Occurrence of RA Whole embryo Whole embryo 
deficiency and the metanephros and the metanephros 
Period of RA deficiency ElO.O to at least E12.0 E10.25 to at least E12.0 
Change in gene expression 
(in comparison to 30.2% decline in c-Ret 89.6% decline in c-Ret 
vehicle-treated control at expression at El2.0 expression at El2.0 
the same stage) 
Apoptosis in the 
metanephros Fulminant apoptosis at Fulminant apoptosis at 
(in comparison to the cranial region of the the cranial region of the 
vehicle-treated control at metanephros metanephros 
the same stage) 
Malformed organs in i. i i , . 
Eye, anus, diaphragm, thymus and testis 
common 
Normalization of c-Ret Normalization of c-Ret 
expression, amelioration expression, amelioration 
Effect of correction of RA of apoptosis and of apoptosis and 
deficiency restoration of kidney restoration of kidney 
development development 
(in vivo rescue) (in vitro rescue) 
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The major discrepancy between these two models was that some 
malformations, such as truncation of tail, absence of external ears, sirenomelia 
(fusion of legs) and ectrodactyly (absence of digits in the hand or foot), were 
observed in RA-treated fetuses but not in bisdiamine-treated fetuses. While 
RA-induced renal malformations could be caused by the prolonged RA deficiency 
subsequent to excess RA injection, other malformations, which were exclusively 
observed in RA-treated fetuses, were likely to be caused by other RA teratogenic 
mechanisms mentioned in section 1.2.3.1. Taking truncation of the tail as an 
example, it was demonstrated that excessive apoptosis induced by RA in the tail 
bud mesenchyme, which contains progenitor cells for forming the lower vertebrae, 
was the cause of tail truncation in RA-treated embryos (Padmanabhan, 1998; 
Shum et al., 1999). This may also explain the different incidences of renal 
agenesis between the two models, in which bilateral renal agenesis occurred more 
frequently in RA-treated fetuses. In addition to the proposed pathway through RA 
deficiency, it is possible that exogenous RA might concurrently exert its 
teratogenic effect through some of the other teratogenic pathways. For instance, 
excess RA might induce apoptosis directly in some of the renal progenitor cells in 
the intermediate mesoderm shortly after the teratogenic insult. Although the 
metanephros was able to form at Ell.O, its susceptibility to RA 
deficiency-induced degeneration might be increased due to reduction of cell mass. 
Further investigations have to be carried out to address some 
unresolved questions in this thesis. First, to study whether development of 
bisdiamine-treated kidney can be restored to a greater extent, in vivo 
supplementation of low doses of RA may be conducted. Similar to the rescued 
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RA-treated metanephros, low doses of RA (1.25 to 2.5 mg/kg) can be 
administered to pregnant ICR mice at 12-hour interval starting from El0.25, the 
time point when RA deficiency was first detected. This approach allows the RA 
deficit to be compensated throughout the period of early kidney development. 
Renal, together with non-renal malformations can be examined to see whether 
normalization of RA deficiency can restore the bisdiamine-induced congenital 
defects in the fetus. Second, to determine whether excessive apoptosis was the 
cause of renal agenesis observed in bisdiamine-treated fetuses, experiments to 
inhibit apoptosis in the bisdiamine-treated metanephros have to be performed. 
This could be achieved by application of inhibitors of effector proteins of 
apoptosis, such as caspases (Araki et al., 1999; Araki et al., 2003) and p53 
(Komarov et al., 1999). If inhibition of apoptosis could indeed restore 
development of bisdiamine-treated metanephroi, it could be confirmed that 
bisdiamine-induced renal agenesis was mediated by apoptosis. Third, the 
deregulated gene(s) which caused fulminant apoptosis in the metanephros of 
bisdiamine-treated embryos has/have to be determined. As discussed in Chapter 4, 
a number of RA-responsive genes, such as AP-2 and Bcl-2, are involved in 
regulation of apoptosis in the metanephric rudiment. Expression of these genes in 
bisdiamine-treated metanephroi, in addition to RA-treated ones, should be 
examined to look for a common pathogenic pathway (if any) between these two 
models at the molecular level. 
To conclude, results of this thesis suggest that RA deficiency, induced 
by bisdiamine from about ElO to E12, can cause renal agenesis. Comparison of 
this bisdiamine-induced renal agenesis mouse model and the RA-induced renal 
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agenesis mouse model have provided support to a novel RA teratogenic 
mechanism that excess RA can lead to severe renal malformations by causing RA 
deficiency. This mechanism may not be applicable only to RA-induced renal 
malformations, but may also be involved in congenital malformations of other 
organs which are observed in both cases of excess RA and RA deprivation. 
Moreover, RA also plays a key role in regulating cell proliferation and 
differentiation in postnatal life. As mentioned in section 1.2.3, reitnoids have been 
used as dietary supplements and active ingredients in some drugs for treating skin 
diseases and cancer. Thus, a better understanding of the interaction between 
exogenously applied RA and endogenous RA synthesis may provide insight into 
the use of retinoids in these areas. 
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